<SEC-DOCUMENT>0001437749-25-036389.txt : 20251126
<SEC-HEADER>0001437749-25-036389.hdr.sgml : 20251126
<ACCEPTANCE-DATETIME>20251126085809
ACCESSION NUMBER:		0001437749-25-036389
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20251126
DATE AS OF CHANGE:		20251126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pyxis Oncology, Inc.
		CENTRAL INDEX KEY:			0001782223
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831160910
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291801
		FILM NUMBER:		251524790

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		(617) 221-9059

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>pyxs20251125_s3.htm
<DESCRIPTION>FORM S-3
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:pyxs="http://pyxisoncology.com/20251231" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>pyxs20251125_s3.htm</title>


	<!-- Generated by ThunderDome Portal - 11/26/2025 11:11:35 AM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-4334">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-4335">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AmendmentFlag" id="ixv-4336">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCentralIndexKey" id="ixv-4337">0001782223</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="pyxs-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-01-01_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>

<div><img alt="pyxislogo.jpg" src="pyxislogo.jpg"/></div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>As filed with the Securities and Exchange Commission on November 26, 2025.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No. 333- </b></p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentType" id="c3">S-3</ix:nonNumeric></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REGISTRATION STATEMENT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>UNDER</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>THE SECURITIES ACT OF 1933</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityRegistrantName" id="c4">PYXIS ONCOLOGY, INC</ix:nonNumeric>.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityIncorporationStateCountryCode" id="c5" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityTaxIdentificationNumber" id="c6">83-1160910</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or other jurisdiction of</p>
			</td>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">incorporation or organization)</p>
			</td>
			<td style="vertical-align:bottom;width:26.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Identification Number)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressAddressLine1" id="c7">321 Harrison Avenue</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressCityOrTown" id="c8">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressStateOrProvince" id="c9" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></b><b>&#160;<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressPostalZipCode" id="c10">02118</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CityAreaCode" id="c11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:LocalPhoneNumber" id="c12">453-3596</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Lara Sullivan, M.D.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Executive Officer</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>321&#160;Harrison Avenue</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Boston, Massachusetts&#160;02118</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(617) 453-3596</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Copies to:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Asher Rubin, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Istvan A. Hajdu, Esq.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sidley Austin LLP</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>787 Seventh Avenue</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>New York, NY 10019</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(212) 839-5599</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Approximate date of commencement of proposed sale to the public: </b>From time to time after this registration statement becomes effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. &#9746;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:9.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:25.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
			<td style="vertical-align:top;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
			</td>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:9.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFilerCategory" id="c13" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:25.6%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9746;</p>
			</td>
			<td style="vertical-align:top;width:4.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
			</td>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:top;width:1.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntitySmallBusiness" id="c14" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:9.8%;">&#160;</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:25.6%;">&#160;</td>
			<td style="vertical-align:top;width:4.3%;">&#160;</td>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company</p>
			</td>
			<td style="vertical-align:top;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:1.1%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityEmergingGrowthCompany" id="c15" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityExTransitionPeriod" id="c16" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPLANATORY NOTE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This registration statement contains two prospectuses:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a base prospectus which covers the offering, issuance and sale by the Registrant of up to a maximum aggregate offering price of $350,000,000 of the Registrant&#8217;s common stock, preferred stock, warrants, debt securities, rights to purchase common stock, preferred stock, debt securities and/or units, and units; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a sales agreement prospectus covering the offering, issuance and sale by the Registrant of up to a maximum aggregate offering price of $150,000,000 of shares of the Registrant&#8217;s common stock that may be offered, issued and sold from time to time under a sales agreement, dated November 26, 2025, with Leerink Partners LLC.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The common stock that may be offered, issued and sold by the Registrant under the sales agreement prospectus is included in the $350,000,000 of securities that may be offered, issued and sold by the Registrant and/or selling stockholders under the base prospectus. Upon termination of the sales agreement with Leerink Partners LLC, any portion of the $150,000,000 included in the sales agreement prospectus that is not sold pursuant to such sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement related to any such other offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">&#160;</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160; &#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="color:#ff0000;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state or jurisdiction where such offer or sale is not permitted.</span></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ff0000;"><b>Subject to Completion, Dated November 26, 2025</b></span></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS</b></p>

<div style="text-align: center;"><img alt="pyxislogo.jpg" src="pyxislogo.jpg"/></div>

<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>$350,000,000</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 20pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PYXIS ONCOLOGY, INC.</b></p>

<p style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Common Stock</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Preferred Stock</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Warrants</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Debt Securities</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Rights to Purchase Common Stock, Preferred Stock,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Debt Securities or Units</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Units</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may offer and sell from time to time our shares of common stock, shares of preferred stock, debt securities, warrants, rights to purchase common stock, preferred stock, debt securities or units, as well as units that include any of these securities. We may sell any combination of these securities in one or more offerings with an aggregate offering price of up to $350,000,000.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This prospectus provides a general description of the securities we may offer. Each time we offer securities pursuant to this prospectus, we will provide a prospectus supplement containing specific terms of the particular offering together with this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest in any securities. The prospectus supplement also may add, update or change information contained in this prospectus.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>This prospectus may not be used to offer and sell securities unless accompanied by the applicable prospectus supplement. </b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;PYXS.&#8221; On November 25, 2025, the last reported sale price of our common stock was $5.34.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may sell the securities directly or to or through underwriters or dealers, and also to other purchasers or through agents. The names of any underwriters or agents that are included in a sale of securities to you, and any applicable commissions or discounts, will be stated in an accompanying prospectus supplement. In addition, the underwriters, if any, may over-allot a portion of the securities. We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See &#8220;Summary &#8212; Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Investing in our securities involves significant risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any accompanying prospectus supplement, as well as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange Commission. See </b>&#8220;<a href="#RISK_FACTORS" style="-sec-extract:exhibit;"><b>Risk Factors</b></a>&#8221;<b> on page 2&#160;of this prospectus.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus is November 26, 2025</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" href="#"></a>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tbody><tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#ABOUT" style="-sec-extract:exhibit;">ABOUT THIS PROSPECTUS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#ABOUT">1</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#RISK_FACTORS" style="-sec-extract:exhibit;">RISK FACTORS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#RISK_FACTORS">2</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#FORWARD" style="-sec-extract:exhibit;">FORWARD-LOOKING STATEMENTS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#FORWARD">2</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PYXIS" style="-sec-extract:exhibit;">PYXIS ONCOLOGY, INC.</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PYXIS">3</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#USE_OF_PROCEEDS" style="-sec-extract:exhibit;">USE OF PROCEEDS</a></p>
			</td>
			<td style="vertical-align: top; width: 4.7%; text-align: right;"><a class="tocPGNUM" href="#USE_OF_PROCEEDS">4</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#CAPITAL_STOCK" style="-sec-extract:exhibit;">DESCRIPTION OF CAPITAL STOCK</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#CAPITAL_STOCK">5</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WARRANTS" style="-sec-extract:exhibit;">DESCRIPTION OF WARRANTS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WARRANTS">10</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#DEBT_SECURITIES" style="-sec-extract:exhibit;">DESCRIPTION OF DEBT SECURITIES</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#DEBT_SECURITIES">12</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#RIGHTS" style="-sec-extract:exhibit;">DESCRIPTION OF RIGHTS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#RIGHTS">19</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#UNITS" style="-sec-extract:exhibit;">DESCRIPTION OF UNITS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#UNITS">20</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#DISTRIBUTION" style="-sec-extract:exhibit;">PLAN OF DISTRIBUTION</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#DISTRIBUTION">21</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#LEGAL_MATTERS" style="-sec-extract:exhibit;">LEGAL MATTERS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#LEGAL_MATTERS">23</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#EXPERTS1" style="-sec-extract:exhibit;">EXPERTS</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#EXPERTS1">24</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHERE_YOU_CAN_FIND" style="-sec-extract:exhibit;">WHERE YOU CAN FIND MORE INFORMATION</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHERE_YOU_CAN_FIND">25</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:53.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#REFERENCE" style="-sec-extract:exhibit;">INFORMATION INCORPORATED BY REFERENCE</a></p>
			</td>
			<td style="vertical-align:top;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#REFERENCE">26</a></p>
			</td>
		</tr>

</tbody></table>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="ABOUT" href="#"></a>ABOUT THIS PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, (the &#8220;SEC&#8221;), using a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer and sell from time to time any combination of the securities described in this prospectus in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering, with an aggregate offering price of up to $350,000,000. This prospectus provides you with a general description of the securities we may offer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each time we offer securities, we will provide a prospectus supplement that describes the terms of the relevant offering. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you should read carefully both this prospectus and any prospectus supplement together with the documents incorporated by reference into this prospectus as described below under the heading &#8220;Information Incorporated by Reference.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">You should read both this prospectus and any accompanying prospectus supplement together with the additional information incorporated by reference. See &#8220;Where You Can Find More Information&#8221; and &#8220;Information Incorporated by Reference.&#8221; We have not authorized anyone to provide you with different information. You should not assume that the information in this prospectus or any supplement to this prospectus is accurate at any date other than the date indicated on the cover page of these documents or the filing date of any document incorporated by reference, regardless of its time of delivery. We are not making an offer to sell the securities in any jurisdiction where the offer or sale is not permitted.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We may sell our securities to or through underwriters, dealers or agents, directly to purchasers or through a combination of any of these methods of sale, as designated from time to time. We and our agents reserve the sole right to accept or reject in whole or in part any proposed purchase of our securities. An applicable prospectus supplement, which we will provide each time we offer the securities, will set forth the names of any underwriters, dealers or agents involved in the sale of our securities, and any related fee, commission or discount arrangements. See &#8220;Plan of Distribution.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The terms &#8220;Pyxis Oncology,&#8221; the &#8220;Company,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;we,&#8221; as used in this prospectus, refer to Pyxis Oncology, Inc., a Delaware corporation, and its subsidiaries unless we state otherwise or the context indicates otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="RISK_FACTORS" href="#"></a>RISK FACTORS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Investing in our securities involves risk. You should carefully consider the specific risks discussed or incorporated by reference into the applicable prospectus supplement, together with all the other information contained in the prospectus or incorporated by reference into this prospectus and the applicable prospectus supplement. You should also consider the risks, uncertainties and assumptions discussed under the caption </i>&#8220;<i>Risk Factors</i>&#8221;<i> included in our Annual Report on Form 10-K for the year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q for the periods ended March 31, June 30, and September 30, 2025 and in subsequent filings, which are incorporated by reference into this prospectus. These risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future or by a prospectus supplement relating to a particular offering of our securities. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any prospectus supplement or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="FORWARD" href="#"></a>FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus includes and incorporates by reference &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this prospectus. Unless the context requires otherwise references in this prospectus to &#8220;Pyxis Oncology,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Pyxis Oncology, Inc. and its subsidiaries. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;to be,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements about:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to develop and advance our current product candidate and program, and to successfully initiate and complete clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the ability of our clinical trials to demonstrate the safety, purity and potency of our product candidate and other positive results;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the size of the market opportunity for our product candidate, including our estimates of the number of patients who suffer from the cancers we are targeting;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our manufacturing, commercialization and marketing capabilities and strategy;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the timing or likelihood of regulatory filings and approvals for our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory developments in the United States and other foreign jurisdictions;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our expectations and plans to obtain funding for our operations, including from our existing and potential future collaboration and licensing agreements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to receive milestone or royalty payments under existing or future agreements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our continued reliance on third parties to manufacture our product candidate for clinical studies, and to conduct clinical trials and manufacture our product candidate for such clinical trials; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus and, although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In evaluating such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein. Any forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus and the documents incorporated by reference, may also contain estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="PYXIS" href="#"></a>PYXIS ONCOLOGY, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Company Overview</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our product candidate, micvotabart pelidotin (MICVO), formerly referred to as PYX-201, is an investigational novel antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM). The tumor ECM is a complex network of fibrous proteins and molecules with unique composition that play an important role in cell development and tumor growth and in some instances, in supporting metastasis. The fibronectin strands within the ECM give the tumor shape and support the clustering of tumor cells.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Implications of Being an Emerging Growth Company and Smaller Reporting Company</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Jumpstart Our Business Startups Act (the JOBS Act) was enacted in April 2012 with the intention of encouraging capital formation in the United States and reducing the regulatory burden on newly public companies that qualify as emerging growth companies. We are an &#8220;emerging growth company&#8221; within the meaning of the JOBS Act. We will cease to be an emerging growth company upon the earliest of (1) the end of the fiscal year following the fifth anniversary of our initial public offering; (2) the last day of the fiscal year during which our annual gross revenues are $1.235 billion or more; (3) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; and (4) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements in our Annual Report on Form 10-K, and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stocks held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter and our annual revenue exceeds $100 million during such completed fiscal year, or (ii) the market value of our common stock held by non-affiliates exceeds $700 million, regardless of our annual revenue, as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our consolidated financial statements with other public companies difficult or impossible.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We were incorporated in the state of Delaware on June 11, 2018 and launched with our first employee and Series A funding in July 2019. Our principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts 02118, and our telephone number is (617) 453-3596. Our website address is www.pyxisoncology.com. The information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="USE_OF_PROCEEDS" href="#"></a>USE OF PROCEEDS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any prospectus supplement or any related free writing prospectus that we may authorize to be provided to you, we currently intend to use the net proceeds from the sale of the securities offered hereby for general corporate purposes, including working capital, operating expenses and capital expenditures. We may also use a portion of the net proceeds to acquire or invest in businesses and products that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. We intend to invest the net proceeds to us from the sale of securities offered hereby that are not used as described above in short-term, investment-grade, interest-bearing instruments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="CAPITAL_STOCK" href="#"></a>DESCRIPTION OF CAPITAL STOCK</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>The following description is a general summary of the terms of the shares of common stock or shares of preferred stock that we may issue. The description below and in any prospectus supplement does not include all of the terms of the shares of common stock or shares of preferred stock and should be read together with our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, copies of which have been filed previously with the SEC. For more information on how you can obtain copies of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, see </i>&#8220;<i>Where You Can Find More Information.</i>&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>General</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and restated bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the Delaware General Corporation Law (the </i>&#8220;<i>DGCL</i>&#8221;<i>).</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation authorizes 190,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per share, the rights, preferences and privileges of which may be designated from time to time by our board of directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividend Rights</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and only then at the times and in the amounts that our board of directors may determine.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Voting Rights</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. We have a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>No Preemptive or Similar Rights</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our common stock is not entitled to preemptive rights and is not subject to redemption or sinking fund provisions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Right to Receive Liquidation Distributions</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and might adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Anti-Takeover Provisions</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The provisions of the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of incorporation and our bylaws could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids and encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Section 203 of the DGCL</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the date that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">before the stockholder became interested, our board of directors approved either the business combination or the transaction, which resulted in the stockholder becoming an interested stockholder;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">upon consummation of the transaction, which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans in some instances, but not the outstanding voting stock owned by the interested stockholder; or</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at or after the time the stockholder became interested, the business combination was approved by our board and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock, which is not owned by the interested stockholder.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 203 defines a business combination to include:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any merger or consolidation involving the corporation and the interested stockholder;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">subject to exceptions, any transaction that results in the issuance of transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Amended and Restated Certificate of Incorporation and Bylaw Provisions</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation and our bylaws include a number of provisions that may have the effect of deterring hostile takeovers, or delaying or preventing changes in control of our management team or changes in our board of directors or our governance or policy, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Board Vacancies</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation and bylaws authorize generally only our board of directors to fill vacant directorships resulting from any cause or created by the expansion of our board of directors. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Classified Board</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation and bylaws provide that our board of directors is classified into three classes of directors. The existence of a classified board of directors could delay a successful tender offeror from obtaining majority control of our board of directors, and the prospect of that delay might deter a potential offeror.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Directors Removed Only for Cause</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our amended and restated certificate of incorporation provides that stockholders may remove directors only for cause.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Supermajority Requirements for Amendments of Our Amended and Restated Certificate of Incorporation and Bylaws</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the classified board, the size of the board of directors, removal of directors, special meetings, actions by written consent and designation of our preferred stock. The affirmative vote of holders of at least two-thirds of the voting power of our outstanding common stock is required to amend or repeal certain provisions of our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stockholder Action; Special Meetings of Stockholders</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, holders of our capital stock are not able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws. Our amended and restated certificate of incorporation and our bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairperson of our board of directors or our chief executive officer, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Advance Notice Requirements for Stockholder Proposals and Director Nominations</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. To be timely, a stockholder&#8217;s notice generally must be delivered to us not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting of stockholders. Our bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">With respect to nominations of persons for election to our board of directors, the notice shall provide information about the nominee, including, among other things, name, age, address, principal occupation, ownership of our capital stock and whether they meet applicable independence requirements. With respect to the proposal of other business to be considered by our stockholders at an annual meeting, the notice shall provide a brief description of the business desired to be brought before the meeting, the text of the proposal or business, the reasons for conducting such business at the meeting and any material interest in such business by such stockholder and any beneficial owners and associated persons on whose behalf the notice is made, or the proposing persons. In addition, a stockholder&#8217;s notice must set forth certain information related to the proposing persons, including, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the name and address of the proposing persons;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">information as to the ownership by the proposing persons of our capital stock and any derivative interest or short interest in any of our securities held by the proposing persons;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">information as to any material relationships and interest between the proposing persons and us, any of our affiliates and any of our principal competitors;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a representation that the stockholder is a holder of record of our stock entitled to vote at that meeting and that the stockholder intends to appear in person or by proxy at the meeting to propose such nomination or business; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a representation whether the proposing persons intend or are part of a group which intends to deliver a proxy statement or form of proxy to holders of at least the percentage of our outstanding capital stock required to elect the nominee or carry the proposal.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>No Cumulative Voting</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation and bylaws do not provide for cumulative voting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Issuance of Undesignated Preferred Stock</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Exclusive Forum</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine or (5) any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section 115 of the Delaware General Corporation Law, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware, or the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation also provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">8</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Transfer Agent and Registrar</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transfer agent and registrar for our common stock is Broadridge Corporate Issuer Solutions, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exchange Listing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;PYXS.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="WARRANTS" href="#"></a>DESCRIPTION OF WARRANTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We may issue warrants for the purchase of shares of our common stock, shares of our preferred stock or debt securities. The following description sets forth certain general terms and provisions of the warrants that we may offer pursuant to this prospectus. The particular terms of the warrants and the extent, if any, to which the general terms and provisions may apply to the warrants so offered will be described in the applicable prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrants may be issued independently or together with other securities and may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A copy of the forms of the warrant agreement and the warrant certificate relating to any particular issue of warrants will be filed with the SEC each time we issue warrants, and you should read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the warrant agreement and the related warrant certificate, see &#8220;Where You Can Find More Information.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Stock Warrants</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The prospectus supplement relating to a particular issue of warrants to issue shares of our common stock or shares of our preferred stock will describe the terms of the common share warrants and preferred share warrants, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the title of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the offering price for the warrants, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the aggregate number of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the designation and terms of the shares of common stock or shares of preferred stock that may be purchased upon exercise of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms for changes or adjustments to the exercise price of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the designation and terms of the securities that the warrants are issued with and the number of warrants issued with each security;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the number of shares of common stock or shares of preferred stock that may be purchased upon exercise of a warrant and the price at which the shares may be purchased upon exercise;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the dates on which the right to exercise the warrants commence and expire;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the currency or currency units in which the offering price, if any, and the exercise price are payable;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, a discussion of material U.S. Federal income tax considerations;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">anti-dilution provisions of the warrants, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">redemption or call provisions, if any, applicable to the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants; and</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other information we think is important about the warrants.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Debt Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The prospectus supplement relating to a particular issue of warrants to issue debt securities will describe the terms of those warrants, including the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the title of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the offering price for the warrants, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the aggregate number of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the designation and terms of the debt securities purchasable upon exercise of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms for changes or adjustments to the exercise price of the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the designation and terms of the debt securities that the warrants are issued with and the number of warrants issued with each debt security;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the date from and after which the warrants and any debt securities issued with them will be separately transferable;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the principal amount of debt securities that may be purchased upon exercise of a warrant and the price at which the debt securities may be purchased upon exercise;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the dates on which the right to exercise the warrants will commence and expire;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the warrants represented by the warrant certificates or debt securities that may be issued upon exercise of the warrants will be issued in registered or bearer form;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">information relating to book-entry procedures, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the currency or currency units in which the offering price, if any, and the exercise price are payable;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, a discussion of material U.S. Federal income tax considerations;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">anti-dilution provisions of the warrants, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">redemption or call provisions, if any, applicable to the warrants;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants; and</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other information we think is important about the warrants.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Exercise of Warrants</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each warrant will entitle the holder of the warrant to purchase at the exercise price set forth in the applicable prospectus supplement the number of shares of common stock, shares of preferred stock or the principal amount of debt securities being offered. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants are void. Holders may exercise warrants as set forth in the prospectus supplement relating to the warrants being offered.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Until a holder exercises the warrants to purchase our shares of common stock, shares of preferred stock or debt securities, the holder will not have any rights as a holder of our shares of common stock, shares of preferred stock or debt securities, as the case may be, by virtue of ownership of warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="DEBT_SECURITIES" href="#"></a>DESCRIPTION OF DEBT SECURITIES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a general description of the terms of debt securities we may issue from time to time unless we provide otherwise in the applicable prospectus supplement. Particular terms of any debt securities we offer will be described in the prospectus supplement relating to such debt securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As required by federal law for all bonds and notes of companies that are publicly offered, any debt securities we issue will be governed by a document called an &#8220;indenture.&#8221; We have summarized the general features of the debt securities to be governed by the indenture. The summary is not complete. An indenture is a contract between us and a financial institution acting as trustee on behalf of the holders of the debt securities and is subject to and governed by the Trust Indenture Act of 1939, as amended. The trustee has two main roles. First, the trustee can enforce holders&#8217; rights against us if we default. There are some limitations on the extent to which the trustee acts on holders&#8217; behalf, described in the second paragraph under &#8220;Description of Debt Securities &#8212; Events of Default.&#8221; Second, the trustee performs certain administrative duties, such as sending interest and principal payments to holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Because this section is a summary, it does not describe every aspect of any debt securities we may issue or the indenture governing any such debt securities. Particular terms of any debt securities we offer will be described in the prospectus supplement relating to such debt securities, and we urge you to read the applicable executed indenture, which will be filed with the SEC at the time of any offering of debt securities, because it, and not this description, will define the rights of holders of such debt securities.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">A prospectus supplement will describe the particular terms of any series of debt securities we may issue, including some or all of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the designation, ranking, or title of the series of debt securities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the total principal amount of the series of debt securities, the denominations in which the offered debt securities will be issued and whether the offering may be reopened for additional securities of that series and on what terms;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the percentage of the principal amount at which the series of debt securities will be offered;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the date or dates on which principal will be payable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the rate or rates (which may be either fixed or variable) and/or the method of determining such rate or rates of interest, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the date or dates from which any interest will accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms for redemption, extension or early repayment, if any;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the currencies in which the series of debt securities are issued and payable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the amount of payments of principal, interest or premium, if any, on a series of debt securities will be determined with reference to an index, formula or other method and how these amounts will be determined;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the place or places of payment, transfer, conversion and/or exchange of the debt securities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the provision for any sinking fund;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any restrictive covenants;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">events of default and any addition to, deletion of or change to the events of default;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the series of debt securities are issuable in certificated form;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any provisions for legal defeasance or covenant defeasance;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether and under what circumstances we will pay additional amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities rather than pay the additional amounts (and the terms of this option);</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any provisions for convertibility or exchangeability of the debt securities into or for any other securities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the debt securities are subject to subordination and the terms of such subordination;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any listing of the debt securities on any securities exchange;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, a discussion of material U.S. Federal income tax considerations, including those related to original issue discount, if applicable; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other material terms.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The debt securities may be secured or unsecured obligations. Unless the prospectus supplement states otherwise, principal, interest and premium, if any, will be paid by us in immediately available funds.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>General</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The indenture may provide that any debt securities proposed to be sold under this prospectus and the applicable prospectus supplement relating to such debt securities (&#8220;offered debt securities&#8221;) and any debt securities issuable upon conversion or exchange of other offered securities (&#8220;underlying debt securities&#8221;) may be issued under the indenture in one or more series.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For purposes of this prospectus, any reference to the payment of principal of, or interest or premium, if any, on, debt securities will include additional amounts if required by the terms of the debt securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Debt securities issued under an indenture, when a single trustee is acting for all debt securities issued under the indenture, are called the &#8220;indenture securities.&#8221; The indenture may also provide that there may be more than one trustee thereunder, each with respect to one or more different series of securities issued thereunder. See &#8220;Description of Debt Securities &#8212; Resignation of Trustee&#8221; below. At a time when two or more trustees are acting under an indenture, each with respect to only certain series, the term &#8220;indenture securities&#8221; means the one or more series of debt securities with respect to which each respective trustee is acting. In the event that there is more than one trustee under an indenture, the powers and trust obligations of each trustee described in this prospectus will extend only to the one or more series of indenture securities for which it is trustee. If two or more trustees are acting under an indenture, then the indenture securities for which each trustee is acting would be treated as if issued under separate indentures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We refer you to the applicable prospectus supplement relating to any debt securities we may issue from time to time for information with respect to any deletions from, modifications of or additions to the Events of Default or covenants that are described below, including any addition of a covenant or other provision providing event risk or similar protection, that will be applicable with respect to such debt securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have the ability to issue indenture securities with terms different from those of indenture securities previously issued and, without the consent of the holders thereof, to reopen a previous issue of a series of indenture securities and issue additional indenture securities of that series unless the reopening was restricted when that series was created.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Conversion and Exchange</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If any debt securities are convertible into or exchangeable for other securities, the related prospectus supplement will explain the terms and conditions of the conversion or exchange, including the conversion price or exchange ratio (or the calculation method), the conversion or exchange period (or how the period will be determined), if conversion or exchange will be mandatory or at the option of the holder or us, provisions for adjusting the conversion price or the exchange ratio and provisions affecting conversion or exchange in the event of the redemption of the underlying debt securities. These terms may also include provisions under which the number or amount of other securities to be received by the holders of the debt securities upon conversion or exchange would be calculated according to the market price of the other securities as of a time stated in the prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Payment and Paying Agents</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will pay interest to the person listed in the applicable trustee&#8217;s records as the owner of the debt security at the close of business on a particular day in advance of each due date for interest, even if that person no longer owns the debt security on the interest due date. That day, often approximately two weeks in advance of the interest due date, is called the &#8220;record date.&#8221; Because we will pay all the interest for an interest period to the holders on the record date, holders buying and selling debt securities must work out between themselves the appropriate purchase price. The most common manner is to adjust the sales price of the debt securities to prorate interest fairly between buyer and seller based on their respective ownership periods within the particular interest period. This prorated interest amount is called &#8220;accrued interest.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Events of Default</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Holders of debt securities of any series will have rights if an Event of Default occurs in respect of the debt securities of such series and is not cured, as described later in this subsection. The term &#8220;Event of Default&#8221; in respect of the debt securities of any series means any of the following:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we do not pay the principal of, or any premium on, a debt security of the series on its due date;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we do not pay interest on a debt security of the series within 30 days of its due date;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we remain in breach of a covenant in respect of debt securities of the series for 90 days after we receive a written notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of debt securities of the series;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur; and</p>
			</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other Event of Default occurs in respect of debt securities of the series described in the prospectus supplement.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">An Event of Default for a particular series of debt securities does not necessarily constitute an Event of Default for any other series of debt securities issued under the same or any other indenture. The trustee may withhold notice to the holders of debt securities of any default, except in the payment of principal, premium or interest, if it considers the withholding of notice to be in the best interests of the holders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Remedies if an Event of Default Occurs</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If an Event of Default has occurred and has not been cured or waived (other than in the case of a bankruptcy proceeding), the trustee or the holders of not less than 25% in principal amount of the debt securities of the affected series may declare the entire principal amount of all the debt securities of that series to be due and immediately payable. This is called a declaration of acceleration of maturity. A declaration of acceleration of maturity may be canceled by the holders of a majority in principal amount of the debt securities of the affected series if the default is cured or waived and certain other conditions are satisfied.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Except in cases of default, where the trustee has some special duties, the trustee typically is not required to take any action under an indenture at the request of any holders unless the holders offer the trustee reasonable protection from expenses and liability (called an &#8220;indemnity&#8221;). If reasonable indemnity is provided, the holders of a majority in principal amount of the outstanding debt securities of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. The trustee may refuse to follow those directions in certain circumstances.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Before a holder is allowed to bypass the trustee and bring its own lawsuit or other formal legal action or take other steps to enforce its rights or protect its interests relating to any debt securities, the following must occur:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the holder must give the trustee written notice that an Event of Default has occurred and remains uncured;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action because of the default and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the holders of a majority in principal amount of the debt securities must not have given the trustee a direction inconsistent with the above notice during that 60-day period.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">However, a holder is entitled at any time to bring a lawsuit for the payment of money due on its debt securities on or after the due date. Each year, we will furnish to each trustee a written statement of certain of our officers certifying that to their knowledge we are in compliance with the indenture and the debt securities, or else specifying any default.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Waiver of Default</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The holders of a majority in principal amount of the relevant series of debt securities may waive a default for all such series of debt securities. If this happens, the default will be treated as if it had not occurred. No one can waive a payment default on a holder&#8217;s debt security, however, without the holder&#8217;s approval.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">14</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Merger or Consolidation</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Under the terms of an indenture, we may be permitted to consolidate or merge with another entity. We may also be permitted to sell all or substantially all of our assets to another entity. However, typically we may not take any of these actions unless all the following conditions are met:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if we do not survive such transaction or we convey, transfer or lease our properties and assets substantially as an entirety, the acquiring company must be a corporation, limited liability company, partnership or trust, or other corporate form, organized under the laws of any state of the United States or the District of Columbia, and such company must agree to be legally responsible for our debt securities, and, if not already subject to the jurisdiction of any state of the United States or the District of Columbia, the new company must submit to such jurisdiction for all purposes with respect to the debt securities and appoint an agent for service of process;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">alternatively, we must be the surviving company;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">immediately after the transaction no Event of Default will exist;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we must deliver certain certificates and documents to the trustee; and</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we must satisfy any other requirements specified in the prospectus supplement relating to a particular series of debt securities.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Modification or Waiver</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There are three types of changes we may make to an indenture and the debt securities issued thereunder.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><b><i>Changes Requiring Approval</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">First, there are changes that we cannot make to debt securities without specific approval of all of the holders. The following is a list of the types of changes that may require specific approval:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">change the stated maturity of the principal of or rate of interest on a debt security;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce any amounts due on a debt security;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the amount of principal payable upon acceleration of the maturity of a security following a default;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at any time after a change of control has occurred, reduce any premium payable upon a change of control;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">change the place or currency of payment on a debt security (except as otherwise described in the prospectus or prospectus supplement);</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">impair the right of holders to sue for payment;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">adversely affect any right to convert or exchange a debt security in accordance with its terms;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the percentage of holders of debt securities whose consent is needed to modify or amend the indenture;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the percentage of holders of debt securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to the quorum or voting requirements or the waiver of certain covenants; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">change any obligation we have to pay additional amounts.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-align: center;">15</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><b><i>Changes Not Requiring Approval</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The second type of change does not require any vote by the holders of the debt securities. This type is limited to clarifications and certain other changes that would not adversely affect holders of the outstanding debt securities in any material respect, including the addition of covenants. We also do not need any approval to make any change that affects only debt securities to be issued under the indenture after the change takes effect.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><b><i>Changes Requiring Majority Approval</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any other change to the indenture and the debt securities may require the following approval:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if the change affects only one series of debt securities, it must be approved by the holders of a majority in principal amount of that series; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if the change affects more than one series of debt securities issued under the same indenture, it must be approved by the holders of a majority in principal amount of all of the series affected by the change, with all affected series voting together as one class for this purpose.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">The holders of a majority in principal amount of all of the series of debt securities issued under an indenture, voting together as one class for this purpose, may waive our compliance obligations with respect to some of our covenants in that indenture. However, we cannot obtain a waiver of a payment default or of any of the matters covered by the bullet points included above under &#8220;Description of Debt Securities &#8212; Modification or Waiver &#8212; Changes Requiring Approval.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">16</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Defeasance</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following provisions will be applicable to each series of debt securities unless we state in the applicable prospectus supplement that the provisions of covenant defeasance and legal defeasance will not be applicable to that series.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Covenant Defeasance</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We can make the deposit described below and be released from some of the restrictive covenants in the indenture under which the particular series was issued. This is called &#8220;covenant defeasance.&#8221; In that event, the holders would lose the protection of those restrictive covenants but would gain the protection of having money and government securities set aside in trust to repay holders&#8217; debt securities. If applicable, a holder also would be released from the subordination provisions described under &#8220;Description of Debt Securities &#8212; Indenture Provisions &#8212; Subordination&#8221; below. In order to achieve covenant defeasance, we must do the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be required to deliver to the trustee a legal opinion of our counsel confirming that, under current U.S. Federal income tax law, we may make the above deposit without causing the beneficial owners of the debt securities to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We must deliver to the trustee certain documentation stating that all conditions precedent to covenant defeasance have been complied with.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we accomplish covenant defeasance, holders can still look to us for repayment of the debt securities if there were a shortfall in the trust deposit or the trustee is prevented from making payment. In fact, if one of the remaining Events of Default occurred (such as our bankruptcy) and the debt securities became immediately due and payable, there might be a shortfall. Depending on the event causing the default, holders may not be able to obtain payment of the shortfall.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Legal Defeasance</i></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">As described below, we can legally release ourselves from all payment and other obligations on the debt securities of a particular series (called &#8220;legal defeasance&#8221;), (1) if there is a change in U.S. Federal tax law that allows us to effect the release without causing the holders to be taxed any differently than if the release had not occurred, and (2) if we put in place the following other arrangements for holders to be repaid:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We may be required to deliver to the trustee a legal opinion confirming that there has been a change in current U.S. Federal tax law or an Internal Revenue Service ruling that allows us to make the above deposit without causing the beneficial owners of the debt securities to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity. Under current U.S. Federal tax law, the deposit and our legal release from the debt securities would be treated as though we paid each beneficial owner its share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for its debt securities and beneficial owners would recognize gain or loss on the debt securities at the time of the deposit; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We must deliver to the trustee a legal opinion and officers&#8217;&#160;certificate stating that all conditions precedent to legal defeasance have been complied with.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">17</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If we ever did accomplish legal defeasance, as described above, holders would have to rely solely on the trust deposit for repayment of the debt securities. Holders could not look to us for repayment in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if we ever became bankrupt or insolvent. If applicable, holders would also be released from the subordination provisions described later under &#8220;Description of Debt Securities &#8212; Indenture Provisions &#8212; Subordination.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Resignation of Trustee</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each trustee may resign or be removed with respect to one or more series of indenture securities provided that a successor trustee is appointed to act with respect to such series. In the event that two or more persons are acting as trustee with respect to different series of indenture securities under the indenture, each of the trustees will be a trustee of a trust separate and apart from the trust administered by any other trustee.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Indenture Provisions </b>&#8212;<b> Subordination</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon any distribution of our assets upon our dissolution, winding up, liquidation or reorganization, the payment of the principal of (and premium, if any) and interest on any indenture securities denominated as subordinated debt securities is to be subordinated to the extent provided in the indenture in right of payment to the prior payment in full of all Senior Indebtedness (defined below), but our obligation to holders to make payment of the principal of (and premium, if any) and interest on such subordinated debt securities will not otherwise be affected. In addition, no payment on account of principal (or premium, if any), interest or sinking fund, if any, may be made on such subordinated debt securities at any time unless full payment of all amounts due in respect of the principal (and premium, if any), interest and sinking fund, if any, on Senior Indebtedness has been made or duly provided for in money or money&#8217;s worth.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the event that, notwithstanding the foregoing, any payment from us is received by the trustee in respect of subordinated debt securities or by the holders of any of such subordinated debt securities before all Senior Indebtedness is paid in full, the payment or distribution must be paid over to the holders of the Senior Indebtedness or on their behalf for application to the payment of all the Senior Indebtedness remaining unpaid until all the Senior Indebtedness has been paid in full, after giving effect to any concurrent payment or distribution to the holders of the Senior Indebtedness. Subject to the payment in full of all Senior Indebtedness, the holders of such subordinated debt securities will be subrogated to the rights of the holders of the Senior Indebtedness to the extent of payments made to the holders of the Senior Indebtedness out of the distributive share of such subordinated debt securities.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By reason of this subordination, in the event of a distribution of our assets upon our insolvency, certain of our senior creditors may recover more, ratably, than holders of any subordinated debt securities. The related indenture will provide that these subordination provisions will not apply to money and securities held in trust under the defeasance provisions of the indenture.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Senior Indebtedness&#8221; will be defined in an applicable indenture as the principal of (and premium, if any) and unpaid interest on:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed (other than indenture securities issued under the indenture and denominated as subordinated debt securities), unless in the instrument creating or evidencing the same or under which the same is outstanding it is provided that this indebtedness is not senior or prior in right of payment to the subordinated debt securities; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">renewals, extensions, modifications and refinancings of any of such indebtedness.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The prospectus supplement accompanying any series of indenture securities denominated as subordinated debt securities will set forth the approximate amount of our Senior Indebtedness outstanding as of a recent date.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Trustee</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We intend to name the indenture trustee for each series of indenture securities in the related prospectus supplement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Certain Considerations Relating to Foreign Currencies</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Debt securities denominated or payable in foreign currencies may entail significant risks. These risks include the possibility of significant fluctuations in the foreign currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved and will be more fully described in the applicable prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">18</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="RIGHTS" href="#"></a>DESCRIPTION OF RIGHTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a general description of the terms of the rights we may issue from time to time unless we provide otherwise in the applicable prospectus supplement. Particular terms of any rights we offer will be described in the prospectus supplement relating to such rights.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We may issue rights to purchase common stock, preferred stock, debt securities or units. Rights may be issued independently or together with other securities and may or may not be transferable by the person purchasing or receiving the rights. In connection with any rights offering to our stockholders, we may enter into a standby underwriting, backstop or other arrangement with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered securities remaining unsubscribed for after such rights offering. In connection with a rights offering to our stockholders, we would distribute certificates evidencing the rights and a prospectus supplement to our stockholders on or about the record date that we set for receiving rights in such rights offering.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The applicable prospectus supplement will describe the following terms of any rights we may issue, including some or all of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the title and aggregate number of the rights;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the subscription price or a formula for the determination of the subscription price for the rights and the currency or currencies in which the subscription price may be payable;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the designation and terms of the securities with which the rights are issued and the number of rights issued with each such security or each principal amount of such security;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the number or a formula for the determination of the number of the rights issued to each stockholder;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the extent to which the rights are transferable;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">in the case of rights to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one right;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">in the case of rights to purchase common stock or preferred stock, the type of stock and number of shares of stock purchasable upon exercise of one right;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the date on which the right to exercise the rights will commence, and the date on which the rights will expire (subject to any extension);</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the minimum or maximum amount of the rights that may be exercised at any one time;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the procedures for adjusting the subscription price and number of shares of common stock or preferred stock purchasable upon the exercise of each right upon the occurrence of certain events, including stock splits, reverse stock splits, combinations, subdivisions or reclassifications of common stock or preferred stock;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the effect on the rights of any merger, consolidation, sale or other disposition of our business;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms of any rights to redeem or call the rights;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">information with respect to book-entry procedures, if any;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms of the securities issuable upon exercise of the rights;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, the material terms of any standby underwriting, backstop or other purchase arrangement that we may enter into in connection with the rights offering;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if applicable, a discussion of material U.S. Federal income tax considerations; and</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto; vertical-align: top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other terms of the rights, including terms, procedures and limitations relating to the exchange and exercise of the rights.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exercise of Rights</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each right will entitle the holder to purchase for cash or other consideration such shares of stock or principal amount of securities at the subscription price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised as set forth in the applicable prospectus supplement beginning on the date specified therein and continuing until the close of business on the expiration date set forth in the prospectus supplement relating to the rights offered thereby. After the close of business on the expiration date, unexercised rights will become void.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Upon receipt of payment and a subscription certificate properly completed and duly executed at the corporate trust office of the subscription agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the securities purchasable upon such exercise. If less than all of the rights represented by such subscription certificate are exercised, a new subscription certificate will be issued for the remaining rights. If we so indicate in the applicable prospectus supplement, holders of the rights may surrender securities as all or part of the exercise price for rights.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may determine to offer any unsubscribed offered securities directly to stockholders, persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting, backstop or other arrangements, as set forth in the applicable prospectus supplement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Prior to exercising their rights, holders of rights will not have any of the rights of holders of the securities purchasable upon subscription, including, in the case of rights to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise any voting rights or, in the case of rights to purchase debt securities, the right to receive principal, premium, if any, or interest payments, on the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">19</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="UNITS" href="#"></a>DESCRIPTION OF UNITS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We may issue units comprising one or more securities described in this prospectus in any combination. The following description sets forth certain general terms and provisions of the units that we may offer pursuant to this prospectus. The particular terms of the units and the extent, if any, to which the general terms and provisions may apply to the units so offered will be described in the applicable prospectus supplement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each unit will be issued so that the holder of the unit also is the holder of each security included in the unit. Thus, the unit will have the rights and obligations of a holder of each included security. Units will be issued pursuant to the terms of a unit agreement, which may provide that the securities included in the unit may not be held or transferred separately at any time or at any time before a specified date. A copy of the forms of the unit agreement and the unit certificate relating to any particular issue of units will be filed with the SEC each time we issue units, and you should read those documents for provisions that may be important to you. For more information on how you can obtain copies of the forms of the unit agreement and the related unit certificate, see &#8220;Where You Can Find More Information.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The prospectus supplement relating to any particular issuance of units will describe the terms of those units, including, to the extent applicable, the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the designation and terms of the units and the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any provision for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the units will be issued in fully registered or global form.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">20</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%; margin: 0pt;">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="DISTRIBUTION" href="#"></a>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may sell the securities offered by this prospectus in any one or more of the following ways from time to time:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to or through one or more underwriters, brokers or dealers;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">through agents to investors or the public;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">in short or long transactions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">through put or call option transactions relating to our common stock;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">directly to agents or other purchasers;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">in &#8220;at the market offerings&#8221;&#160;within the meaning of Rule 415(a)(4) of the Securities Act of 1933, as amended, or the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">though a combination of any such methods of sale; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">through any other method described in the applicable prospectus supplement.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing securityholders. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the applicable prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus supplement relating to such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The distribution of the securities may be effected from time to time in one or more transactions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at a fixed price, or prices, which may be changed from time to time;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at market prices prevailing at the time of sale;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at prices related to such prevailing market prices; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at negotiated prices.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The applicable prospectus supplement will set forth the terms of the offering and the method of distribution and will identify any firms acting as underwriters, dealers or agents in connection with the offering, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the terms of the offering;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the names of any underwriters, dealers or agents;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the name or names of any managing underwriter or underwriters;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the purchase price of the securities and the proceeds to us from the sale;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any over-allotment options under which the underwriters may purchase additional shares of common stock from us;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any underwriting discounts, concessions, commissions or agency fees and other items constituting compensation to underwriters, dealers or agents;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any delayed delivery arrangements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any public offering price;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any discounts or concessions allowed or re-allowed or paid by underwriters or dealers to other dealers; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any securities exchange or market on which the common stock offered in the prospectus supplement may be listed.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If we use underwriters for a sale of securities, the underwriters will acquire the securities for their own account for resale to the public, either on a firm commitment basis or a best efforts basis. The underwriters may resell the securities in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may offer the securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. If an underwriter or underwriters are used in the sale of securities hereunder, an underwriting agreement will be executed with the underwriter or underwriters at the time an agreement for sale is reached. Unless we inform you otherwise in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions. We may change from time to time any public offering price and any discounts or concessions the underwriters allow or pay to dealers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During and after an offering through underwriters, the underwriters may purchase and sell the securities in the open market. These transactions may include overallotment and stabilizing transactions and purchases to cover syndicate short positions created in connection with the offering. The underwriters may also impose a penalty bid, which means that selling concessions allowed to syndicate members or other broker-dealers for the offered securities sold for their account may be reclaimed by the syndicate if the offered securities are repurchased by the syndicate in stabilizing or covering transactions. These activities may stabilize, maintain or otherwise affect the market price of the offered securities, which may be higher than the price that might otherwise prevail in the open market. If commenced, the underwriters may discontinue these activities at any time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree otherwise or the securities are sold by us to an underwriter in a firm commitment underwritten offering. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Some or all of the securities that we offer though this prospectus may be new issues of securities with no established trading market. Any underwriters to whom we sell our securities for public offering and sale may make a market in those securities, but they will not be obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities that we offer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">If dealers are used for the sale of securities, we, or an underwriter, will sell the securities to them as principals. The dealers may then resell those securities to the public at varying prices determined by the dealers at the time of resale. We will include in the applicable prospectus supplement the names of the dealers and the terms of the transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may also sell the securities through agents designated from time to time. In the applicable prospectus supplement, we will name any agent involved in the offer or sale of the offered securities, and we will describe any commissions payable to the agent. Unless we inform you otherwise in the applicable prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may sell the securities directly in transactions not involving underwriters, dealers or agents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities. We will describe the terms of any such sales in the prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Underwriters, dealers and agents that participate in the distribution of the securities may be underwriters as defined in the applicable securities laws and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts and commissions under the applicable securities laws. We will identify in the applicable prospectus supplement any underwriters, dealers or agents and will describe their compensation. We may have agreements with the underwriters, dealers and agents to indemnify them against specified civil liabilities, including liabilities under the applicable securities laws.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Underwriters, dealers and agents may engage in transactions with or perform services for us in the ordinary course of&#160;their businesses for which they may receive customary fees and reimbursement of expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may use underwriters with whom we have a material relationship. We will describe the nature of such relationship in the applicable prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under the securities laws of some states, the securities offered by this prospectus may be sold in those states only through registered or licensed brokers or dealers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We may enter into hedging transactions with broker-dealers and the broker-dealers may engage in short sales of the securities in the course of hedging the positions they assume with us, including, without limitation, in connection with distributions of the securities by those broker-dealers. We may enter into option or other transactions with broker-dealers that involve the delivery of the securities offered hereby to the broker-dealers, who may then resell or otherwise transfer those securities. We may also loan or pledge the securities offered hereby to a broker-dealer and the broker-dealer may sell the securities offered hereby so loaned or upon a default may sell or otherwise transfer the pledged securities offered hereby.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">22</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="LEGAL_MATTERS" href="#"></a>LEGAL MATTERS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The validity of the securities being offered hereby will be passed upon for us by Sidley Austin LLP, New York, New York.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">23</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="EXPERTS1" href="#"></a>EXPERTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements of Pyxis Oncology, Inc. appearing in Pyxis Oncology, Inc.&#8217;s Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst &amp; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">24</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="WHERE_YOU_CAN_FIND" href="#"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to the securities offered by this prospectus and any applicable prospectus supplement. This prospectus and any applicable prospectus supplement do not contain all of the information set forth in the registration statement and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus and any applicable prospectus supplement, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus and any applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&#8217;s website at http://www.sec.gov.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at http://www.sec.gov. We also make these documents available on our website at <i>www.pyxisoncology.com</i>. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus or any prospectus supplement, and you should not consider it part of this prospectus or any prospectus supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">25</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="REFERENCE" href="#"></a>INFORMATION INCORPORATED BY REFERENCE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">SEC rules permit us to incorporate information by reference in this prospectus and any applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and any applicable prospectus supplement, except for information superseded by information contained in this prospectus or any applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and any applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (Commission File No. 001-40881), other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Annual Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025040771/pyxs-20241231.htm" style="-sec-extract:exhibit;">Form 10-K</a> for the year ended December 31, 2024, filed with the SEC on March 18, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information contained in our definitive proxy statement on <a href="http://www.sec.gov/Archives/edgar/data/1782223/000095017025059573/2025_pyxs-14a.htm" style="-sec-extract:exhibit;">Schedule 14A</a> for our 2025 annual meeting of stockholders filed with the SEC on April 29, 2025, to the extent incorporated by reference in Part III of the Form 10-K;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025071996/pyxs-20250331.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended March 31, 2025, filed with the SEC on May 15, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025108906/pyxs-20250630.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended June 30, 2025, filed with the SEC on August 14, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000119312525261696/pyxs-20250930.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended September 30, 2025, filed with the SEC on November 3, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Current Reports on Form 8-K, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025012846/pyxs-20250204.htm" style="-sec-extract:exhibit;">February 4, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025027330/pyxs-20250225.htm" style="-sec-extract:exhibit;">February 26, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025040767/pyxs-20250318.htm" style="-sec-extract:exhibit;">March 18, 2025</a> (Item 5.02 only), <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025087907/pyxs-20250618.htm" style="-sec-extract:exhibit;">June 18, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025093456/pyxs-20250701.htm" style="-sec-extract:exhibit;">July 3, 2025</a> and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025101618/pyxs-20250804.htm" style="-sec-extract:exhibit;">August 4, 2025</a>; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The description of our common stock contained in our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1782223/000119312521292187/d223177d8a12b.htm" style="-sec-extract:exhibit;">Form 8-A</a>, filed with the SEC on October 5, 2021, and any other amendment or report filed for the purpose of updating such description.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or any applicable prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">You can obtain any of the filings incorporated by reference into this prospectus or any applicable prospectus supplement through us or from the SEC through the SEC&#8217;s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus or any applicable prospectus supplement. Prospective investors may obtain documents incorporated by reference in this prospectus or any applicable prospectus supplement by requesting them in writing or by telephone from us at our executive offices at:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">321 Harrison Avenue</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Boston, Massachusetts 02118</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(617) 453-3596</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our reports and documents incorporated by reference herein may also be found in the &#8220;Investors&#8221; section of our website at www.pyxisoncology.com. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under &#8220;Incorporation of Certain Documents by Reference&#8221;) is not incorporated by reference into this prospectus or any applicable prospectus supplement and you should not consider it a part of this prospectus, any applicable prospectus supplement, or the registration statement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">26</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="color:#ff0000;">The information in this prospectus is not complete and may be changed. We may not sell these securities or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting offers to buy these securities in any state or jurisdiction where such offer or sale is not permitted.</span></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#ff0000;"><b>SUBJECT TO COMPLETION, DATED NOVEMBER 26, 2025</b></span></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Up to $150,000,000</b></p>

<p style="font-family: Times New Roman; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="pyxislogo.jpg" src="pyxislogo.jpg"/></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Leerink Partners LLC (&#8220;Leerink Partners&#8221;) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time through Leerink&#160;Partners acting as our agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our common stock is listed on The NASDAQ Global Select Market under the symbol &#8220;PYXS.&#8221; On November 25, 2025, the last reported sale price of our common stock on The NASDAQ Global Select Market was $5.34 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sales of our common stock, if any, under this prospectus will be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Leerink Partners is not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Leerink Partners and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The compensation to Leerink Partners for sales of common stock sold pursuant to the Sales Agreement will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, Leerink Partners will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Leerink Partners will be deemed to be underwriting commissions or discounts. See &#8220;Plan of Distribution&#8221; beginning on page S-11 for additional information regarding the compensation to be paid to Leerink Partners. We have also agreed to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; under federal securities laws and as such, have elected to comply with reduced public company reporting requirements for this prospectus and the documents incorporated by reference herein and may elect to comply with reduced public company reporting requirements in future filings. See &#8220;Summary&#8212;Implications of Being an Emerging Growth Company and Smaller Reporting Company.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our business and an investment in our common stock involve significant risks. These risks are described under the caption </b>&#8220;<a href="#RISK" style="-sec-extract:exhibit;"><b><span style="text-decoration: underline; ">Risk Factors</span></b></a>&#8221;<b> beginning on page S-6 of this prospectus and in the documents incorporated by reference into this prospectus.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Leerink Partners</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#about" style="-sec-extract:exhibit;">ABOUT THIS PROSPECTUS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#about">S-1</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#MARKET" style="-sec-extract:exhibit;">MARKET DATA</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#MARKET">S-2</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PROSPECTUS" style="-sec-extract:exhibit;">PROSPECTUS SUMMARY</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PROSPECTUS">S-3</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Offering" style="-sec-extract:exhibit;">THE OFFERING</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#Offering">S-5</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#RISK" style="-sec-extract:exhibit;">RISK FACTORS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#RISK">S-6</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#SPECIAL" style="-sec-extract:exhibit;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#SPECIAL">S-9</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#USE" style="-sec-extract:exhibit;">USE OF PROCEEDS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#USE">S-10</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#PLAN" style="-sec-extract:exhibit;">PLAN OF DISTRIBUTION</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#PLAN">S-11</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#LEGAL" style="-sec-extract:exhibit;">LEGAL MATTERS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#LEGAL">S-12</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#EXPERTS" style="-sec-extract:exhibit;">EXPERTS</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#EXPERTS">S-12</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#WHERE" style="-sec-extract:exhibit;">WHERE YOU CAN FIND MORE INFORMATION</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#WHERE">S-12</a></p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="11" style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#INCORPORATION" style="-sec-extract:exhibit;">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></p>
			</td>
			<td style="vertical-align:bottom;width:11.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#INCORPORATION">S-13</a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="about" href="#"></a>ABOUT THIS PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus is part of a shelf registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $150,000,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of the offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1) this at-the-market sales agreement prospectus, which describes the specific details regarding this offering; and (2) the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If information in this at-the-market sales agreement prospectus is inconsistent with the accompanying base prospectus, you should rely on this prospectus. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. We have not, and Leerink Partners has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and Leerink Partners is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus, the documents incorporated by reference into this prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this prospectus entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus outside the United States. This prospectus does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In this prospectus, the terms &#8220;Pyxis,&#8221; the &#8220;Company,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;we,&#8221; as used in this prospectus, refer to Pyxis Oncology, Inc., a Delaware corporation, and its subsidiaries unless we state otherwise or the context indicates otherwise.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus are the property of their respective owners.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="MARKET" href="#"></a>MARKET DATA</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus and the documents incorporated by reference herein contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus and the documents incorporated by reference herein, their estimates, in particular, as they relate to projections, involve numerous assumptions and limitations, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and &#8220;Forward-Looking Statements&#8221; and elsewhere in this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="PROSPECTUS" href="#"></a>PROSPECTUS SUMMARY</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the securities covered by this prospectus. For a more complete understanding of Pyxis and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information referred to under the heading </i>&#8220;<i>Risk Factors</i>&#8221;<i> in this prospectus beginning on page S-6.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our product candidate, micvotabart pelidotin (MICVO), formerly referred to as PYX-201, is an investigational novel antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix (ECM). The tumor ECM is a complex network of fibrous proteins and molecules with unique composition that play an important role in cell development and tumor growth and in some instances, in supporting metastasis. The fibronectin strands within the ECM give the tumor shape and support the clustering of tumor cells.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Implications of Being an Emerging Growth Company and Smaller Reporting Company</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Jumpstart Our Business Startups Act (the JOBS Act) was enacted in April 2012 with the intention of encouraging capital formation in the United States and reducing the regulatory burden on newly public companies that qualify as emerging growth companies. We are an &#8220;emerging growth company&#8221; within the meaning of the JOBS Act. We will cease to be an emerging growth company upon the earliest of (1) the end of the fiscal year following the fifth anniversary of our initial public offering; (2) the last day of the fiscal year during which our annual gross revenues are $1.235 billion or more; (3) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt securities; and (4) the end of any fiscal year in which the market value of our common stock held by non-affiliates exceeded $700.0 million as of the end of the second quarter of that fiscal year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements in our Annual Report on Form 10-K, and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stocks held by non-affiliates exceeds $250 million as of the end of that year&#8217;s second fiscal quarter and our annual revenue exceeds $100 million during such completed fiscal year, or (ii) the market value of our common stock held by non-affiliates exceeds $700 million, regardless of our annual revenue, as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our consolidated financial statements with other public companies difficult or impossible.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Information</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We were incorporated in the state of Delaware on June 11, 2018 and launched with our first employee and Series A funding in July 2019. Our principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts 02118, and our telephone number is (617) 453-3596.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our website address is www.pyxisoncology.com. The information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="Offering" href="#"></a>The Offering</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock offered by us</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Shares having an aggregate offering price of up to $150,000,000</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common stock to be outstanding after this offering</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">Up to 91,004,514 shares, assuming the sale of $150,000,000 of shares at a sales price of $5.34 per share, which was the last reported sale price on The NASDAQ Global Select Market on November 25, 2025. The actual number of shares issued and outstanding will vary depending on the sales price under this offering.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Manner of offering</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">&#8220;At-the-market&#8221;&#160;offering that may be made from time to time through our sales agent, Leerink Partners. See &#8220;Plan of Distribution&#8221;&#160;on page S-11 of this prospectus.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Use of proceeds</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">Our management will retain broad discretion regarding the allocation and use of the net proceeds from this offering. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including for preclinical studies, clinical trials, the acquisition of product candidates or programs and the advancement of our product candidate and working capital. See &#8220;Use of Proceeds&#8221;&#160;on page S-10 of this prospectus.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NASDAQ Global Select Market symbol</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">&#8220;PYXS&#8221;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:20.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Risk factors</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 18pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221;&#160;beginning on page S-6 of this prospectus and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors that you should carefully consider before deciding to invest in shares of our common stock.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The number of shares of common stock shown above to be outstanding immediately following this offering is based on 62,149,664 shares outstanding, as of September 30, 2025 and excludes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">12,580,264 shares of common stock, with a weighted-average exercise price of $3.98 per share, issuable upon exercise of stock options outstanding as of September 30, 2025 under our equity incentive plans;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5,788,087 shares of common stock reserved for issuance pursuant to future awards under our equity incentive plans or our Employee Stock Purchase Plan as of September 30, 2025, plus any future increases in the number of shares of common stock reserved for issuance under our equity incentive plans or our Employee Stock Purchase Plan pursuant to provisions thereof that automatically increase the share reserve under the plan each year;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1,035,127 shares of common stock issuable upon vesting of restricted stock units outstanding as of September 30, 2025; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1,003,191 shares of common stock, with a weighted-average exercise price of $45.61 per share, issuable upon exercise of replacement warrants issued upon merger with Apexigen Inc., outstanding as of September 30, 2025</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus reflects and assumes no exercise of outstanding options or warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-5</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="RISK" href="#"></a>RISK FACTORS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Investing in our securities involves risk. You should carefully consider the specific risks discussed below, together with all the other information contained in the prospectus or incorporated by reference into this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the caption </i>&#8220;<i>Risk Factors</i>&#8221;<i> included in our Annual Report on Form 10-K for the year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q for the periods ended March 31, June 30 and September 20, 2025, and in subsequent filings, which are incorporated by reference into this prospectus. These risk factors may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our securities could decline and you might lose all or part of your investment.</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to This Offering</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have broad discretion in the use of the net proceeds from this offering.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways with which you may not agree. Accordingly, you will be relying on the judgment of our management with regard to the use of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the net proceeds will be invested or otherwise used in a way that does not yield a favorable, or any, return for the Company.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our stockholders may experience significant dilution as a result of future equity issuances and exercise of outstanding options.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In addition, we have a number of securities allowing the purchase of, our common stock. As of September 30, 2025, 5,788,087 shares of common stock were reserved for future issuance under our stock incentive plans. As of that date, there were also stock options to purchase 12,580,264 shares of our common stock, restricted stock units to purchase 1,800,089 shares of our common stock and warrants to purchase 1,003,191 shares of our common stock outstanding. The exercise of outstanding options and warrants having an exercise price per share that is less than the offering price per share in this offering will increase dilution to investors in this offering.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If you purchase the common stock, you may experience immediate dilution as a result of this offering.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Since the price per share of our common stock being offered may be higher than the net tangible book value per share of our common stock, which was $1.07 per share as of September 30, 2025, you may suffer immediate dilution in the net tangible book value of the common stock you purchase in this offering.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>It is not possible to predict the aggregate proceeds resulting from sales made under the Sales Agreement.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners at any time throughout the term of the Sales Agreement. The number of shares that are sold through Leerink Partners after delivering a placement notice will fluctuate based on a number of factors, including the market price of our common stock during the sales period, any limits we may set with Leerink Partners in any applicable placement notice and the demand for our common stock. Because the price per share of each share sold pursuant to the Sales Agreement will fluctuate over time, it is not currently possible to predict the aggregate proceeds to be raised in connection with sales under the Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-6</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The common stock offered hereby will be sold in </i></b>&#8220;<b><i>at-the-market offerings</i></b>&#8221;<b><i> and investors who buy shares at different times will likely pay different prices.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering. In addition, subject to the final determination by our board of directors or any restrictions we may place in any applicable placement notice, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The actual number of shares of common stock we will issue under the Sales Agreement in this offering, at any one time or in total, is uncertain.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to certain limitations in the Sales Agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Leerink Partners at any time throughout the term of the offering under this prospectus. The number of shares of common stock that are sold by Leerink Partners after delivering a placement notice will fluctuate based on the market price of the shares of common stock during the sales period and limits we set with Leerink Partners. Because the price per share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of common stock that will be ultimately issued or the gross proceeds to be raised in connection with those sales.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock in this offering.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell our common stock at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">results of our clinical trials, if any, of our product candidates, or those of our competitors or our existing or future collaborators;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of competitive products or technologies;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">actions taken by regulatory agencies with respect to our products, preclinical studies, clinical trials, manufacturing process or sales and marketing terms;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">developments concerning any future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">market conditions in the pharmaceutical and biotechnology sectors;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability or inability to raise additional capital and the terms on which we raise it;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the recruitment or departure of key personnel;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in the structure of healthcare payment systems;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our failure or the failure of our competitors to meet analysts&#8217;&#160;projections or guidance that we or our competitors may give to the market;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-7</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">announcement and expectation of additional financing efforts;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">speculation in the press or investment community;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">trading volume of our common stock;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">sales of our common stock by us, our insiders or our other stockholders;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">expiration of market stand-off or lock-up agreements;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the concentrated ownership of our common stock;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in accounting principles;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">terrorist acts, acts of war or periods of widespread civil unrest;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">general economic, industry and market conditions; and</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the other factors described in the &#8220;Risk Factors&#8221;&#160;sections of our Form 10-K for the year ended December 31, 2024 and in our Quarterly Reports on Form 10-Q for the periods ended March 31, June 30 and September 30, 2025, and in subsequent filings, which are incorporated by reference into this prospectus.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">S-8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="SPECIAL" href="#"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">This prospectus includes and incorporates by reference &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this prospectus. Unless the context requires otherwise references in this prospectus to &#8220;Pyxis Oncology,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Pyxis Oncology, Inc. and its subsidiaries. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;to be,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements about:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to develop and advance our current product candidate and program, and to successfully initiate and complete clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the ability of our clinical trials to demonstrate the safety, purity and potency of our product candidate and other positive results;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the size of the market opportunity for our product candidate, including our estimates of the number of patients who suffer from the cancers we are targeting;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our manufacturing, commercialization and marketing capabilities and strategy;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the timing or likelihood of regulatory filings and approvals for our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory developments in the United States and other foreign jurisdictions;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our expectations and plans to obtain funding for our operations, including from our existing and potential future collaboration and licensing agreements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to receive milestone or royalty payments under existing or future agreements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our continued reliance on third parties to manufacture our product candidate for clinical studies, and to conduct clinical trials and manufacture our product candidate for such clinical trials; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In addition, statements such as &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus and, although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events or otherwise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein. Any forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This prospectus and the documents incorporated by reference, may also contain estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-9</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="USE" href="#"></a>USE OF PROCEEDS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We may issue and sell shares of our common stock having an aggregate sales proceeds of up to $150,000,000 from time to time. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under, or fully utilize, the Sales Agreement with Leerink Partners as a source of financing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including for preclinical studies, clinical trials, the acquisition of product candidates or programs and the advancement of our product candidate and working capital. The amount and timing of these expenditures will depend on a number of factors, such as the timing, scope, progress and results of our research and development efforts, the timing and progress of any partnership efforts, and the competitive environment for our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering, if any. As a result, our management will have broad discretion regarding the timing and application of the net proceeds from this offering. Pending the application of the net proceeds, we intend to invest the net proceeds in short-term, investment grade, interest-bearing securities.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="PLAN" href="#"></a>PLAN OF DISTRIBUTION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have entered into a Sales Agreement with Leerink Partners under which we may issue and sell up to $150,000,000 of shares of our common stock from time to time through Leerink Partners as our sales agent. Sales of shares of our common stock, if any, will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, including sales made directly on or through The Nasdaq Global Select Market, on or through any other existing trading market for our common stock or to or through a market maker.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Leerink Partners will offer our common stock subject to the terms and conditions of the Sales Agreement on a daily basis or as otherwise agreed upon by us and Leerink Partners. We will designate the maximum number or amount of common stock to be sold through Leerink Partners on a daily basis or otherwise determine such maximum number or amount together with Leerink Partners. Subject to the terms and conditions of the Sales Agreement, Leerink Partners will use commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market to sell on our behalf all of the common stock requested to be sold by us. We may instruct Leerink Partners not to sell common stock if the sales cannot be effected at or above a minimum price designated by us in any such instruction. Leerink Partners or we may suspend the offering of our common stock being made through Leerink Partners under the Sales Agreement upon proper notice to the other party. Leerink Partners and we each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party&#8217;s sole discretion at any time. The offering of our common stock pursuant to the Sales Agreement will otherwise terminate upon the termination of the Sales Agreement as provided therein.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The compensation payable to Leerink Partners as sales agent will be an amount up to 3.0% of the gross proceeds of any shares of common stock sold through it pursuant to the Sales Agreement. We have also agreed to reimburse Leerink Partners for certain actual outside legal expenses incurred by Leerink Partners in connection with this offering, including Leerink Partners&#8217; counsel fees in an amount up to $75,000, plus an additional amount of up to $25,000 in connection with each diligence bring-down thereafter. We estimate that the total expenses of the offering payable by us, excluding commissions payable to Leerink Partners under the Sales Agreement, will be approximately $250,000.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory, or self- regulatory organization in connection with the sales of our common stock, will equal our net proceeds for the sale of such common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Leerink Partners will provide written confirmation to us no later than the next succeeding trading day on The Nasdaq Global Select Market after each day on which common stock is sold through it as sales agent under the Sales Agreement. Each confirmation will include the number or amount of shares of common stock sold through it as sales agent on that day, the volume weighted average price of the shares sold, the percentage of the daily trading volume and the net proceeds to us from such sales. We will report at least quarterly the number of shares of common stock sold through Leerink Partners under the Sales Agreement, the net proceeds to us and the compensation paid by us to Leerink Partners in connection with the sales of common stock during the relevant period. Settlement for sales of common stock will occur, unless the parties agree otherwise, on the second trading day following the date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In connection with the sale of our common stock on our behalf pursuant to the Sales Agreement, Leerink Partners may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation paid to Leerink Partners may be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution to Leerink Partners with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act. As sales agent, Leerink Partners will not engage in any transactions that stabilize our common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our common stock is listed and traded on The Nasdaq Global Select Market under the symbol &#8220;PYXS.&#8221; The transfer agent and registrar of our common stock is Broadridge Corporate Issuer Solutions, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Leerink Partners and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services they have received, and may in the future receive, customary fees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-11</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="LEGAL" href="#"></a>LEGAL MATTERS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain legal matters in connection with the securities offered hereby will be passed upon for us by Sidley Austin LLP, New York, New York. Leerink Partners is being represented in connection with this offering by Latham &amp; Watkins LLP, New York, New York.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="EXPERTS" href="#"></a>EXPERTS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements of Pyxis Oncology, Inc. appearing in Pyxis Oncology, Inc.&#8217;s Annual Report (Form 10-K) for the year ended December 31, 2024, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon the report of Ernst &amp; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="WHERE" href="#"></a>WHERE YOU CAN FIND MORE INFORMATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), with respect to the securities offered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement, of which it is a part, and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits via the SEC&#8217;s website at http://www.sec.gov.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We are subject to the information and periodic reporting requirements of the Exchange Act, and we file annual, quarterly and current reports, proxy statements and other documents with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC at http://www.sec.gov.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We also make these documents available on our website at www.pyxisoncology.com. Our website and the information contained or accessible through our website is not incorporated by reference in this prospectus, and you should not consider it part of this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-12</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="INCORPORATION" href="#"></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEC rules permit us to incorporate information by reference in this prospectus. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus, except for information superseded by information contained in this prospectus itself or in any subsequently filed incorporated document. This prospectus incorporates by reference the documents set forth below that we have previously filed with the SEC (Commission File No. 001-40881), other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Annual Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025040771/pyxs-20241231.htm" style="-sec-extract:exhibit;">Form 10-K</a> for the year ended December 31, 2024, filed with the SEC on March 18, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The information contained in our definitive proxy statement on <a href="http://www.sec.gov/Archives/edgar/data/1782223/000095017025059573/2025_pyxs-14a.htm" style="-sec-extract:exhibit;">Schedule 14A</a> for our 2025 annual meeting of stockholders filed with the SEC on April 29, 2025, to the extent incorporated by reference in Part III of the Form 10-K;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025071996/pyxs-20250331.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended March 31, 2025, filed with the SEC on May 15, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025108906/pyxs-20250630.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended June 30, 2025, filed with the SEC on August 14, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Quarterly Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000119312525261696/pyxs-20250930.htm" style="-sec-extract:exhibit;">Form 10-Q</a> for the period ended September 30, 2025, filed with the SEC on November 3, 2025;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Current Reports on Form 8-K, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025012846/pyxs-20250204.htm" style="-sec-extract:exhibit;">February 4, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025027330/pyxs-20250225.htm" style="-sec-extract:exhibit;">February 26, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025040767/pyxs-20250318.htm" style="-sec-extract:exhibit;">March 18, 2025</a> (Item 5.02 only), <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025087907/pyxs-20250618.htm" style="-sec-extract:exhibit;">June 18, 2025</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025093456/pyxs-20250701.htm" style="-sec-extract:exhibit;">July 3, 2025</a> and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001782223/000095017025101618/pyxs-20250804.htm" style="-sec-extract:exhibit;">August 4, 2025</a>; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 36pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The description of our common stock contained in our Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/1782223/000119312521292187/d223177d8a12b.htm" style="-sec-extract:exhibit;">Form 8-A</a>, filed with the SEC on October 5, 2021, and any other amendment or report filed for the purpose of updating such description.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus and any previously filed documents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC&#8217;s website at http://www.sec.gov. Upon request, we will provide, without charge, a copy of any or all of the reports and documents referred to above which have been incorporated by reference into this prospectus. Prospective investors may obtain documents incorporated by reference in this prospectus by requesting them in writing or by telephone from us at our executive offices at:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">321&#160;Harrison Avenue,</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Boston, Massachusetts 02118</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(617) 453-3596</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our reports and documents incorporated by reference herein may also be found in the &#8220;Investors&#8221; section of our website at www.pyxisoncology.com. The content of our website and any information that is linked to or accessible from our website (other than our filings with the SEC that are incorporated by reference, as set forth under &#8220;Incorporation of Certain Documents by Reference&#8221;) is not incorporated by reference into this prospectus and you should not consider it a part of this prospectus or the registration statement.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">S-13</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to $150,000,000</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="pyxislogo.jpg" src="pyxislogo.jpg"/></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Leerink Partners</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>November 26, 2025</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item 14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Other Expenses of Issuance and Distribution</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Set forth below is an estimate (except in the case of the registration fee) of the amount of fees and expenses to be incurred in connection with the issuance and distribution of the offered securities, other than underwriting discounts and commissions. All amounts are estimates except the SEC registration fee and the FINRA filing fee.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC registration fee</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,335</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FINRA filing fee</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">53,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal fees and expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting fees and expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Printing expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Transfer agent and registrar fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Trustee fees (including counsel fees)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Miscellaneous</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:auto;">&#160;</td>
			<td style="vertical-align:top;width:9.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">*</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Estimated expenses not presently known.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Item 15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Indemnification of Directors and Officers</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that none of our directors shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors are not personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any transaction from which the director derived an improper personal benefit.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our amended and restated certificate of incorporation and our bylaws require us to indemnify our directors and officers, and allow us to indemnify other employees and agents, to the fullest extent permitted by the DGCL. Subject to certain limitations and limited exceptions, our amended and restated certificate of incorporation requires us to advance expenses incurred by our directors and officers for the defense of any action for which indemnification is required or permitted.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">II-1</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have entered into indemnification agreements with each of our directors and our executive officers. These agreements will provide that we will indemnify each of our directors and such officers to the fullest extent permitted by law and our amended and restated certificate of incorporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Sales Agreement filed as Exhibit 1.2 to this registration statement provides for indemnification of us and our directors and officers by Leerink Partners against certain liabilities under the Securities Act and the Exchange Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The underwriting agreement, to be filed by an amendment to this registration statement, will provide for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Insofar as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended, or the Securities Act, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:5.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 16.</b></p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;"><b><i>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</i></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td colspan="1" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.1&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form(s) of underwriting agreement(s).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.2</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_893483.htm" style="-sec-extract:exhibit;">Sales Agreement, dated as of November 26, 2025, between the Registrant and Leerink Partners LLC.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1*</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;"><a href="http://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_1.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation of Pyxis Oncology, Inc. (previously filed as Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q&#160;dated September&#160;30, 2021, filed with the SEC on November&#160;15, 2021 and incorporated herein by reference).</a></td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2*</p>
			</td>
			<td style="vertical-align: bottom; width: 37.4%;"><a href="http://www.sec.gov/Archives/edgar/data/1782223/000095017021004476/pyxs-ex3_2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Bylaws of Pyxis Oncology, Inc. (previously filed with the Company</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">10-Q</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">dated September</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">30, 2021, filed with the SEC on November</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">15, 2021 and incorporated herein by reference).</span></a></td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_893482.htm" style="-sec-extract:exhibit;">Form of Indenture.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Debt Security.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form(s) of Rights Agreement(s) (including form(s) of Rights).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4*</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1782223/000119312521290298/d156228dex41.htm" style="-sec-extract:exhibit;">Specimen Common Stock Certificate, $0.001 par value per share, of the Registrant (previously filed in the Company&#8217;s Registration Statement on Form S-1/A, Registration No. 333-259627).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Certificate of Designation of Preferred Stock.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Warrant Agreement and Warrant Certificate.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.7&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Certificate for Preferred Stock.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.8*</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1782223/000119312521288350/d156228dex101.htm" style="-sec-extract:exhibit;">Amended and Restated Investors&#8217;&#160;Rights Agreement (previously filed with the Company&#8217;s Registration Statement on Form S-1/A, Registration No. 333-259627).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.1</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_893455.htm" style="-sec-extract:exhibit;">Opinion of Sidley Austin LLP.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.2</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_893454.htm" style="-sec-extract:exhibit;">Opinion of Sidley Austin LLP.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consent of Sidley Austin LLP (included in <a href="ex_893455.htm" style="-sec-extract:exhibit;">Exhibit 5.1</a> and <a href="ex_893454.htm" style="-sec-extract:exhibit;">Exhibit 5.2</a>).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.2</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_893453.htm" style="-sec-extract:exhibit;">Consent of Ernst &amp; Young LLP.</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">24.1</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included in Signature Page).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">25.1&#8224;&#8224;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Statement of Eligibility of Trustee on Form T-1.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">107</p>
			</td>
			<td colspan="1" style="vertical-align:bottom;width:7.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_893452.htm" style="-sec-extract:exhibit;">Calculation of Registration Fee Table.</a></p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">*</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Previously filed.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8224;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To be filed by amendment or as exhibit(s) to a Current Report of the Registrant on Form 8-K and incorporated herein by reference, as applicable.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8224;&#8224;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To be filed pursuant to Section 305(b)(2) of the U.S. Trust Indenture Act of 1939, as applicable.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">II-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;"><b>Item 17</b><b><i>.</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Undertakings</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:6pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The undersigned Registrant hereby undertakes:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To include any prospectus required by section 10(a)(3) of the Securities Act;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221;&#160;table in the effective registration statement; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">provided, however, that subparagraphs (i), (ii) and (iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">That, for the purpose of determining any liability under the Securities Act, each such post effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">That, for the purpose of determining liability under the Securities Act to any purchaser:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">II-3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:28pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution of the securities:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">The undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:56pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant or their securities provided by or on behalf of the undersigned Registrant; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 56pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iv)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">(b)&#160;&#160;&#160;&#160;The undersigned Registrant hereby further undertakes that, for the purposes of determining any liability under the Securities Act, each filing of the annual reports of the Registrant pursuant to Section 13(a) or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement, if any, shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">(c)&#160;&#160;&#160;&#160;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under Item 15 of this registration statement, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in such the Securities Act and will be governed by the final adjudication of such issue.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:6pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned Registrant hereby undertakes that:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width: 28pt; text-align: justify;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">For purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">The undersigned Registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt; text-align: justify;">(a)&#160;&#160;&#160;&#160;of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section 305(b)(2) of the Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">II-4</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="TOCLink hf-cell" style="width: 100%; display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boston, Massachusetts, on November 26, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 50%;">&#160;</td>
			<td style="width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PYXIS ONCOLOGY, INC.</b></p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">By: <span style="text-decoration: underline; ">/s/ Lara Sullivan</span></p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Lara Sullivan, M.D.</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">President, Chief Executive Officer and Chief Medical Officer</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">By: <span style="text-decoration: underline; ">/s/ Jitendra Wadhane</span></p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Jitendra Wadhane</p>

			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Principal Financial and Accounting Officer</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="display: inline-block; text-align: left;"><a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a></div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" href="#"></a>POWER OF ATTORNEY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">We, the undersigned directors and officers of Pyxis Oncology, Inc. (the Company), hereby severally constitute and appoint Lara Sullivan, M.D. and Jitendra Wadhane, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-3 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, and any registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of the Company, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney. This Power of Attorney does not revoke any power of attorney previously granted by the undersigned, or any of them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated on the date indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">Signature</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Lara Sullivan</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">President, Chief Executive Officer, Chief Medical Officer and Director</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Lara Sullivan, M.D.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer) </i></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jitendra Wadhane</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Principal Financial and Accounting Officer</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Jitendra Wadhane</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ John Flavin</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board of Directors</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>John Flavin</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Thomas Civik</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Thomas Civik</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Darren Cline</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Darren Cline</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Freda Lewis-Hall, M.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Freda Lewis-Hall, M.D.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>&#160;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Rachel Humphrey, M.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Rachel Humphrey, M.D.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jakob Dupont, M.D.</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Jakob Dupont, M.D.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Santhosh Palani, Ph.D., CFA</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Santhosh Palani, Ph.D., CFA</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Michael A. Metzger</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">November 26, 2025</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:17.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Michael A. Metzger</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:23.4%;">&#160;</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:bottom;width:11.4%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>ex_893483.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<html><head>
	<title>ex_893483.htm</title>

	<!-- Generated by ThunderDome Portal - 11/26/2025 1:35:09 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 1.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PYXIS ONCOLOGY, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares of Common Stock</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">($0.001 par value per share)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>SALES AGREEMENT</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">November 26, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEERINK PARTNERS LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1301 Avenue of the Americas, 5<sup style="vertical-align:top;line-height:120%;">th</sup> Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">New York, New York 10019</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pyxis Oncology, Inc., a Delaware corporation (the &#8220;<b><u>Company</u></b>&#8221;), confirms its agreement (this &#8220;<b><u>Agreement</u></b>&#8221;) with Leerink Partners LLC (the &#8220;<b><u>Agent</u></b>&#8221;), as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Issuance and Sale of Shares</u>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through the Agent shares of common stock, $0.001 par value per share, of the Company (the &#8220;<b><u>Common Stock</u></b>&#8221;), subject to the limitations set forth in Section 5(c) (the &#8220;<b><u>Placement Shares</u></b>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the aggregate gross sales price of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares through the Agent will be effected pursuant to the Registration Statement (as defined below) to be filed by the Company with the Securities and Exchange Commission (the &#8220;<b><u>Commission</u></b>&#8221;) and to be declared effective by the Commission, although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has prepared and will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#8220;<b><u>Securities Act</u></b>&#8221;), with the Commission a registration statement on Form S-3, including (a) a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#8220;<b><u>Exchange Act</u></b>&#8221;), and (b) a prospectus supplement specifically relating to the Placement Shares to be issued from time to time pursuant to this Agreement (the &#8220;<b><u>Prospectus Supplement</u></b>&#8221;) to the base prospectus included as part of such registration statement. The Company will furnish to the Agent, for use by the Agent, copies of the base prospectus included as part of such registration statement at the time it becomes effective, as supplemented by the Prospectus Supplement. Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or Rule 462(b) under the Securities Act, is herein called the &#8220;<b><u>Registration Statement</u></b>.&#8221; The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#8220;issuer free writing prospectus&#8221; (as used herein, as defined in Rule 433 under the Securities Act (&#8220;<b><u>Rule 433</u></b>&#8221;)), relating to the Placement Shares that (i)&nbsp;is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule&nbsp;433(d)(5)(i), in each case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g), is herein called the &#8220;<b><u>Prospectus</u></b>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any reference herein to the Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the documents, if any, that are or are deemed to be incorporated by reference therein (the &#8220;<b><u>Incorporated Documents</u></b>&#8221;), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the Prospectus Supplement, the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the respective dates of the Prospectus Supplement, Prospectus or such issuer free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic Application system when used by the Commission (collectively, &#8220;<b><u>EDGAR</u></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Placements</u>. Each time that the Company wishes to issue and sell any Placement Shares through the Agent hereunder (each, a &#8220;<b><u>Placement</u></b>&#8221;), it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (each such notice, a &#8220;<b><u>Placement Notice</u></b>&#8221;) containing the parameters in accordance with which it desires such Placement Shares to be sold, which at a minimum shall include the maximum number or amount of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on the number or amount of Placement Shares that may be sold in any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters is attached hereto as <b><u>Schedule 1</u></b>. The Placement Notice must originate from one of the individuals authorized to act on behalf of the Company and set forth on <b><u>Schedule 2</u></b> (with a copy to each of the other individuals from the Company listed on such <b><u>Schedule 2</u></b>), and shall be addressed to each of the recipients from the Agent set forth on <b><u>Schedule 2</u></b>, as such <b><u>Schedule 2</u></b> may be updated by either party from time to time by sending a written notice containing a revised <b><u>Schedule 2</u></b> to the other party in the manner provided in Section 12 (including by email correspondence to each of the individuals of the Company set forth on <b><u>Schedule 2</u></b>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply). The Placement Notice shall be effective upon receipt by the Agent unless and until (i)&nbsp;in accordance with the notice requirements set forth in Section 4, the Agent declines to accept the terms contained therein for any reason, in its sole discretion, within two Trading Days of the date the Agent receives the Placement Notice, (ii) in accordance with the notice requirements set forth in Section 4, the Agent suspends sales under the Placement Notice for any reason in its sole discretion, (iii) the entire amount of the Placement Shares has been sold pursuant to this Agreement, (iv)&nbsp;in accordance with the notice requirements set forth in Section&nbsp;4, the Company suspends sales under or terminates the Placement Notice for any reason in its sole discretion, (v) the Company issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated Placement Notice or (vi) this Agreement has been terminated pursuant to the provisions of Section 11. The amount of any discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares effected through the Agent shall be calculated in accordance with the terms set forth in <b><u>Schedule 3</u></b>. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control with respect to the matters covered thereby.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;<u>Sale of Placement Shares by the Agent</u>. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set forth, including Section 5(c), upon the Agent&#8217;s acceptance of the terms of a Placement Notice as provided in Section 2, and unless the sale of the Placement Shares described therein has been declined, suspended or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market (&#8220;<b><u>Nasdaq</u></b>&#8221;) to sell such Placement Shares up to the number or amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Agent will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on <b><u>Schedule 2</u></b>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number or amount of Placement Shares sold on such Trading Day, the volume-weighted average price of the Placement Shares sold and the Net Proceeds (as defined below) payable to the Company. Unless otherwise specified by the Company in a Placement Notice, the Agent may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act, including sales made directly on or through Nasdaq, on or through any other existing trading market for the Common Stock or to or through a market maker. If expressly authorized by the Company (including in a Placement Notice), the Agent may also sell Placement Shares in negotiated transactions. Notwithstanding the provisions of Section 6(tt), except as may be otherwise agreed by the Company and the Agent, the Agent shall not purchase Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement Shares as required under this Agreement and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement unless the Company and the Agent enter into a separate written agreement setting forth the terms of such sale. For the purposes hereof, &#8220;<b><u>Trading Day</u></b>&#8221; means any day on which the Common Stock is purchased and sold on Nasdaq.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">&nbsp;4.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Suspension of Sales</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on <b><u>Schedule 2</u></b>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by email correspondence to each of the individuals of the other party set forth on <b><u>Schedule 2</u></b>), suspend any sale of Placement Shares; <i>provided</i>, <i>however</i>, that such suspension shall not affect or impair either party&#8217;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. Each of the parties agrees that no such notice under this Section 4 shall be effective against the other party unless notice is sent by one of the individuals named on <b><u>Schedule 2</u></b> hereto to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on <b><u>Schedule 2</u></b>, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of this Agreement, during any period in which the Company is, or could be deemed to be, in possession of material non-public information, the Company and the Agent agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares and shall cancel any effective Placement Notices instructing the Agent to make any sales and (iii)&nbsp;the Agent shall not be obligated to sell or offer to sell any Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 41pt;">&nbsp;5.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp; <u> Settlement and Delivery of the Placement Shares</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Settlement of Placement Shares</u>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the first Trading Day following the date on which such sales are made (each, a &#8220;<b><u>Settlement Date</u></b>&#8221;). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;<b><u>Net Proceeds</u></b>&#8221;) will be equal to the aggregate gross sales price received by the Agent at which such Placement Shares were sold, after deduction of (i)&nbsp;the Agent&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant to Section 2 hereof, (ii) any other amounts due and payable by the Company to the Agent hereunder pursuant to Section 7(g) hereof and (iii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Placement Shares</u>. On or before each Settlement Date, the Company will issue the Placement Shares being sold on such date and will, or will cause its transfer agent to, electronically transfer such Placement Shares by crediting the Agent&#8217;s or its designee&#8217;s account (provided the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System (&#8220;<b><u>DWAC</u></b>&#8221;) or by such other means of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely tradeable, transferable, registered shares of Common Stock in good deliverable form. On each Settlement Date, the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on or prior to the Settlement Date. The Agent shall be responsible for providing DWAC instructions or other instructions for delivery by other means with regard to the transfer of the Placement Shares being sold. In addition to and in no way limiting the rights and obligations set forth in Section 9(a) hereto, the Company agrees that if the Company or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized, freely tradeable, transferable, registered Placement Shares in good deliverable form by 2:30 P.M., New York City time, on a Settlement Date (other than as a result of a failure by the Agent to provide instructions for delivery), the Company will (i) take all necessary action to cause the full amount of any Net Proceeds that were delivered to the Company&#8217;s account with respect to such settlement, together with any costs incurred by the Agent and/or its clearing firm in connection with recovering such Net Proceeds, to be immediately returned to the Agent or its clearing firm no later than 5:00&nbsp;P.M., New York City time, on such Settlement Date, by wire transfer of immediately available funds to an account designated by the Agent or its clearing firm, (ii) indemnify and hold the Agent and its clearing firm harmless against any loss, claim, damage, or expense (including reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company or its transfer agent (if applicable) and (iii) pay to the Agent any commission, discount or other compensation to which it would otherwise have been entitled absent such default. Certificates for the Placement Shares, if any, shall be in such denominations and registered in such names as the Agent may request in writing one Business Day (as defined below) before the applicable Settlement Date. Certificates for the Placement Shares, if any, will be made available by the Company for examination and packaging by the Agent in New York City not later than 12:00 P.M., New York City time, on the Business Day prior to the applicable Settlement Date; provided that the Agent shall have previously provided the Company with the requested denominations and names for such certificates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitations on Offering Size</u>. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares if, after giving effect to the sale of such Placement Shares, the aggregate number or gross sales proceeds of Placement Shares sold pursuant to this Agreement would exceed the lesser of: (i) the number or dollar amount of shares of Common Stock registered pursuant to, and available for offer and sale under, the Registration Statement pursuant to which the offering of Placement Shares is being made, (ii) the number of authorized but unissued shares of Common Stock of the Company (less shares of Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (iii) the number or dollar amount of shares of Common Stock permitted to be offered and sold by the Company under Form S-3 (including General Instruction I.B.6. thereof, if such instruction is applicable), (iv)&nbsp;the number or dollar amount of shares of Common Stock that the Company&#8217;s board of directors or a duly authorized committee thereof is authorized to issue and sell from time to time, and notified to the Agent in writing, or (v) the dollar amount of shares of Common Stock for which the Company has filed the Prospectus Supplement. Under no circumstances shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized from time to time by the Company&#8217;s board of directors or a duly authorized committee thereof, and notified to the Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance with the limitations set forth in this Section 5(c) on the number or dollar amount of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agent shall have no obligation in connection with such compliance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties of the Company</u>. The Company represents and warrants to, and agrees with, the Agent that as of the date of this Agreement, and as of (i) each Representation Date (as defined in Section 7(m)), (ii) each date on which a Placement Notice is given, (iii) the date and time of each sale of any Placement Shares pursuant to this Agreement and (iv) each Settlement Date (each such time or date referred to in clauses (i) through (iv), an &#8220;<b><u>Applicable Time</u></b>&#8221;):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:41pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement will be filed with the Commission and will be declared effective by the Commission under the Securities Act prior to the issuance of any Placement Notices by the Company. At the time the Registration Statement originally became effective or at the time of the Company&#8217;s most recently filed Annual Report on Form 10-K following the effectiveness of the Registration Statement was filed with the Commission, the Company met the then-applicable requirements for use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement meets, and the offering and sale of Placement Shares as contemplated hereby comply with, the requirements of Rule 415(a)(1)(x) under the Securities Act. The Agent is named as the agent engaged by the Company in the section entitled &#8220;Plan of Distribution&#8221; in the Prospectus Supplement. The Company has not received, and has no notice from the Commission of, any notice pursuant to Rule&nbsp;401(g)(1) under the Securities Act objecting to the use of the shelf registration statement form. No stop order of the Commission preventing or suspending the use of the base prospectus, the Prospectus Supplement or the Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission. At the time of the initial filing of the Registration Statement, the Company paid the required Commission filing fees relating to the securities covered by the Registration Statement, including the Shares that may be sold pursuant to this Agreement, in accordance with Rule 457(o) under the Securities Act. Copies of the Registration Statement, the Prospectus, any such amendments or supplements to any of the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available through EDGAR, to the Agent and its counsel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, at each deemed effective date with respect to the Agent pursuant to Rule&nbsp;430B(f)(2) under the Securities Act and as of each Applicable Time, complied, complies and will comply in all material respects with the requirements of the Securities Act and did not, does not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#8217;s Information (as defined below). The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under the Securities Act, complied, complies and as of each Applicable Time will comply in all material respects with the requirements of the Securities Act, and each Prospectus Supplement, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the foregoing) furnished to the Agent for use in connection with the offering of the Placement Shares was identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. Neither the Prospectus nor any amendment or supplement thereto, as of its date and as of each Applicable Time, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this sentence do not apply to Agent&#8217;s Information. Each Incorporated Document heretofore filed, when it was filed (or, if any amendment with respect to any such document was filed, when such amendment was filed), conformed in all material respects with the requirements of the Exchange Act and were filed on a timely basis with the Commission, and any further Incorporated Documents so filed and incorporated after the date of this Agreement will be filed on a timely basis and, when so filed, will conform in all material respects with the requirements of the Exchange Act; no such Incorporated Document when it was filed (or, if an amendment with respect to any such document was filed, when such amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and no such Incorporated Document, when it is filed, will contain an untrue statement of a material fact or will omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) At the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being used as the determination date for purposes of this clause (ii)), the Company was not and is not an &#8220;ineligible issuer&#8221; (as defined in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is, and since June 21, 2021 has been, an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act (an &#8220;<b><u>Emerging Growth Company</u></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each issuer free writing prospectus, as of its issue date and as of each Applicable Time, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any Incorporated Document deemed to be a part thereof that has not been superseded or modified. Each issuer free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433 or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the Agent&#8217;s distribution of the Placement Shares under this Agreement, will not distribute any offering material in connection with the offering and sale of the Placement Shares other than the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus (as defined below).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. The Company is in compliance with the current listing standards of Nasdaq. The Company has filed a Notification of Listing of Additional Shares with Nasdaq with respect to the Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Placement Shares hereunder, whether as a result of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated hereby or otherwise. Except for the Agent, there is no broker, finder or other party that is entitled to receive from the Company or any of its Subsidiaries (as defined below) any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise stated therein, since the respective dates as of which information is given in the Registration Statement or the Prospectus, (A)&nbsp;there has been no material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company and any of its Subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a &#8220;<b><u>Material Adverse Effect</u></b>&#8221;), (B)&nbsp;there have been no transactions entered into by the Company or any of its Subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and any of its Subsidiaries considered as one enterprise, and (C)&nbsp; there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any &#8220;significant subsidiary&#8221; of the Company (as such term is defined in Rule 1-02 of Regulation S-X) (each, a &#8220;<b><u>Subsidiary</u></b>&#8221;) has been duly organized and is validly existing in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not result in a Material Adverse Effect. Except as otherwise disclosed in the Registration Statement and the Prospectus, all of the issued and outstanding capital stock of any Subsidiary has been duly authorized and validly issued, is fully paid and non&#8209;assessable and is owned by the Company, directly or through any of its Subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock of any Subsidiary were issued in violation of the preemptive or similar rights of any securityholder of any such Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has the authorized and outstanding capitalization as set forth in the Company&#8217;s quarterly report on Form 10-Q for the most recent fiscal quarter, or annual report on Form 10-K for the most recent fiscal year, as applicable, as of the dates referred to therein (subject, in each case, to the issuance of Placement Shares under this Agreement, the issuance of shares of Common Stock upon exercise of share options and warrants disclosed as outstanding as of the date hereof in the Registration Statement and the Prospectus and the grant of options under existing share option plans described in the Registration Statement and the Prospectus). The Common Stock conforms in all material respects to the description thereof contained in the Registration Statement and the Prospectus, including under the heading &#8220;Description of Capital Stock.&#8221; All of the issued and outstanding share capital or other equity or ownership interest of the Company (including the Common Stock) has been duly authorized and validly issued and is fully paid and nonassessable, has been issued in compliance with all federal, state and local securities laws and is free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase or subscribe for, or equity or debt securities convertible into or exchangeable or exercisable for, any share capital of the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party or by which any of them may be bound. The descriptions of the Company&#8217;s equity incentive plan, stock option plans and other stock plans or arrangements described in the Prospectus and in effect as of the date hereof (collectively, the &#8220;<b><u>Stock Plans</u></b>&#8221;) and the options or other rights granted thereunder, set forth in the Registration Statement and the Prospectus accurately and fairly present the information required to be shown with respect to such Stock Plans and the options or other rights granted thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Placement Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable and will conform in all material respects to the description thereof contained in the Prospectus. The issuance and sale of the Placement Shares as contemplated hereby shall not be subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Placement Shares. When issued and delivered by the Company against payment therefor pursuant to this Agreement, the purchasers of the Placement Shares issued and sold hereunder will acquire good, marketable and valid title to such Placement Shares, free and clear of all pledges, liens, security interests, charges, claims or encumbrances. The issuance and sale of the Placement Shares as contemplated hereby will not cause any holder of any share capital, securities convertible into or exchangeable or exercisable for share capital or options, warrants or other rights to purchase share capital or any other securities of the Company to have any right to acquire any preferred shares of the Company. There are no restrictions upon the voting or transfer of the Common Stock under the Company&#8217;s amended and restated certificate of incorporation or amended and restated bylaws or any agreement or other instrument to which the Company is a party or otherwise filed as an exhibit to the Registration Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no statute, regulation, contract, agreement or other document required to be described in the Registration Statement, Prospectus or in any Incorporated Document, or to be filed as an exhibit to the Registration Statement or any Incorporated Document which is not described or filed as required. The statements set forth or incorporated by reference in the Prospectus, insofar as they purport to constitute summaries of the terms of the statutes, regulations, contracts, agreements or other documents described and filed, constitute accurate summaries of the terms thereof in all material respects. The statements set forth or incorporated by reference in the Prospectus under the headings &#8220;Risk Factors,&#8221; &#8220;Business&#8212;Licensing and Collaboration Agreements,&#8221; &#8220;Business&#8212;Intellectual Property,&#8221; &#8220;Business&#8212;Government Regulation,&#8221; &#8220;Legal Proceedings,&#8221; and &#8220;Description of Capital Stock,&#8221; insofar as such statements summarize legal matters, agreements, documents or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements, documents or proceedings. Neither the Company nor any of its Subsidiaries have sent or received any communication regarding termination of, or intent not to renew or render performance under, any of the contracts or agreements referred to or described in the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, or any Incorporated Document, and no such termination or non-renewal has been threatened by the Company or any of its Subsidiaries or, to the Company&#8217;s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no contracts or documents which are required under the Securities Act to be described in the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly authorized, executed and delivered by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not required, and upon the issuance and sale of the Placement Shares as herein contemplated and the application of the net proceeds therefrom as described in the Registration Statement and the Prospectus will not be required, to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;<b><u>1940 Act</u></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any Governmental Entity (as defined below) is necessary or required for the performance by the Company of its obligations hereunder, in connection with the offering, issuance or sale of the Placement Shares hereunder or the consummation of the transactions contemplated by this Agreement, except such as have been already obtained or as may be required under the Securities Act or the rules and regulations promulgated thereunder, the rules of the Nasdaq Global Market, state securities laws or the rules of the Financial Industry Regulatory Authority (&#8220;<b><u>FINRA</u></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its Subsidiaries is (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company or any of its Subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or assets of the Company or any of its Subsidiaries is subject (collectively, &#8220;<b><u>Agreements and Instruments</u></b>&#8221;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its Subsidiaries or any of their respective properties, assets or operations (each, a &#8220;<b><u>Governmental Entity</u></b>&#8221;), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration Statement and the Prospectus (including the issuance and sale of the Placement Shares and the use of the proceeds from the sale of the Placement Shares as described therein under the caption &#8220;Use of Proceeds&#8221;) and compliance by the Company with its obligations hereunder have been duly authorized by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any of its Subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of the provisions of the (x) charter, by-laws or similar organizational document of the Company or any of its Subsidiaries or (y) any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except, in the case of clause (y) for such violations as would not, singly or in the aggregate, result in a Material Adverse Effect. As used herein, a &#8220;<b><u>Repayment Event</u></b>&#8221; means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its Subsidiaries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the Securities Act pursuant to this Agreement, other than those rights that have been disclosed in the Registration Statement and the Prospectus and have been waived.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements included or incorporated by reference in the Registration Statement and the Prospectus, together with the related schedules and notes, present fairly in all material respects the financial position of the Company and any of its Subsidiaries at the dates indicated and the statement of operations, stockholders&#8217; equity and cash flows of the Company and of its consolidated Subsidiaries for the periods specified; said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;<b><u>GAAP</u></b>&#8221;) applied on a consistent basis throughout the periods involved, except, in the case of unaudited interim financial statements, subject to normal year end audit adjustments and the exclusion of certain footnotes as permitted by the applicable rules of the Commission. The supporting schedules, if any, present fairly in all material respects in accordance with GAAP the information required to be stated therein. The summary financial information included in or incorporated by reference in the Registration Statement and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included or incorporated by reference in the Registration Statement or the Prospectus under the Securities Act or the regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Registration Statement and the Prospectus, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, which might result in a Material Adverse Effect, or which might materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any of its Subsidiaries is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement and the Prospectus, including ordinary routine litigation incidental to the business, would not result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries have good and marketable title to all real property owned by them and good title to all other properties owned by them, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such as (A) are described in the Registration Statement and the Prospectus or (B) do not, singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of its Subsidiaries; and all of the leases and subleases material to the business of the Company or any of its Subsidiaries, considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement or the Prospectus, are in full force and effect, and neither the Company nor any of its Subsidiaries has any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any of its Subsidiaries under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or any of its Subsidiaries to the continued possession of the leased or subleased premises under any such lease or sublease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst &amp; Young LLP, whose report on the consolidated financial statements of the Company is filed with the Commission as part of the Company&#8217;s most recent annual report on Form 10-K filed with the Commission and incorporated by reference in the Registration Statement and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act and the rules of the PCAOB, (ii) in compliance with the applicable requirements relating to the qualification of the accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn. Ernst &amp; Young LLP has not been engaged by the Company to perform any &#8220;prohibited activities&#8221; or provided to the Company any &#8220;non-audit services&#8221; (as defined in Section 10A of the Exchange Act).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no transfer taxes or other similar fees or charges under federal law, the laws of any state, any foreign law, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by the Company of the Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All United States federal income tax returns of the Company and any of its Subsidiaries required by law to be filed have been filed and all material United States federal income taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been provided. The Company and any of its Subsidiaries have filed all other tax returns that are required to have been filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company and any of its Subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company or except insofar as the failure to pay such taxes would not result in a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent, and there is no existing, and the Company is not aware of any imminent labor disturbance by the employees of any of its or any of its Subsidiaries&#8217; principal suppliers, manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries carry or are entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by similarly sized companies of established repute engaged in the same or similar business, and all such insurance is in full force and effect. The Company has no reason to believe that it or any of its Subsidiaries will not be able (A)&nbsp;to renew its existing insurance coverage as and when such policies expire or (B)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries have been denied any insurance coverage which it has sought or for which it has applied.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries possess such permits, licenses, approvals, consents, certificates, certifications, clearances, registrations, exemptions, and other authorizations (collectively, &#8220;<b><u>Governmental Licenses</u></b>&#8221;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and any of its Subsidiaries are and during the past three (3) years, have been in compliance with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries maintain effective internal control over financial reporting (as defined under Rule 13&#8209;a15 and 15d&#8209;15 under the Exchange Act and the rules and regulations promulgated thereunder) and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management&#8217;s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. Except as described in the Registration Statement and the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (1) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (2) no change in the Company&#8217;s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares or to result in a violation of Regulation M under the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Registration Statement and the Prospectus or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company nor any of its Subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or, to the knowledge of the Company, threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, &#8220;<b><u>Hazardous Materials</u></b>&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;<b><u>Environmental Laws</u></b>&#8221;), (B) the Company and any of its Subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements, (C) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental Law against the Company or any of its Subsidiaries and (D) there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company or any of its Subsidiaries relating to Hazardous Materials or any Environmental Laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as would not reasonably be expected to result in a Material Adverse Effect or as set forth in or contemplated by the Registration Statement and the Prospectus, (A) each, if any, &#8220;employee benefit plan&#8221; (within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#8220;<b><u>ERISA</u></b>&#8221;)) for which the Company or any member of its &#8220;<b><u>Controlled Group</u></b>&#8221; (defined as any organization which is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the &#8220;<b><u>Code</u></b>&#8221;)) would have any liability (each a &#8220;<b><u>Plan</u></b>&#8221;) has been maintained in compliance with its terms and with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; and (B)&nbsp;each, if any, Plan maintained by the Company that is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter or is comprised of a master prototype plan that has received an opinion letter from the Internal Revenue Service covering all tax law changes prior to the Economic Growth and Tax Relief Reconciliation Act of 2001 (or has submitted, or is within the remedial amendment period for submitting, an application for a determination letter and is awaiting a response from the Internal Revenue Service), and, to the knowledge of the Company, no event has occurred and no condition exists that would result in the revocation or failure to issue any such determination letter or opinion letter. To the extent applicable, except as would not reasonably be expected to result in a Material Adverse Effect,&nbsp;with respect to each Plan subject to Title IV of ERISA (X)&nbsp;no &#8220;reportable event&#8221; (within the meaning of Section 4043(c) of ERISA, other than events with respect to which the 30-day notice requirement under Section&nbsp;4043 of ERISA have been waived by the United States Department of Labor) has occurred or is reasonably expected to occur, (Y)&nbsp;no &#8220;accumulated funding deficiency&#8221; (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code), whether or not waived, has occurred or is reasonably expected to occur, and (Z)&nbsp;neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the PBGC in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221;, within the meaning of Section&nbsp;4001(c)(3) of ERISA).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is in compliance with, and there is and has been no failure on the part of the Company and, to the Company&#8217;s knowledge, any of the Company&#8217;s directors or officers, in their capacities as such, to comply with, any provision of the Sarbanes-Oxley Act of 2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof (the &#8220;<b><u>Sarbanes-Oxley Act</u></b>&#8221;) with which the Company is required to comply, and is actively taking steps to ensure that it will be in compliance with other provisions of the Sarbanes-Oxley Act not currently in effect or which will become applicable to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its Subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;<b><u>FCPA</u></b>&#8221;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The operations of the Company and any of its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#8220;<b><u>Money Laundering Laws</u></b>&#8221;); and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or any of its Subsidiaries is an individual or entity (&#8220;<b><u>Person</u></b>&#8221;) currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (&#8220;<b><u>OFAC</u></b>&#8221;), the United Nations Security Council (&#8220;<b><u>UNSC</u></b>&#8221;), the European Union, His Majesty&#8217;s Treasury (&#8220;<b><u>HMT</u></b>&#8221;), the Swiss State Secretariat for Economic Affairs or other relevant sanctions authority (collectively, &#8220;<b><u>Sanctions</u></b>&#8221;), nor is the Company or any of its Subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic (each, a &#8220;<b><u>Sanctioned Country</u></b>&#8221;); and the Company will not directly or indirectly use the proceeds of the sale of the Placement Shares, or lend, contribute or otherwise make available such proceeds to any of its Subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any Sanctioned Country or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries own or possess, or can acquire on reasonable terms, all patents, patent rights, licenses, inventions, copyrights, know&#8209;how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, domain names, technology and other intellectual property in the United States and foreign jurisdictions (collectively, &#8220;<b><u>Intellectual Property</u></b>&#8221;) necessary to carry on the business as now operated by them and as proposed to be operated by them as described in the Registration Statement and the Prospectus. The Company and any of its Subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its Subsidiaries, and all such agreements are in full force and effect. Furthermore, (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any Intellectual Property of the Company; (B) there is no pending or threatened, action, suit, proceeding or claim by others challenging the Company&#8217;s or any of its Subsidiaries&#8217; rights in or to any such Intellectual Property, neither the Company nor any of its Subsidiaries has received any notice of any such claim, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C) other than as disclosed in the Registration Statement and the Prospectus, there are no third parties who have rights to any Company-owned Intellectual Property, including no liens, security interest, or other encumbrances, except for (i) customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company any of its Subsidiaries or (ii) rights or Intellectual Property that are not material to the Company; (D) the Intellectual Property owned by the Company and any of its Subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the Company and any of its Subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property; (E) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company or any of its Subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and neither the Company nor any of its Subsidiaries has received any written notice of such claim; (F) to the knowledge of the Company the conduct of the Company&#8217;s and any of its Subsidiaries&#8217; business as now conducted or as proposed to be conducted does not and will not infringe or otherwise violate any Intellectual Property or other proprietary right of any third party; (G) the issued patents included in the Intellectual Property of the Company are valid and enforceable and the Company is unaware of any facts that would preclude the issuance of a valid and enforceable patent on any pending patent application included in such Intellectual Property; (H) the Company has taken reasonable steps necessary to secure the interests of the Company in the Intellectual Property purported to be owned by the Company from all employees, consultants, agents or contractors that developed (in whole or in part) such Intellectual Property; (I) no government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property that is owned or purported to be owned by the Company that would confer upon any governmental agency or body, university, college, other educational institution or research center any claim or right in or to any such Intellectual Property; and (J) all patents and patent applications owned by or licensed to the Company or any of its Subsidiaries have been duly and properly filed, prosecuted and maintained in all material respects, have been assigned to the Company or the licensor to the Company, and the patents are subsisting and have not lapsed and the patent applications in the Intellectual Property are subsisting and have not been abandoned.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preclinical tests and clinical trials, as applicable, conducted or sponsored by or on behalf of the Company or in which the Company&#8217;s or any of its Subsidiaries&#8217; product candidates participated (&#8220;<b><u>Studies</u></b>&#8221;) were and, if still pending, are being conducted in all material respects in accordance with all applicable laws, rules, and regulations, including, without limitation, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.) and its implementing regulations at 21 C.F.R. Parts 50, 54, 56, Part 58, as applicable, and 312; each description of such Studies, and the results thereof, contained in the Registration Statement and the Prospectus is accurate in all material respects, and the Company has no knowledge of any other Studies the results of which are materially inconsistent with, or otherwise reasonably call into question, the results described or referred to in the Registration Statement and the Prospectus; the Company has not received any written notices or other written correspondence from any governmental authority requiring the termination, suspension or material adverse modification of any Studies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries is, and during the last three (3) years, has been, in compliance with all Health Care Laws, except where failure to comply would not be reasonably expected, individually or in the aggregate, to result in a Material Adverse Effect. For purposes of this Agreement, &#8220;<b><u>Health Care Laws</u></b>&#8221; means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.) and the Public Health Service Act (42 U.S.C. Section 201 et seq.); (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286, 287, 1347 and 1349, the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act (42 U.S.C. Section 1320d et seq.) (&#8220;<b><u>HIPAA</u></b>&#8221;), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) all other similar local, state, federal, national, supranational and foreign laws; and (v) the regulations promulgated pursuant to such laws set forth in subparts (i) through (iv). Except as would not be reasonably expected, individually or in the aggregate, to result in a Material Adverse Effect, during the last three (3) years, the Company has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental authority alleging that any product, operation, or activity is in violation of any Health Care Laws nor, to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. Except as would not be reasonably expected, individually or in the aggregate, to result in a Material Adverse Effect, during the last three (3) years, the Company has filed, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments (&#8220;<b><u>Submissions</u></b>&#8221;) as required by any Health Care Laws, and all such Submissions were accurate on the date filed (or were corrected or supplemented by a subsequent submission). The Company is not a party to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Entity. During the last three (3) years, neither the Company nor any of its respective employees, officers, directors, or, to the Company&#8217;s knowledge, agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) There has been no security breach or incident, unauthorized access or disclosure, or other compromise of information relating to an identified or identifiable person (&#8220;<b><u>Personal Data</u></b>&#8221;) or the Company&#8217;s or any of its Subsidiaries&#8217; information technology and computer systems networks, hardware, software, data and databases (including the data and information of their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and any of its Subsidiaries, and any such data processed or stored by third parties on behalf of the Company and any of its Subsidiaries), equipment or technology (collectively, &#8220;<b><u>IT Systems and Data</u></b>&#8221;), (B) neither the Company nor any of its Subsidiaries have been notified of, and each of them have no knowledge of any event or condition that could result in, any security breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data or Personal Data, (C) the Company and any of its Subsidiaries have implemented commercially reasonable controls, policies, procedures, and technological safeguards designed to maintain and protect the integrity, continuous operation, and security of their IT Systems and Data and Personal Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards, (D) the Company and any of its Subsidiaries have implemented commercially reasonable backup and disaster recovery technology consistent with industry standards and practices, and (E) the Company&#8217;s and any of its Subsidiaries&#8217; IT Systems and Data are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and any of its Subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and any of its Subsidiaries have at all times been and are presently in material compliance with all applicable laws, statutes, regulations, and contractual obligations relating to the privacy and security of IT Systems and Data and Personal Data, including the collection, storage, transfer (including, without limitation, any transfer across national borders), processing and/or use of Personal Data and securing a valid legal basis for the foregoing, and to the protection of such IT Systems and Data and Personal Data from unauthorized use, access, misappropriation or modification (collectively, the &#8220;<b><u>Privacy Laws</u></b>&#8221;). In order to comply with the Privacy Laws, the Company and any of its Subsidiaries have in place, comply with, and take commercially reasonable steps designed to comply in all material respects with its policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<b><u>Policies</u></b>&#8221;). The Company and any of its Subsidiaries have at all times made all disclosures to users or customers required by applicable Privacy Laws in any material respect, and none of such disclosures made or contained in any Policy have, to the Company&#8217;s knowledge, been inaccurate or in violation of any applicable Privacy Laws in any material respect. The Company and any of its Subsidiaries (A) have not received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, (B) are not currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law except as would be expected in the ordinary course of business to comply with or implement requirements under Privacy Laws (e.g., routine patching), and (C) are not a party to any order, decree, or agreement that imposes any obligation or liability by any governmental or regulatory authority under any Privacy Law. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Privacy Laws or Policies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Registration Statement and the Prospectus, the Company (i)&nbsp;does not have any&nbsp;material lending or other relationship with any bank or lending affiliate of the Agent and (ii)&nbsp;does not intend to use any of the proceeds from the sale of the Placement Shares to repay any outstanding debt owed to any affiliate of the Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any statistical and market-related data included or incorporated by reference in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that the Agent has informed the Company that the Agent may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect; <i>provided</i>, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent the Agent may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &#8220;riskless principal&#8221; or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent, except as may be otherwise agreed by the Company and the Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity transaction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not required to register as a &#8220;broker&#8221; or &#8220;dealer&#8221; in accordance with the provisions of the Exchange Act and does not, directly or indirectly through one or more intermediaries, control or have any other association with (within the meaning of Article I of the By-laws of FINRA) any member firm of FINRA. No relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers or shareholders of the Company, on the other hand, which is required by the rules of FINRA to be described in the Registration Statement and the Prospectus, which is not so described. All of the information (including, but not limited to, information regarding affiliations, security ownership and trading activity) provided to the Agent or its counsel by the Company, its officers and directors and the holders of any securities (debt or equity) or warrants, options or rights to acquire any securities of the Company in connection with the filing to be made and other supplemental information to be provided to FINRA pursuant to FINRA Rule 5110 in connection with the transactions contemplated by this Agreement is true, complete and correct.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the close of trading on Nasdaq on November 25, 2025, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by those persons other than affiliates of the Company (pursuant to Rule 144 of the Securities Act, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the &#8220;<b><u>Non-Affiliate Shares</u></b>&#8221;), was approximately $315.59 million (calculated by multiplying (x) the price at which the common equity of the Company was last sold on Nasdaq on November 25, 2025 by (y) the number of Non-Affiliate Shares outstanding on November 25, 2025). The Company is not a shell company (as defined in Rule 405) and has not been a shell company for at least 12 calendar months previously.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor, to the Company&#8217;s knowledge, any of its affiliates (within the meaning of Rule 144 under the Securities Act) has, prior to the date hereof, made any offer or sale of any securities which could be &#8220;integrated&#8221; (within the meaning of the Securities Act) with the offer and sale of the Placement Shares hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the independent directors (or independent director nominees, once appointed, if applicable) named in the Registration Statement and Prospectus satisfies the independence standards established by Nasdaq and, with respect to members of the Company&#8217;s audit committee, the enhanced independence standards contained in Rule 10A-3(b)(1) promulgated by the Commission under the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each financial or operational projection or other &#8220;forward-looking statement&#8221; (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) as required, is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of a director or senior manager of the Company that was false or misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not in or subject to a bankruptcy or insolvency proceeding in any jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any certificate signed by any officer of the Company and delivered to the Agent or its counsel in connection with the offering of the Placement Shares shall be deemed a representation and warranty by the Company, as to matters covered thereby, to the Agent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Covenants of the Company</u>. The Company covenants and agrees with the Agent that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement Amendments</u>. After the date of this Agreement and during any period in which the Prospectus relating to any Placement Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule); (i) the Company will notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than Incorporated Documents, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information; (ii) the Company will prepare and file with the Commission, promptly upon the Agent&#8217;s request, any amendments or supplements to the Registration Statement or Prospectus that, in the Agent&#8217;s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that the failure of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agent shall have with respect to the failure by the Company to make such filing (but without limiting the Agent&#8217;s rights under Section 9 hereof) will be to cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus, other than Incorporated Documents, relating to the Placement Shares or a security convertible into or exchangeable or exercisable for the Placement Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing and the Agent has not reasonably objected thereto (provided, however, that the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and the Company shall have no obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to object to such filing if the filing does not name the Agent or does not relate to the Placement Shares or the transactions contemplated by this Agreement; and provided, further, that the only remedy the Agent shall have with respect to the Company&#8217;s making such filing notwithstanding the Agent&#8217;s objection (but without limiting the Agent&#8217;s rights under Section 9 hereof) will be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of filing thereof a copy of any Incorporated Document, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act and, in the case of any Incorporated Document, to be filed with the Commission as required pursuant to the Exchange Act, within the time period prescribed (the determination to file or not to file any amendment or supplement with the Commission under this Section 7(a), based on the Company&#8217;s reasonable opinion or reasonable objections, shall be made exclusively by the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Commission Stop Orders</u>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly after it receives any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or for additional information related to the offering of the Placement Shares or for additional information related to the Registration Statement or the Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Prospectus; Subsequent Changes</u>. During any period in which the Prospectus relating to the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance provided, however, that the Company may delay the filing of any amendment or supplement if, in the reasonable judgment of the Company, it would adversely affect the Company not to do so. If the Company has omitted any information from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its reasonable best efforts to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said Rule 430B and to notify the Agent promptly of all such filings if not available on EDGAR.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Listing of Placement Shares</u>. During any period in which the Prospectus relating to the Placement Shares is required to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on Nasdaq. The Company will timely file with Nasdaq all material documents and notices required by Nasdaq of companies that have or will issue securities that are traded on Nasdaq.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delivery of Registration Statement and Prospectus</u>. The Company will furnish to the Agent and its counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all Incorporated Documents) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which the Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all Incorporated Documents filed with the Commission during such period), in each case as soon as reasonably practicable and in such quantities as the Agent may from time to time reasonably request and, at the Agent&#8217;s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; <i>provided</i>, <i>however</i>, that the Company shall not be required to furnish any document (other than the Prospectus) to the Agent to the extent such document is available on EDGAR.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Earnings Statement</u>. The Company will make generally available to its security holders and to the Agent as soon as practicable, but in any event not later than 15 months after the end of the Company&#8217;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses</u>. The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated in accordance with the provisions of Section 11 hereunder, will pay all expenses incident to the performance of its obligations hereunder, including expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of the Prospectus and of each amendment and supplement thereto and of this Agreement and such other documents as may be required in connection with the offering, purchase, sale, issuance or delivery of the Placement Shares, (ii) the preparation, issuance, sale and delivery of the Placement Shares and any taxes due or payable in connection therewith, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of Section&nbsp;7(w) of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for the Agent in connection therewith shall be paid by the Agent except as set forth in clauses (vii) and (viii) below), (iv) the printing and delivery to the Agent and its counsel of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi) the filing fees and expenses, if any, owed to the Commission or FINRA and the fees and expenses of any transfer agent or registrar for the Placement Shares, (vii) the fees and associated expenses of the Agent&#8217;s outside legal counsel for filings with the FINRA Corporate Financing Department in an amount not to exceed $15,000 (excluding FINRA filing fees referred to in clause (vi) above and in addition to the fees and disbursements referred to in clause (viii) below), and (viii) the reasonable fees and disbursements of the Agent&#8217;s outside legal counsel (A) in an amount not to exceed $75,000 arising out of executing this Agreement and the Company&#8217;s delivery of the initial certificate pursuant to Section 7(m) and (B) in an amount not to exceed $25,000 in connection with each Representation Date (as defined below) on which the Company is required to provide a certificate pursuant to Section 7(m) (in addition to the fees and associated expenses referred to in clause (vii) above).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &#8220;Use of Proceeds.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Other Sales</u>. Without the prior written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any rights to purchase or acquire shares of Common Stock during the period beginning on the fifth Trading Day immediately prior to the date on which any Placement Notice is delivered to Agent hereunder and ending on the second Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other &#8220;at the market offering&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any shares of Common Stock (other than the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable or exercisable for shares of Common Stock, warrants or any rights to purchase or acquire, shares of Common Stock prior to the later of the termination of this Agreement and the sixtieth day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement Notice; <i>provided</i>, <i>however</i>, that such restrictions will not be required in connection with the Company&#8217;s issuance or sale of (i)&nbsp;shares of Common Stock, options to purchase shares of Common Stock, other securities under the Company&#8217;s existing equity incentive plans, or shares of Common Stock issuable upon the exercise of options or vesting of other securities, pursuant to any employee or director stock option or benefits plan, inducement grant award, stock ownership plan or dividend reinvestment plan (but not shares of Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii)&nbsp;shares of Common Stock issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii)&nbsp;shares of Common Stock or securities convertible into or exchangeable for shares of Common Stock as consideration for mergers, acquisitions, other business combinations or strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Circumstances</u>. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise the Agent promptly after it shall have received notice or obtained knowledge of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document provided or required to be provided to the Agent pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Due Diligence Cooperation</u>. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by the Agent, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Required Filings Relating to Placement of Placement Shares</u>. The Company agrees that on or prior to such dates as the Securities Act shall require, the Company will (i) file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant period, the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market; <i>provided</i>, that, unless a prospectus supplement containing such information is required to be filed under the Securities Act, the requirement of this Section 7(l) may be satisfied by Company&#8217;s inclusion in the Company&#8217;s Form 10-K or Form 10-Q, as applicable, of the number or amount of Placement Shares sold through the Agent, the Net Proceeds to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares during the relevant period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation Dates; Certificate</u>. On or prior to the date on which the Company first delivers a Placement Notice pursuant to this agreement (the &#8220;<b><u>First Placement Notice Date</u></b>&#8221;) and each time the Company:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section 7(l) of this Agreement) by means of a post-effective amendment, sticker or supplement but not by means of incorporation of document(s) by reference into the Registration Statement or the Prospectus relating to the Placement Shares;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material amendment to the previously filed Form 10-K);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;files a quarterly report on Form 10-Q under the Exchange Act; or</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;files a current report on Form 8-K containing amended financial information (other than an earnings release that is &#8220;furnished&#8221; pursuant to Item 2.02 or Item 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &#8220;<b><u>Representation Date</u></b>&#8221;),</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company shall furnish the Agent (but in the case of clause (iv) above only if (1) a Placement Notice is pending or in effect and (2) the Agent requests such certificate within three Business Days after the filing of such Form 8-K with the Commission) with a certificate, in the form attached hereto as <b><u>Exhibit 7(m)</u></b><b> </b>(modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of any Representation Date. The requirement to provide a certificate under this Section 7(m) shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending or in effect, which waiver shall continue until the earlier to occur of (1) the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and (2) the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date on which the Company relied on the waiver referred to in the previous sentence and did not provide the Agent with a certificate under this Section 7(m), then before the Company delivers a Placement Notice or the Agent sells any Placement Shares pursuant thereto, the Company shall provide the Agent with a certificate, in the form attached hereto as <b><u>Exhibit</u></b><u>&nbsp;</u><b><u>7(m)</u></b>, dated the date of such Placement Notice. Within two Trading Days of each Representation Date, the Company shall have furnished to the Agent such further information, certificates and documents as the Agent may reasonably request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Opinions</u>. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion and negative assurance letter of Sidley Austin LLP, counsel to the Company, or such other counsel satisfactory to the Agent (&#8220;<b><u>Company Counsel</u></b>&#8221;), in form and substance satisfactory to the Agent and its counsel, dated the date that the opinion and negative assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; <i>provided</i>, <i>however</i>, that in lieu of such opinion and negative assurance letter for subsequent Representation Dates, Company Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion or negative assurance letter delivered by such counsel under this Section 7(n) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion or negative assurance letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property Opinion</u>. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause to be furnished to the Agent the written opinion of Saul Ewing LLP, counsel for the Company with respect to intellectual property matters, or such other intellectual property counsel satisfactory to the Agent (&#8220;<b><u>Intellectual Property Counsel</u></b>&#8221;), in form and substance satisfactory to the Agent and its counsel, dated the date that the opinion letter is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; <i>provided</i>, <i>however</i>, that in lieu of such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish the Agent with a letter to the effect that the Agent may rely on a prior opinion letter delivered by such counsel under this Section 7(o) to the same extent as if it were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Comfort Letter</u>. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for which no waiver is applicable, the Company shall cause its independent registered public accounting firm (and any other independent accountants whose report is included in the Registration Statement or the Prospectus) to furnish the Agent letters (the &#8220;<b><u>Comfort Letters</u></b>&#8221;), dated the date the Comfort Letter is delivered, which shall meet the requirements set forth in this Section 7(p); <i>provided</i>, that if requested by the Agent, the Company shall cause a Comfort Letter to be furnished to the Agent within 10 Trading Days of the occurrence of any material transaction or event that necessitates the filing of additional, pro forma, amended or revised financial statements (including any restatement of previously issued financial statements). Each Comfort Letter shall be in form and substance satisfactory to the Agent and each Comfort Letter from the Company&#8217;s independent registered public accounting firm shall (i) confirm that they are an independent registered public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) state, as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to underwriters in connection with registered public offerings (the first such letter, the &#8220;<b><u>Initial Comfort Letter</u></b>&#8221;) and (iii) update the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Market Activities</u>. The Company will not, directly or indirectly, and will cause its officers, directors and Subsidiaries not to (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of shares of Common Stock or (ii) sell, bid for, or purchase shares of Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent; <i>provided</i>, <i>however</i>, that the Company may bid for and purchase shares of Common Stock in accordance with Rule 10b-18 under the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>. The Company and its Subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable and customary for the business for which it is engaged.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws</u>. The Company each of its Subsidiaries shall maintain, or cause to be maintained, all material environmental certificates, authorizations or permits required by federal, state and local law in order to conduct their businesses as described in the Prospectus (collectively, &#8220;<b><u>Permits</u></b>&#8221;), and the Company and each of its Subsidiaries shall conduct their businesses, or cause their businesses to be conducted, in substantial compliance with such Permits and with applicable Environmental Laws, except where the failure to maintain or be in compliance with such Permits could not reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Company Act</u>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its Subsidiaries will be or become, at any time prior to the termination of this Agreement, an &#8220;investment company,&#8221; as such term is defined in the Investment Company Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Act and Exchange Act</u>. The Company will use its reasonable best efforts to comply with all requirements imposed upon it by the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Offer to Sell</u>. Other than a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by the Company and the Agent, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity as agent) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Blue Sky and Other Qualifications</u>. The Company will use its commercially reasonable efforts, in cooperation with the Agent, to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement); <i>provided, however</i>, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such statements and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sarbanes-Oxley Act</u>. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and including those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company&#8217;s financial statements in accordance with GAAP, (iii) that receipts and expenditures of the Company are being made only in accordance with management&#8217;s and the Company&#8217;s directors&#8217; authorization, and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on its financial statements. The Company will maintain such controls and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and to ensure that material information relating to the Company is made known to it by others within the Company, particularly during the period in which such periodic reports are being prepared.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Emerging Growth Company</u>. The Company will promptly notify the Agent if the company ceases to be an Emerging Growth Company at any time prior to the completion of the Agent&#8217;s distribution of the Placement Shares pursuant to this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Renewal of Registration Statement.</u> If, immediately prior to the third anniversary of the initial effective date of the Registration Statement (the &#8220;<b><u>Renewal Date</u></b>&#8221;), any of the Placement Shares remain unsold and this Agreement has not been terminated, the Company will, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic shelf registration statement relating to the Common Stock that may be offered and sold pursuant to this Agreement (which shall include a prospectus reflecting the number or amount of Placement Shares that may be offered and sold pursuant to this Agreement), in a form satisfactory to the Agent and its counsel, and, if such registration statement is not an automatic shelf registration statement, will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Date. The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale of the Placement Shares to continue as contemplated in the expired registration statement and this Agreement. From and after the effective date thereof, references herein to the &#8220;Registration Statement&#8221; shall include such new shelf registration statement or such new automatic shelf registration statement, as the case may be.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>General Instruction I.B.6. of Form S-3</u>. If, from and after the date of this Agreement, the Company is no longer eligible to use Form S-3 (including pursuant to General Instruction I.B.6.) at the time it files with the Commission an annual report on Form 10-K or any post-effective amendment to the Registration Statement, then it shall promptly notify the Agent and, within two Business Days after the date of filing of such annual report on Form 10-K or amendment to the Registration Statement, the Company shall file a new prospectus supplement with the Commission reflecting the number of shares of Common Stock available to be offered and sold by the Company under this Agreement pursuant to General Instruction I.B.6. of Form S-3; <i>provided</i>, <i>however</i>, that the Company may delay the filing of any such prospectus supplement for up to 30 days if, in the reasonable judgment of the Company, it is in the best interest of the Company to do so, provided that no Placement Notice is in effect or pending during such time. Until such time as the Company shall have corrected such misstatement or omission or effected such compliance, the Company shall not notify the Agent to resume the offering of Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Indemnity</u>. The Company will indemnify and hold harmless the Agent against any documentary, stamp or similar issue tax, including any interest and penalties, on the issue and sale of the Placement Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transfer Agent</u>. The Company has engaged and will maintain, at its sole expense, a transfer agent and registrar for the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to the Agent</u><u>&#8217;</u><u>s Obligations</u>. The obligations of the Agent hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to the Agent in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Registration Statement Effective</u>. The Registration Statement shall be effective and shall be available for all offers and sales of Placement Shares (i) that have been issued pursuant to all prior Placement Notices and (ii) that will be issued pursuant to any Placement Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Reserved.</u>]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Notices</u>. None of the following events shall have occurred and be continuing: (i) receipt by the Company or any of its Subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company or any of its Subsidiaries of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material Incorporated Document untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or Incorporated Documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus, so that it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Misstatement or Material Omission</u>. The Agent shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s opinion is material, or omits to state a fact that in the Agent&#8217;s opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Changes</u>. Except as contemplated in the Prospectus, or disclosed in the Company&#8217;s reports filed with the Commission, there shall not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse Effect or any development that could reasonably be expected to result in a Material Adverse Effect, or any downgrading in or withdrawal of the rating assigned to any of the Company&#8217;s securities (other than asset backed securities), if any, by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company&#8217;s securities (other than asset backed securities), if any, the effect of which, in the judgment of the Agent (without relieving the Company of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares on the terms and in the manner contemplated in the Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Company Counsel Legal Opinions</u>. The Agent shall have received the opinions and negative assurance letters, as applicable, of Company Counsel and Intellectual Property Counsel required to be delivered pursuant to Section 7(n) and Section 7(o), as applicable, on or before the date on which such delivery of such opinions and negative assurance letters are required pursuant to Section 7(n) and Section&nbsp;7(o), as applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Agent</u><u>&#8217;</u><u>s Counsel Legal Opinion</u>. The Agent shall have received from Latham &amp; Watkins LLP, counsel for the Agent, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 7(n), with respect to such matters as the Agent may reasonably require, and the Company shall have furnished to such counsel such documents as they may request to enable them to pass upon such matters.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Comfort Letter</u>. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 7(p) on or before the date on which such delivery of such Comfort Letter is required pursuant to Section 7(p).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representation Certificate</u>. The Agent shall have received the certificate required to be delivered pursuant to Section 7(m) on or before the date on which delivery of such certificate is required pursuant to Section 7(m).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Secretary</u><u>&#8217;</u><u>s Certificate</u>. On or prior to the First Placement Notice Date, the Agent shall have received a certificate, signed on behalf of the Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date and in form and substance satisfactory to the Agent and its counsel, certifying as to (i) the amended and restated certificate of incorporation of the Company, (ii) the amended and restated bylaws of the Company, (iii) the resolutions of the board of directors of the Company or duly authorized committee thereof authorizing the execution, delivery and performance of this Agreement and the issuance and sale of the Placement Shares and (iv) the incumbency of the officers of the Company duly authorized to execute this Agreement and the other documents contemplated by this Agreement (including each of the officers set forth on <b><u>Schedule 2</u></b>).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Suspension</u>. The Common Stock shall be duly listed, and admitted and authorized for trading, subject to official notice of issuance, on Nasdaq. Trading in the Common Stock shall not have been suspended on, and the Common Stock shall not have been delisted from, Nasdaq.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Materials</u>. On each date on which the Company is required to deliver a certificate pursuant to Section 7(m), the Company shall have furnished to the Agent such appropriate further information, opinions, certificates, letters and other documents as the Agent may have reasonably requested. All such information, opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof. The Company shall have furnished the Agent with conformed copies of such opinions, certificates, letters and other documents as the Agent may have reasonably requested.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Securities Act Filings Made</u>. All filings with the Commission required by Rule 424(b) or Rule 433 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or Rule 433, as applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Approval for Listing</u>. Either (i) the Placement Shares shall have been approved for listing on Nasdaq, subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the First Placement Notice Date and Nasdaq shall have reviewed such application and not provided any objections thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>FINRA</u>. FINRA shall have raised no objection to the terms of the offering contemplated hereby and the amount of compensation allowable or payable to the Agent as described in the Prospectus.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Termination Event</u>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant to Section 11(a).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification and Contribution</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Company Indemnification</u>. The Company agrees to indemnify and hold harmless the Agent, its affiliates and their respective partners, members, directors, officers, employees and agents, and each person, if any, who (i) controls the Agent within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Agent, in each case from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal and other expenses reasonably incurred in connection with, and any and all amounts paid in settlement (in accordance with this Section 9), any action, suit, investigation or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party (including any governmental or self-regulatory authority, or otherwise, or any claim asserted or threatened), as and when incurred, to which the Agent, or any such other person may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based, directly or indirectly, on (x)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus (or any amendment or supplement to the Registration Statement or the Prospectus) or in any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Stock under the securities laws thereof or filed with the Commission, (y) the omission or alleged omission to state in any such document a material fact required to be stated therein or necessary to make the statements therein (solely with respect to the Prospectus, in light of the circumstances under which they were made) not misleading or (z) any breach by any of the indemnifying parties of any of their respective representations, warranties or agreements contained in this Agreement; <i>provided</i>, <i>however</i>, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused, directly or indirectly, by an untrue statement or omission, or alleged untrue statement or omission, made in reliance upon and in conformity with the Agent&#8217;s Information. This indemnity agreement will be in addition to any liability that the Company might otherwise have.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Agent Indemnification</u>. The Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company who signed the Registration Statement, and each person, if any, who (i)&nbsp;controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 9(a), as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Agent&#8217;s Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Procedure</u>. Any party that proposes to assert the right to be indemnified under this Section 9 will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 9, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this Section 9 and (ii)&nbsp;any liability that it may have to any indemnified party under the foregoing provision of this Section 9 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to such fees, disbursements and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified party, from all liability arising out of such claim, action or proceeding and (2) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Settlement Without Consent if Failure to Reimburse</u><i>. </i> If an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this Section 9, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section&nbsp;9(a) effected without its written consent if (i)&nbsp;such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Contribution</u>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit, investigation or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the Agent from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions pursuant to this Section 9(e) were to be determined by<i> pro rata</i> allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, referred to above in this Section 9(e) shall be deemed to include, for the purpose of this Section 9(e), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action, suit, investigation, proceeding or claim to the extent consistent with this Section 9. Notwithstanding the foregoing provisions of this Section 9(e), the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9(e), any person who controls a party to this Agreement within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, any affiliates of the Agent, any partners, members, directors, officers, employees and agents of the Agent and each person that is controlled by or under common control with the Agent will have the same rights to contribution as that party, and each officer and director of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this Section 9(e), will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this Section 9(e) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section 9(c) hereof or pursuant to Section 9(d) hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to Section 9(c) hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Agreements to Survive Delivery</u>. The indemnity and contribution agreements contained in Section 9 of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company (or any of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Agent shall have the right, by giving notice as hereinafter specified, at any time to terminate this Agreement if (i) any Material Adverse Effect, or any development that could reasonably be expected to result in a Material Adverse Effect, has occurred that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; <i>provided</i>, <i>however</i>, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion or letter required under Section 7(m), Section 7(n), Section 7(o) or Section 7(p), the Agent&#8217;s right to terminate shall not arise unless such failure to deliver (or cause to be delivered) continues for more than 15 calendar days from the date such delivery was required, (iii) any other condition of the Agent&#8217;s obligations hereunder is not fulfilled, (iv) any suspension or limitation of trading in the Placement Shares or in securities generally on Nasdaq shall have occurred, (v) a general banking moratorium shall have been declared by any of United States federal or New York authorities, or (vi)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States or international political, financial or economic conditions that, in the judgment of the Agent, may materially impair the ability of the Agent to sell the Placement Shares hereunder or to enforce contracts for the sale of securities. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section&nbsp;10, Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section 11(a), the Agent shall provide the required notice as specified in Section 12.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have the right, by giving 10 days&#8217; prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Agent shall have the right, by giving 10 days&#8217; prior notice as hereinafter specified, to terminate this Agreement in its sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; <i>provided</i> that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding such termination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall remain in full force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise by mutual agreement of the parties; <i>provided</i>, <i>however</i>, that any such termination by mutual agreement shall in all cases be deemed to provide that Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 shall remain in full force and effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any termination of this Agreement shall be effective on the date specified in such notice of termination; <i>provided, however</i>, that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay to the Agent any discount or commission with respect to any Placement Shares not otherwise sold by the Agent under this Agreement; <i>provided</i>, <i>however</i>, that the Company shall remain obligated to reimburse the Agent&#8217;s expenses pursuant to Section 7(g).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agent, shall be delivered to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">Leerink Partners LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">1301 Avenue of the Americas, 5<sup style="vertical-align:top;line-height:120%;">th</sup> Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">New York, New York 10019</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">Attention: Peter M. Fry</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">E-mail: peter.fry@leerink.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">with a copy (which shall not constitute notice) to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">Leerink Partners LLC</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">1301 Avenue of the Americas, 5<sup style="vertical-align:top;line-height:120%;">th</sup> Floor</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">New York, New York 10019</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">Attention: Legal Department</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 32pt;">E-mail: LegalNotice@leerink.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">and if to the Company, shall be delivered to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Pyxis Oncology, Inc.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">321 Harrison Avenue</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Boston, MA 02118</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Attention: Jitendra Wadhane</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">E-mail: jwadhane@pyxisoncology.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">with copies (which shall not constitute notice) to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Sidley Austin LLP</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">Attention: Asher Rubin</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">E-mail: arubin@sidley.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#8220;<b><u>Business Day</u></b>&#8221; shall mean any day on which the Nasdaq and commercial banks in the City of New York are open for business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">An electronic communication (&#8220;<b><u>Electronic Notice</u></b>&#8221;) shall be deemed written notice for purposes of this Section 12 if sent to the electronic mail address specified by the receiving party in Section 12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives actual acknowledgment of receipt from the person whom the notice is sent, other than via auto-reply. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&#8220;<b><u>Nonelectronic Notice</u></b>&#8221;), which shall be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns</u>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective successors and the affiliates, controlling persons, officers, directors and other persons referred to in Section 9 hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of each such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the persons referred to in the preceding sentence and their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; <i>provided, however</i>, that the Agent may assign its rights and obligations hereunder to an affiliate of the Agent without obtaining the Company&#8217;s consent, so long as such affiliate is a registered broker-dealer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments for Share Splits</u>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement; Amendment; Severability; Waiver</u>. This Agreement (including all schedules (as amended pursuant to this Agreement) and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent; <i>provided</i>, <i>however</i>, that <b><u>Schedule 2</u></b> of this Agreement may be amended by either party from time to time by sending a notice containing a revised <b><u>Schedule 2</u></b> to the other party in the manner provided in Section 12 and, upon such amendment, all references herein to <b><u>Schedule 2</u></b> shall automatically be deemed to refer to such amended <b><u>Schedule 2</u></b>. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege hereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><u>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</u></b><b>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consent to Jurisdiction</u>. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan,<b> </b>for the adjudication of any dispute hereunder or in connection with any of the transactions contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum, or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy (certified or registered mail, return receipt requested) to such party at the address in effect for notices under Section 12 of this Agreement and agrees that such service shall constitute good and sufficient notice of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. <b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Construction</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The section and exhibit headings herein are for convenience only and shall not affect the construction hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Words defined in the singular shall have a comparable meaning when used in the plural, and vice versa.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The words &#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Wherever the word &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; is used in this Agreement, it shall be deemed to be followed by the words &#8220;without limitation.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References herein to any gender shall include each other gender.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="34" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Permitted Free Writing Prospectuses</u>. Each of the Company and the Agent represents, warrants and agrees that, unless it obtains the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make any offer relating to the Placement Shares that would constitute an issuer free writing prospectus, or that would otherwise constitute a free writing prospectus (as defined in Rule 405), required to be filed with the Commission. Any such free writing prospectus consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a &#8220;<b><u>Permitted Free Writing Prospectus</u></b>.&#8221; The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an issuer free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Absence of Fiduciary Relationship</u>. The Company acknowledges and agrees that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Agent has been retained to act as sales agent in connection with the sale of the Placement Shares, the Agent has acted at arms&#8217; length and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand, and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters and the Agent has no duties or obligations to the Company with respect to the transactions contemplated by this Agreement except the obligations expressly set forth herein;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company is capable of evaluating, and understanding and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;neither the Agent nor its affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company has been advised and is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that the Agent and its affiliates have no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise, provided that the Agent hereby agrees not to engage in any such transaction which would be prohibited under Regulation M; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Company waives, to the fullest extent permitted by law, any claims it may have against the Agent or its affiliates for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the transactions contemplated by this Agreement and agrees that the Agent and its affiliates shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors or employees of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="35" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Recognition of the U.S. Special Resolution Regimes</u>. In the event that the Agent is a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event that the Agent is a Covered Entity and the Agent or a BHC Act Affiliate of the Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For purposes of this Agreement, (A) &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); (B) &#8220;Covered Entity&#8221; means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); (C) &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and (D) &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Information</u>.&nbsp;&nbsp;&nbsp;&nbsp;The Agent may not provide any information gained in connection with this Agreement and the transactions contemplated by this Agreement, including due diligence, to any third party other than its legal counsel advising it on this Agreement and the transactions contemplated by this Agreement unless expressly approved by the Company in writing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Agent</u><u>&#8217;</u><u>s Information</u>. As used in this Agreement, &#8220;<b><u>Agent</u></b><u>&#8217;</u><b><u>s Information</u></b>&#8221; means solely the following information in the Registration Statement and the Prospectus: the ninth paragraph under the heading &#8220;Plan of Distribution&#8221; in the Prospectus Supplement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All references in this Agreement to the Registration Statement, the Prospectus Supplement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to EDGAR. All references in this Agreement to financial statements and schedules and other information that is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement or the Prospectus, as the case may be.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="36" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All references in this Agreement to &#8220;supplements&#8221; to the Prospectus shall include any supplements, &#8220;wrappers&#8221; or similar materials prepared in connection with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>[Remainder of Page Intentionally Blank]</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="37" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Very truly yours,</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PYXIS ONCOLOGY, INC.</b></p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">By:&nbsp; /s/ Jitendra Wadhane</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Jitendra Wadhane</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: Principal Financial and Accounting Officer</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>ACCEPTED as of the date</b></p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>first-above written:</b></p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>LEERINK PARTNERS LLC</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">/s/ Peter Fry</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Peter Fry</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:&nbsp;Head of Alternative Equities</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[<i>Signature Page to Sales Agent Agreement</i>]</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>SCHEDULE 1</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>FORM OF PLACEMENT NOTICE</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ]</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt;">[TITLE]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 72pt;">Pyxis Oncology, Inc.</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cc:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;]</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Leerink Partners LLC</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Subject:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Leerink Partners&#8212;At the Market Offering&#8212;Placement Notice</p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Pursuant to the terms and subject to the conditions contained in the Sales Agreement, dated November 26, 2025 (the &#8220;<b><u>Agreement</u></b>&#8221;), by and between Pyxis Oncology, Inc., a Delaware corporation (the &#8220;<b><u>Company</u></b>&#8221;), and Leerink Partners LLC (&#8220;<b><u>Leerink Partners</u></b>&#8221;), I hereby request on behalf of the Company that Leerink Partners sell up to [ ] shares of common stock, $0.001 par value per share, of the Company (the &#8220;<b><u>Shares</u></b>&#8221;), at a minimum market price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share[; <i>provided</i> that no more than [ ] Shares shall be sold in any one Trading Day (as such term is defined in Section 3 of the Agreement)]. Sales should begin [on the date of this Placement Notice] and end on [DATE] [until all Shares that are the subject of this Placement Notice are sold].</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>SCHEDULE 2</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>The Company</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LSullivan@pyxisoncology.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">JWadhane@pyxisoncology.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Leerink Partners</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">atm@leerink.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dan.Dubin@leerink.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sean.Pitt@leerink.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>SCHEDULE 3</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Compensation</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company shall pay Leerink Partners compensation in cash up to 3.00% of the gross proceeds from the sales of Placement Shares pursuant to the terms of the Sales Agreement of which this <b><u>Schedule 3</u></b> forms a part.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b><u>Exhibit 7(m)</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>OFFICERS&#8217; CERTIFICATE</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each of Lara Sullivan, M.D., the duly qualified and elected Chief Executive Officer of Pyxis Oncology, Inc., a Delaware corporation (the &#8220;<b><u>Company</u></b>&#8221;), and Jitendra Wadhane, the duly qualified and elected Principal Financial and Accounting Officer of the Company, does hereby certify in their respective capacity and on behalf of the Company, pursuant to Section 7(m) of the Sales Agreement, dated November 26, 2025 (the &#8220;<b><u>Sales Agreement</u></b>&#8221;), by and between the Company and Leerink Partners LLC, that, after due inquiry, to the best of the knowledge of the undersigned:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Company in Section 6 of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or Material Adverse Effect, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date hereof, (A) the Registration Statement complies in all material respects with the requirements of the Securities Act and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading, (B) the Prospectus complies in all material respects with the requirements of the Securities Act does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading and (C) no event has occurred as a result of which it is necessary to amend or supplement the Registration Statement or the Prospectus in order to make the statements therein not untrue or misleading or for clauses (A) and (B) above, to be true and correct.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects of the Company and any of its Subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, since the date as of which information is given in the Prospectus, as amended or supplemented to the date hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company does not possess any material non-public information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The maximum amount of Placement Shares that may be sold pursuant to the Sales Agreement has been duly authorized by the Company&#8217;s board of directors or a duly authorized committee thereof pursuant to a resolution or unanimous written consent in accordance with the Company&#8217;s amended and restated articles of incorporation, amended and restated bylaws and applicable law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, each of the undersigned, in such individual&#8217;s respective capacity as Chief Executive Officer or Principal Financial and Accounting Officer of the Company, has executed this Officers&#8217; Certificate on behalf of the Company.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Lara Sullivan, M.D.</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: Chief Executive Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">By:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Jitendra Wadhane</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: Principal Financial and Accounting Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">[<i>Company Signature Page to Officers</i>&#8217;<i> Certificate</i>]</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex_893482.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_893482.htm</title>

	<!-- Generated by ThunderDome Portal - 11/25/2025 11:21:28 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 4.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>PYXIS ONCOLOGY, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>INDENTURE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Dated as of , 20</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">[ ]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Trustee</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 212pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 74%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%; text-align: right;"><u>Page</u></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE</p>
			</td>
			<td style="vertical-align: bottom; width: 13%; text-align: right;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 1.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Definitions</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 1.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Other Definitions</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 1.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Incorporation by Reference of Trust Indenture Act</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 1.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Rules of Construction</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">4</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%; text-align: right;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE II. THE SECURITIES</p>
			</td>
			<td style="vertical-align: bottom; width: 13%; text-align: right;">4</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Issuable in Series</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Establishment of Terms of Series of Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Execution and Authentication</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Registrar and Paying Agent</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">7</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Paying Agent to Hold Money in Trust</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">7</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Securityholder Lists</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">7</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.7.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Mutilated, Destroyed, Lost and Stolen Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.8.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Outstanding Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.9.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Treasury Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">8</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.10.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Temporary Securities</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">9</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.11.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Cancellation</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">9</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.12.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Defaulted Interest</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">9</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.13.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Global Securities</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">9</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 2.14.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">CUSIP Numbers</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE III. REDEMPTION</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Notice to Trustee</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Selection of Securities to be Redeemed</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Notice of Redemption</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Effect of Notice of Redemption</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Deposit of Redemption Price</td>
			<td colspan="3" style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 3.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 5pt;">Securities Redeemed in Part</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE IV. COVENANTS</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 4.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Payment of Principal and Interest</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 4.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">SEC Reports</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 4.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Compliance Certificate</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 4.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Stay, Extension and Usury Laws</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">12</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE V. SUCCESSORS</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 5.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">When Company May Merge, Etc.</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 5.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Successor Corporation Substituted</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">13</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE VI. DEFAULTS AND REMEDIES</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Events of Default</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Acceleration of Maturity; Rescission and Annulment</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Collection of Indebtedness and Suits for Enforcement by Trustee</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Trustee May File Proofs of Claim</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">15</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Trustee May Enforce Claims Without Possession of Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">16</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Application of Money Collected</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">16</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.7.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Limitation on Suits</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">16</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.8.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Unconditional Right of Holders to Receive Principal and Interest</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">16</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.9.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Restoration of Rights and Remedies</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">17</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.10.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Rights and Remedies Cumulative</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">17</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.11.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Delay or Omission Not Waiver</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">17</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.12.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Control by Holders</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">17</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.13.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Waiver of Past Defaults</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">17</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.14.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Undertaking for Costs</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">18</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 6.15.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Subordination</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">18</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE VII. TRUSTEE</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">18</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Duties of Trustee</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">18</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Rights of Trustee</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">19</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Individual Rights of Trustee</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Trustee&#8217;s Disclaimer</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Notice of Defaults</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Reports by Trustee to Holders</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.7.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Compensation and Indemnity</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.8.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Replacement of Trustee</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.9.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Successor Trustee by Merger, Etc.</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">22</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.10.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Eligibility; Disqualification</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">22</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 7.11.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Preferential Collection of Claims Against Company</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">22</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE VIII. SATISFACTION AND DISCHARGE; DEFEASANCE</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">22</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Satisfaction and Discharge of Indenture</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">22</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Application of Trust Funds; Indemnification</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">23</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Legal Defeasance of Securities of any Series</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">23</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Covenant Defeasance</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">24</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="1" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Repayment to Company</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 8.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Reinstatement</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE IX. AMENDMENTS AND WAIVERS</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Without Consent of Holders</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">With Consent of Holders</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">26</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Compliance with Trust Indenture Act</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Revocation and Effect of Consents</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Notation on or Exchange of Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 9.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Trustee Protected</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE X. MISCELLANEOUS</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Trust Indenture Act Controls</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Notices</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">28</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Communication by Holders with Other Holders</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.4.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Certificate and Opinion as to Conditions Precedent</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.5.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Statements Required in Certificate or Opinion</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.6.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Rules by Trustee and Agents</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.7.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Legal Holidays</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.8.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">No Recourse Against Others</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.9.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Counterparts</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">29</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.10.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Governing Law; Waiver of Jury Trial; Consent to Jurisdiction</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.11.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">No Adverse Interpretation of Other Agreements</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.12.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Successors</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.13.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Severability</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.14.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Table of Contents, Headings, Etc.</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.15.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Securities in a Foreign Currency</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.16.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Judgment Currency</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">31</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.17.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">Force Majeure</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">31</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 10.18.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%; padding: 0pt 0pt 0pt 5pt;">U.S.A. Patriot Act</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">31</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="2" style="vertical-align: bottom; width: 13%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 13%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td colspan="2" style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARTICLE XI. SINKING FUNDS</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 11.1.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Applicability of Article</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 11.2.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Satisfaction of Sinking Fund Payments with Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">Section 11.3.</p>
			</td>
			<td style="vertical-align: bottom; width: 74%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">Redemption of Securities for Sinking Fund</p>
			</td>
			<td style="vertical-align: bottom; width: 13%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:37.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PYXIS ONCOLOGY, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:37.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Reconciliation and tie between Trust Indenture Act of 1939 and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:37.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Indenture, dated as of , 20</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;&nbsp;310(a)(1)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(2)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(3)</p>
			</td>
			<td nowrap="true" style="vertical-align: bottom; width: 50%; padding: 0px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(4)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(5)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;311(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.11</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;312(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">2.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.3</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.3</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;313(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)(1)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)(2)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)(1)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.6</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;314(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">4.2, 10.5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)(1)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)(2)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)(3)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(f)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">Not&nbsp;Applicable</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;315(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">7.1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(e)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.14</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;316(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">2.10</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(1)(A)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.12</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(1)(B)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.13</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.8</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;317(a)(1)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.3</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a)(2)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">6.4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">2.5</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#167;318(a)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 405pt;">10.1</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note: This reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Indenture dated as of , 20 between Pyxis Oncology, Inc., a Delaware corporation (&#8220;<i>Company</i>&#8221;), and [______] (&#8220;<i>Trustee</i>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ARTICLE I.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">DEFINITIONS AND INCORPORATION BY REFERENCE</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 1.1. <u>Definitions.</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Additional Amounts</i>&#8221; means any additional amounts which are required hereby or by any Security, under circumstances specified herein or therein, to be paid by the Company in respect of certain taxes imposed on Holders specified herein or therein and which are owing to such Holders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Affiliate</i>&#8221; of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person. For the purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), as used with respect to any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities or by agreement or otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Agent</i>&#8221; means any Registrar, Paying Agent or Notice Agent.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Board of Directors</i>&#8221; means the board of directors of the Company or any duly authorized committee thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Board Resolution</i>&#8221; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Business Day</i>&#8221; means any day except a Saturday, Sunday or a legal holiday in The City of New York, New York (or in connection with any payment, the place of payment) on which banking institutions are authorized or required by law, regulation or executive order to close.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Capital Stock</i>&#8221; means any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Company</i>&#8221; means the party named as such above until a successor replaces it and thereafter means the successor.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Company Order</i>&#8221; means a written order signed in the name of the Company by an Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Corporate Trust Office</i>&#8221; means the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally administered.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Default</i>&#8221; means any event which is, or after notice or passage of time or both would be, an Event of Default.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Depositary</i>&#8221; means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency registered under the Exchange Act; and if at any time there is more than one such person, &#8220;Depositary&#8221; as used with respect to the Securities of any Series shall mean the Depositary with respect to the Securities of such Series.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Discount Security</i>&#8221; means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Dollars</i>&#8221; and &#8220;<i>$</i>&#8221; means the currency of The United States of America.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Exchange Act</i>&#8221; means the Securities Exchange Act of 1934, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Foreign Currency</i>&#8221; means any currency or currency unit issued by a government other than the government of The United States of America.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Foreign Government Obligations</i>&#8221; means, with respect to Securities of any Series that are denominated in a Foreign Currency, direct obligations of, or obligations guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;GAAP</i>&#8221;<i> </i>means accounting principles generally accepted in the United States of America set forth in the opinions and pronouncements of the<i> </i>Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Global Security</i>&#8221; or &#8220;<i>Global Securities</i>&#8221; means a Security or Securities, as the case may be, in the form established pursuant to Section 2.2 evidencing all or part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Holder</i>&#8221; or &#8220;<i>Securityholder</i>&#8221; means a person in whose name a Security is registered.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Indenture</i>&#8221; means this Indenture as amended or supplemented from time to time and shall include the form and terms of particular Series of Securities established as contemplated hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;interest</i>&#8221; with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Maturity</i>,&#8221; when used with respect to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Officer</i>&#8221; means the Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Assistant Treasurer, the Secretary or any Assistant Secretary, and any Vice President of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Officer</i>&#8217;<i>s Certificate</i>&#8221; means a certificate signed by any Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Opinion of Counsel</i>&#8221; means a written opinion of legal counsel who is acceptable to the Trustee. The counsel may be an employee of or counsel to the Company. The opinion may contain customary limitations, conditions and exceptions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;person</i>&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;principal</i>&#8221; of a Security means the principal of the Security plus, when appropriate, the premium, if any, on, and any Additional Amounts in respect of, the Security.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Responsible Officer</i>&#8221; means any officer of the Trustee in its Corporate Trust Office having responsibility for administration of this Indenture and also means, with respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with a particular subject.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;SEC</i>&#8221; means the Securities and Exchange Commission.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Securities</i>&#8221; means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered under this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Senior Indebtedness</i>&#8221; means the principal of (and premium, if any) and unpaid interest on (i) the Company indebtedness (including indebtedness of others guaranteed by the Company), whenever created, incurred, assumed or guaranteed, for money borrowed (other than indenture Securities issued under this Indenture and denominated as subordinated debt securities), unless in the instrument creating or evidencing the same or under which the same is outstanding it is provided that this indebtedness is not senior or prior in right of payment to the subordinated Securities; and (ii) renewals, extensions, modifications and refinancings of any such indebtedness.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Series</i>&#8221; or &#8220;<i>Series of Securities</i>&#8221; means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections 2.1 and 2.2 hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Stated Maturity</i>&#8221; when used with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest is due and payable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Subsidiary</i>&#8221; of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;TIA</i>&#8221; means the Trust Indenture Act of 1939 (15 U.S. Code &#167;&#167; 77aaa-77bbbb) as in effect on the date of this Indenture; <u>provided</u>, <u>however</u>, that in the event the Trust Indenture Act of 1939 is amended after such date, &#8220;TIA&#8221; means, to the extent required by any such amendment, the Trust Indenture Act as so amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;Trustee</i>&#8221; means the person named as the &#8220;Trustee&#8221; in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter &#8220;Trustee&#8221; shall mean or include each person who is then a Trustee hereunder, and if at any time there is more than one such person, &#8220;Trustee&#8221; as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;U.S. Government Obligations</i>&#8221; means securities which are direct obligations of, or guaranteed by, The United States of America or an agency of the United States of America for the payment of which its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depository receipt, <i>provided</i> that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary receipt.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 1.2. <u>Other Definitions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">DEFINED</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">IN</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TERM</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">SECTION</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Bankruptcy Law</i>&#8221;</p>
			</td>
			<td style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">6.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Custodian</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">6.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Event of Default</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">6.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Judgment Currency</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.16</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Legal Holiday</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.7</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;mandatory sinking fund payment</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;New York Banking Day</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.16</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Notice Agent</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2.4</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;optional sinking fund payment</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Paying Agent</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2.4</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Registrar</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2.4</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Required Currency</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.16</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;Specified Courts</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10.10</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>&#8220;successor person</i>&#8221;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5.1</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Section 1.3. <u>Incorporation by Reference of Trust Indenture Act</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture. The following&nbsp;TIA terms used in this Indenture have the following meanings:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;Commission</i>&#8221; means the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;indenture securities</i>&#8221; means the Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;indenture security holder</i>&#8221; means a Securityholder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;indenture to be qualified</i>&#8221; means this Indenture.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;indenture trustee</i>&#8221; or &#8220;<i>institutional trustee</i>&#8221; means the Trustee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>&#8220;obligor</i>&#8221; on the indenture securities means the Company and any successor obligor upon the Securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA and not otherwise defined herein are used herein as so defined.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Section 1.4. <u>Rules of Construction</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Unless the context otherwise requires:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a term has the meaning assigned to it;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>&#8220;or</i>&#8221;&nbsp;is not exclusive;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">words in the singular include the plural, and in the plural include the singular; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">provisions apply to successive events and transactions.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ARTICLE II.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">THE SECURITIES</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 2.1. <u>Issuable in Series</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more Series. All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental indenture or an Officer&#8217;s Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer&#8217;s Certificate or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined. Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.2. <u>Establishment of Terms of Series of Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through 2.2.24) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.1. the designation or title (which shall distinguish the Securities of that particular Series from the Securities of any other Series) and ranking (including the terms of any subordination provisions) of the Series;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.2. the total principal amount of the Series, the denominations in which the offered Securities will be issued and whether the offering may be reopened for additional Securities of that Series and on what terms;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.3. the percentage of the principal amount at which the Securities of the Series will be issued;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.4. the date or dates on which principal will be payable;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.5. the rate or rates (which may be either fixed or variable) and/or, if applicable, the method of determining such rate or rates of interest, if any, the date or dates from which any interest shall accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.6. the terms for redemption, extension or early repayment, if any;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.7. the currencies in which the Series are issued and payable;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.8. the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.9. whether the amount of payments of principal, interest or premium, if any, on a Series of the Securities will be determined with reference to an index, formula or other method and how these amounts will be determined;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.10. the place or places of payment, transfer, conversion and/or exchange of the Securities;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.11. any restrictive covenants;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.12. whether the Series of Securities are issuable in certified form</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.13. any provisions for legal defeasance or covenant defeasance;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: justify;">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.14. whether and under what circumstances we will pay Additional Amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the Securities rather than pay the Additional Amounts (and the terms of this option);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.15. if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall be issuable;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.16. the provisions for convertibility or exchangeability of the Securities of the Series into or for any other Securities;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.17. whether the Securities are subject to subordination and the terms of such subordination;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.18. any addition to, deletion of or change in the Events of Default which applies to any Securities of the Series and any change in the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.19. any addition to, deletion of or change in the covenants set forth in Articles IV or V which applies to Securities of the Series;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.20. any listing of Securities of such Series on any securities exchange;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.21. the provisions, if any, relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the option of the Company, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.22. any Depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series if other than those appointed herein;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.23. any other terms of the Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series), including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.2.24. whether any of the Company&#8217;s direct or indirect Subsidiaries will guarantee the Securities of that Series, including the terms of subordination, if any, of such guarantees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All Securities of any one Series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate referred to above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.3. <u>Execution and Authentication</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">An Officer shall sign the Securities for the Company by manual or facsimile signature.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating agent. The signature shall be conclusive evidence that the Security has been authenticated under this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee shall at any time, and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate, upon receipt by the Trustee of a Company Order. Each Security shall be dated the date of its authentication.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section 7.2) shall be fully protected in relying on: (a) the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate establishing the form of the Securities of that Series or of Securities within that Series and the terms of the Securities of that Series or of Securities within that Series, (b) an Officer&#8217;s Certificate complying with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series: (a) if the Trustee, being advised by counsel, determines that such action may not be taken lawfully; or (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a trust committee of directors and/or vice-presidents or a committee of Responsible Officers shall determine that such action would expose the Trustee to personal liability to Holders of any then outstanding Series of Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee may appoint an authenticating agent acceptable to the Company to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent has the same rights as an Agent to deal with the Company or an Affiliate of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.4. <u>Registrar and Paying Agent</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company shall maintain, with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant to Section 2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (&#8220;<i>Paying Agent</i>&#8221;), where Securities of such Series may be surrendered for registration of transfer or exchange (&#8220;<i>Registrar</i>&#8221;) and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (&#8220;<i>Notice Agent</i>&#8221;). The Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange. The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar, Paying Agent or Notice Agent. If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands; <u>provided</u>, <u>however</u>, that any appointment of the Trustee as the Notice Agent shall exclude the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may also from time to time designate one or more co-registrars, additional paying agents or additional notice agents and may from time to time rescind such designations; <u>provided</u>, <u>however</u>, that no such designation or rescission shall in any manner relieve the Company of its obligations to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section 2.2 for Securities of any Series for such purposes. The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or additional notice agent. The term &#8220;<i>Registrar</i>&#8221; includes any co-registrar; the term &#8220;<i>Paying Agent</i>&#8221; includes any additional paying agent; and the term &#8220;<i>Notice Agent</i>&#8221; includes any additional notice agent. The Company or any of its Affiliates may serve as Registrar or Paying Agent.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company hereby appoints the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless another Registrar, Paying Agent or Notice Agent, as the case may be, is appointed prior to the time Securities of that Series are first issued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.5. <u>Paying Agent to Hold Money in Trust</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Securityholders of any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities, and will notify the Trustee in writing of any default by the Company in making any such payment. While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee. The Company at any time may require a Paying Agent to pay all money held by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company) shall have no further liability for the money. If the Company or a Subsidiary of the Company acts as Paying Agent, it shall segregate and hold in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it as Paying Agent. Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying Agent for the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.6. <u>Securityholder Lists</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Securityholders of each Series of Securities and shall otherwise comply with TIA &#167; 312(a). If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.7. <u>Mutilated, Destroyed, Lost and Stolen Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If any mutilated Security is surrendered to the Trustee, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any Security and (ii) such security or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In case any such mutilated, destroyed, lost or stolen Security has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security, pay such Security.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Upon the issuance of any new Security under this Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Every new Security of any Series issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued hereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.8. <u>Outstanding Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section as not outstanding.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If a Security is replaced pursuant to Section 2.7, it ceases to be outstanding until the Trustee receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Paying Agent (other than the Company, a Subsidiary of the Company or an Affiliate of the Company) holds on the Maturity of Securities of a Series money sufficient to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to accrue.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated transactions or otherwise. A Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section 2.9 below).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In determining whether the Holders of the requisite principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof pursuant to Section 6.2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.9. <u>Treasury Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In determining whether the Holders of the required principal amount of Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.10. <u>Temporary Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Until definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities upon a Company Order. Temporary Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities. Without unreasonable delay, the Company shall prepare and the Trustee upon receipt of a Company Order shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities. Until so exchanged, temporary securities shall have the same rights under this Indenture as the definitive Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.11. <u>Cancellation</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company at any time may deliver Securities to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered to them for registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and shall destroy such canceled Securities (subject to the record retention requirement of the Exchange Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company. The Company may not issue new Securities to replace Securities that it has paid or delivered to the Trustee for cancellation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.12. <u>Defaulted Interest</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Company defaults in a payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date. The Company shall fix the record date and payment date. At least 10 days before the special record date, the Company shall send to the Trustee and to each Securityholder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid. The Company may pay defaulted interest in any other lawful manner.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.13. <u>Global Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.13.1. <u>Terms of Securities</u>. A Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate shall establish whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A Global Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such a successor Depositary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.13.2. <u>Legends</u>. Any Global Security issued hereunder shall bear a legend in substantially the following form:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In addition, so long as the Depository Trust Company (&#8220;DTC&#8221;) is the Depositary, each Global Note registered in the name of DTC or its nominee shall bear a legend in substantially the following form:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;UNLESS THIS GLOBAL NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (&#8220;DTC&#8221;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE &amp; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE &amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE &amp; CO., HAS AN INTEREST HEREIN.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.13.3. <u>Acts of Holders</u>. The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.13.4. <u>Payments</u>. Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.13.5 <u>Consents, Declaration and Directions</u>. The Company, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding Securities of such Series represented by a Global Security as shall be specified in a written statement of the Depositary or by the applicable procedures of such Depositary with respect to such Global Security, for purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 2.14. <u>CUSIP Numbers</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company in issuing the Securities may use &#8220;CUSIP&#8221; numbers (if then generally in use), and, if so, the Trustee shall use &#8220;CUSIP&#8221; numbers in notices of redemption as a convenience to Holders; <u>provided</u> that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE III.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">REDEMPTION</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3.1. <u>Notice to Trustee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities. If a Series of Securities is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and the principal amount of Series of Securities to be redeemed. The Company shall give the notice at least 15 days before the redemption date, unless a shorter period is satisfactory to the Trustee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3.2. <u>Selection of Securities to be Redeemed</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Unless otherwise indicated for a particular Series by a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, if less than all the Securities of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows: (a) if the Securities are in the form of Global Securities, in accordance with the procedures of the Depositary, (b) if the Securities are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed, or (c) if not otherwise provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global Securities, to the applicable rules and procedures of the Depositary. The Securities to be redeemed shall be selected from Securities of the Series outstanding not previously called for redemption. Portions of the principal of Securities of the Series that have denominations larger than $1,000 may be selected for redemption. Securities of the Series and portions of them it selected for redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section 2.2.15, the minimum principal denomination for each Series and the authorized integral multiples thereof. Provisions of this Indenture that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 3.3. <u>Notice of Redemption</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, at least 15 days but not more than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures of the Depositary, a notice of redemption to each Holder whose Securities are to be redeemed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The notice shall identify the Securities of the Series to be redeemed and shall state:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the redemption date;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the redemption price;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the name and address of the Paying Agent;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;if any Securities are being redeemed in part, the portion of the principal amount of such Securities to be redeemed and that, after the redemption date and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued in the name of the Holder thereof upon cancellation of the original Security;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">that Securities of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;that interest on Securities of the Series called for redemption ceases to accrue on and after the redemption date unless the Company defaults in the deposit of the redemption price;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the CUSIP number, if any; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any other information as may be required by the terms of the particular Series or the Securities of a Series being redeemed.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">At the Company&#8217;s request, the Trustee shall give the notice of redemption in the Company&#8217;s name and at its expense, provided, however, that the Company has delivered to the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer&#8217;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 3.4. <u>Effect of Notice of Redemption</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Once notice of redemption is sent as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the redemption date and at the redemption price. Except as otherwise provided in the supplemental indenture, Board Resolution or Officer&#8217;s Certificate for a Series, a notice of redemption may not be conditional. Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued interest to the redemption date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3.5. <u>Deposit of Redemption Price</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">On or before 11:00 a.m., New York City time, on the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 3.6. <u>Securities Redeemed in Part</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Upon surrender of a Security that is redeemed in part, the Trustee shall authenticate for the Holder a new Security of the same Series and the same maturity equal in principal amount to the unredeemed portion of the Security surrendered.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE IV.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">COVENANTS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 4.1. <u>Payment of Principal and Interest</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company covenants and agrees for the benefit of the Holders of each Series of Securities that it will duly and punctually pay the principal of and interest, if any, on the Securities of that Series in accordance with the terms of such Securities and this Indenture. On or before 11:00 a.m., New York City time, on the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 4.2. <u>SEC Reports</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act. The Company also shall comply with the other provisions of TIA &#167; 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section 4.2.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Delivery of reports, information and documents to the Trustee under this Section 4.2 are for informational purposes only and the Trustee&#8217;s receipt of the foregoing shall not constitute constructive or actual notice of any information contained therein or determinable from information contained therein, including the Company&#8217;s compliance with any of their covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer&#8217;s Certificates).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 4.3. <u>Compliance Certificate</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To the extent any Securities of a Series are outstanding, each year, the Company shall furnish to the Trustee an Officer&#8217;s Certificate stating that to their knowledge the Company is in compliance with this Indenture and the Securities, or else specifying any Default.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 4.4. <u>Stay, Extension and Usury Laws</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance of this Indenture or the Securities; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE V.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">SUCCESSORS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 5.1. <u>When Company May Merge, Etc</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company shall not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of its properties and assets to, any person (a &#8220;<i>successor person</i>&#8221;) unless all of the following conditions are met:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;if the Company does not survive such transaction or the Company conveys, transfers or leases its properties and assets substantially as an entirety, the acquiring company must be a corporation, limited liability company, partnership or trust, or other corporate form, organized under the laws of any state of the United States or the District of Columbia, and such company must agree to be legally responsible for our Securities, and, if not already subject to the jurisdiction of any state of the United States or the District of Columbia, the new company must submit to such jurisdiction for all purposes with respect to the Securities and appoint an Agent for service of process;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">alternatively, the Company must be the surviving Company;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Company shall deliver to the Trustee prior to the consummation of the proposed transaction an Officer&#8217;s Certificate to the foregoing effect and an Opinion of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Notwithstanding the above, any Subsidiary of the Company may consolidate with, merge into or transfer all or part of its properties to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Neither an Officer&#8217;s Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 5.2. <u>Successor Corporation Substituted</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Upon any consolidation or merger, or any sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company in accordance with Section 5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor person has been named as the Company herein; <u>provided</u>, <u>however</u>, that the predecessor Company in the case of a sale, conveyance or other disposition (other than a lease) shall be released from all obligations and covenants under this Indenture and the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE VI.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">DEFAULTS AND REMEDIES</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.1. <u>Events of Default</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;"><i>&#8220;Event of Default</i>,&#8221; wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Board Resolution, supplemental indenture or Officer&#8217;s Certificate, it is provided that such Series shall not have the benefit of said Event of Default:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;default in the payment of any interest on any Security of that Series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11:00 a.m., New York City time, on the 30th day of such period); or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">default in the payment of principal of, or any premium on, any Security of that Series at its Maturity; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;the Company remains in breach of a covenant in respect of Securities of the Series for 90 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a &#8220;Notice of Default&#8221; hereunder; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;the Company pursuant to or within the meaning of any Bankruptcy Law:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">commences a voluntary case,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">consents to the entry of an order for relief against it in an involuntary case,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">consents to the appointment of a Custodian of it or for all or substantially all of its property,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iv)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">makes a general assignment for the benefit of its creditors, or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(v)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">generally is unable to pay its debts as the same become due; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">is for relief against the Company in an involuntary case,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">appoints a Custodian of the Company or for all or substantially all of its property, or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">orders the liquidation of the Company,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">and the order or decree remains unstayed and in effect for 60 days; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;any other Event of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, in accordance with Section 2.2.18.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The term &#8220;<i>Bankruptcy Law</i>&#8221; means title 11, U.S. Code or any similar Federal or State law for the relief of debtors. The term &#8220;<i>Custodian</i>&#8221; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.2. <u>Acceleration of Maturity; Rescission and Annulment</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If an Event of Default has occurred and has not been cured or waived (other than an Event of Default referred to in Section 6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount (or, if any Securities of that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable. If an Event of Default specified in Section 6.1(d) or (e) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall <i>ipso facto</i> become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">At any time after such a declaration of acceleration with respect to any Series has been made and before a judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article provided, the Holders of a majority in principal amount of the outstanding Securities of that Series, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities of that Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section 6.13.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">No such rescission shall affect any subsequent Default or impair any right consequent thereon.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.3. <u>Collection of Indebtedness and Suits for Enforcement by Trustee.</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Company covenants that if</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;default is made in the payment of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30 days, or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">default is made in the payment of principal of any Security at the Maturity thereof, or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">default is made in the deposit of any sinking fund payment, if any, when and as due by the terms of a Security,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;"><i>then, </i>the Company will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable<i> </i>on such Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Company or any other obligor upon such Securities, wherever situated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Section 6.4. <u>Trustee May File Proofs of Claim</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be entitled and empowered, by intervention in such proceeding or otherwise,</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;to file and prove a claim for the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to collect and receive any moneys or other property payable or deliverable on any such claims and to distribute the same,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.5. <u>Trustee May Enforce Claims Without Possession of Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.6. <u>Application of Money Collected.</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Any money or property collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and upon surrender thereof if fully paid:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">First: To the payment of all amounts due the Trustee under Section 7.7; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Second: To the payment of the amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Third: To the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.7. <u>Limitation on Suits</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">such Holder has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;the Holders of not less than 25% in principal amount of the outstanding Securities of that Series shall have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;such Holder or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">it being understood, intended and expressly covenanted by the Holder of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.8. <u>Unconditional Right of Holders to Receive Principal and Interest</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.9. <u>Restoration of Rights and Remedies</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.10. <u>Rights and Remedies Cumulative</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 2.7, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.11. <u>Delay or Omission Not Waiver</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.12. <u>Control by Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">such direction shall not be in conflict with any rule of law or with this Indenture,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;subject to the provisions of Section 7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;prior to taking any action as directed under this Section 6.12, the Trustee shall be entitled to indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.13. <u>Waiver of Past Defaults</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all the Securities of such Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences, except a Default in the payment of the principal of or interest on any Security of such Series (provided, however, that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration). Upon any such waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or impair any right consequent thereon.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.14. <u>Undertaking for Costs</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">All parties to this Indenture agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 6.15 <u>Subordination</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Upon any distribution of our assets upon the Company&#8217;s dissolution, winding up, liquidation or reorganization, the payment of the principal of (and premium, if any) and interest on any Securities denominated as subordinated Securities is to be subordinated to the extent provided in this Indenture in right of payment to the prior payment in full of all Senior Indebtedness, but the Company&#8217;s obligation to Holders to make payment of the principal of (and premium, if any) and interest on such subordinated Securities will not otherwise be affected. In addition, no payment on account of principal (or premium, if any), interest or sinking fund, if any, may be made on such subordinated Securities at any time unless full payment of all amounts due in respect of the principal (and premium, if any), interest and sinking fund, if any, on Senior Indebtedness has been made or duly provided for in money or money&#8217;s worth.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">In the event that, notwithstanding the foregoing, any payment from the Company is received by the Trustee in respect of subordinated Securities or by the Holders of any of such subordinated Securities before all Senior Indebtedness is paid in full, the payment or distribution must be paid over to the Holders of the Senior Indebtedness or on their behalf for application to the payment of all the Senior Indebtedness remaining unpaid until all the Senior Indebtedness has been paid in full, after giving effect to any concurrent payment or distribution to the Holders of the Senior Indebtedness. Subject to the payment in full of all Senior Indebtedness, the Holders of such subordinated Securities will be subrogated to the rights of the Holders of the Senior Indebtedness to the extent of payments made to the Holders of the Senior Indebtedness out of the distributive share of such subordinated Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">By reason of this subordination, in the event of a distribution of our assets upon the Company&#8217;s insolvency, certain of our senior creditors may recover more, ratably, than holders of any subordinated Securities. These subordination provisions will not apply to money and Securities held in trust under the defeasance provisions of this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE VII.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">TRUSTEE</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.1. <u>Duties of Trustee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;If an Event of Default has occurred and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person&#8217;s own affairs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Except during the continuance of an Event of Default:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee need perform only those duties that are specifically set forth in this Indenture and no others.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon Officer&#8217;s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture; <u>however</u>, in the case of any such Officer&#8217;s Certificates or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall examine such Officer&#8217;s Certificates and Opinions of Counsel to determine whether or not they conform to the form requirements of this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except that:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This paragraph does not limit the effect of paragraph (b) of this Section.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section 6.12.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Every provision of this Indenture that in any way relates to the Trustee is subject to paragraph (a), (b) and (c) of this Section.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee may refuse to perform any duty or exercise any right or power unless it receives indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in performing such duty or exercising such right or power.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any of its duties, or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections and immunities as are set forth in paragraphs (e), (f) and (g) of this Section and in Section 7.2, each with respect to the Trustee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.2. <u>Rights of Trustee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee may rely on and shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Before the Trustee acts or refrains from acting, it may require an Officer&#8217;s Certificate or an Opinion of Counsel or both. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officer&#8217;s Certificate or Opinion of Counsel.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care. No Depositary shall be deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depositary.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers, provided that the Trustee&#8217;s conduct does not constitute willful misconduct or negligence.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder without willful misconduct or negligence, and in reliance thereon.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="19" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;In no event shall the Trustee be liable to any person for special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The permissive right of the Trustee to take the actions permitted by this Indenture shall not be construed as an obligation or duty to do so.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.3. <u>Individual Rights of Trustee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights. The Trustee is also subject to Sections 7.10 and 7.11.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.4. <u>Trustee</u><u>&#8217;</u><u>s Disclaimer</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the Company&#8217;s use of the proceeds from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.5. <u>Notice of Defaults</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and if it is known to a Responsible Officer of the Trustee, the Trustee shall send to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of such Default or Event of Default. Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Securityholders of that Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.6. <u>Reports by Trustee to Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Within 60 days after each anniversary of the date of this Indenture, the Trustee shall transmit by mail to all Securityholders, as their names and addresses appear on the register kept by the Registrar, a brief report dated as of such anniversary date, in accordance with, and to the extent required under, TIA &#167; 313.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">A copy of each report at the time of its mailing to Securityholders of any Series shall be filed with the SEC and each national securities exchange on which the Securities of that Series are listed. The Company shall promptly notify the Trustee in writing when Securities of any Series are listed on any national securities exchange.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.7. <u>Compensation and Indemnity</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company shall pay to the Trustee from time to time compensation for its services as the Company and the Trustee shall from time to time agree upon in writing. The Trustee&#8217;s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee upon request for all reasonable out of pocket expenses incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee&#8217;s agents and counsel.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="20" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Company shall indemnify each of the Trustee and any predecessor Trustee (including for the cost of defending itself) against any cost, expense or liability, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it except as set forth in the next paragraph in the performance of its duties under this Indenture as Trustee or Agent. The Trustee shall notify the Company promptly of any claim for which it may seek indemnity. Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder, unless and to the extent that the Company is materially prejudiced thereby. The Company shall defend the claim and the Trustee shall cooperate in the defense. The Trustee may have one separate counsel and the Company shall pay the reasonable fees and expenses of such counsel. The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld. This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Company need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through willful misconduct or negligence.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">To secure the Company&#8217;s payment obligations in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The provisions of this Section shall survive the termination of this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.8. <u>Replacement of Trustee</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">A resignation or removal of the Trustee and appointment of a successor Trustee shall become effective only upon the successor Trustee&#8217;s acceptance of appointment as provided in this Section.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Trustee may resign with respect to the Securities of one or more Series by so notifying the Company at least 30 days prior to the date of the proposed resignation. The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so notifying the Trustee and the Company. The Company may remove the Trustee with respect to Securities of one or more Series if:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Trustee fails to comply with Section 7.10;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a Custodian or public officer takes charge of the Trustee or its property; or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Trustee becomes incapable of acting.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee. Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the successor Trustee appointed by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">If a successor Trustee with respect to the Securities of any one or more Series does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent jurisdiction for the appointment of a successor Trustee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture. A successor Trustee shall mail a notice of its succession to each Securityholder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company&#8217;s obligations under Section 7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to such replacement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="21" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.9. <u>Successor Trustee by Merger, Etc</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business to, another corporation, the successor corporation without any further act shall be the successor Trustee, subject to Section 7.10.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.10. <u>Eligibility; Disqualification</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Indenture shall always have a Trustee who satisfies the requirements of TIA &#167; 310(a)(1), (2) and (5). The Trustee shall always have a combined capital and surplus of at least $35,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA &#167; 310(b).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 7.11. <u>Preferential Collection of Claims Against Company</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Trustee is subject to TIA &#167; 311(a), excluding any creditor relationship listed in TIA &#167; 311(b). A Trustee who has resigned or been removed shall be subject to TIA &#167; 311(a) to the extent indicated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE VIII.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">SATISFACTION AND DISCHARGE; DEFEASANCE</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.1. <u>Satisfaction and Discharge of Indenture</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">This Indenture shall upon Company Order be discharged with respect to the Securities of any Series and cease to be of further effect as to all Securities of such Series (except as hereinafter provided in this Section 8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging satisfaction and discharge of this Indenture, when</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">(a) either</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;all Securities of such Series theretofore authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(ii)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">all such Securities of such Series not theretofore delivered to the Trustee for cancellation</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">have become due and payable by reason of sending a notice of redemption or otherwise, or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">will become due and payable at their Stated Maturity within one year, or</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(3)&nbsp;&nbsp;&nbsp;&nbsp;have been called for redemption or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">are deemed paid and discharged pursuant to Section 8.3, as applicable;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">and the Company, in the case of (1), (2) or (3) above, shall have irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S. Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the Company has paid or caused to be paid all other sums payable hereunder by the Company; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the satisfaction and discharge contemplated by this Section have been complied with.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="22" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Company to the Trustee under Section 7.7, and, if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 8.2 and 8.5 shall survive.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.2. <u>Application of Trust Funds; Indemnification</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of Section 8.5, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated by Sections 8.1, 8.3 or 8.4.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf of Holders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Trustee shall deliver or pay to the Company from time to time upon Company Order any U.S. Government Obligations or Foreign Government Obligations or money held by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations or money were deposited or received. This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.3. <u>Legal Defeasance of Securities of any Series</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Unless this Section 8.3 is otherwise specified, pursuant to Section 2.2, to be inapplicable to Securities of any Series, the Company shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging the same), except as to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;the rights of Holders of Securities of such Series to receive, from the trust funds described in subparagraph (d) hereof, (i) payment of the principal of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or installment of principal or interest and (ii) the benefit of any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the provisions of Sections 2.4, 2.5, 2.7, 7.7, 8.2, 8.3, 8.5 and 8.6; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the rights, powers, trusts and immunities of the Trustee hereunder and the Company&#8217;s obligations in connection therewith;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">provided that, the following conditions shall have been satisfied:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have irrevocably deposited or caused to be deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds specifically pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of&nbsp;money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal of and interest, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund payments are due;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="23" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during the period ending on the 91st day after such date;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel to the effect that (i) the Company has received from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating that the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the defeasance contemplated by this Section have been complied with.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.4. <u>Covenant Defeasance</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unless this Section 8.4 is otherwise specified pursuant to Section 2.2 to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the Securities of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein, any additional covenants specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 (and the failure to comply with any such covenants shall not constitute a Default or Event of Default with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as specified above, the remainder of this Indenture and such Securities will be unaffected thereby; provided that the following conditions shall have been satisfied:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;with reference to this Section 8.4, the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal (including mandatory sinking fund or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="24" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;the Company shall have delivered to the Trustee an Officers&#8217; Certificate and an Opinion of Counsel to the effect that the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit and covenant defeasance and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit and covenant defeasance had not occurred;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section have been complied with.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.5. <u>Repayment to Company</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Subject to applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal and interest that remains unclaimed for two years. After that, Securityholders entitled to the money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 8.6. <u>Reinstatement</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Trustee or the Paying Agent is unable to apply any money deposited with respect to Securities of any Series in accordance with Section 8.1 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the obligations of the Company under this Indenture with respect to the Securities of such Series and under the Securities of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1 until such time as the Trustee or the Paying Agent is permitted to apply all such money in accordance with Section 8.1; <u>provided</u>, <u>however</u>, that if the Company has made any payment of principal of or interest on or any Additional Amounts with respect to any Securities because of the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE IX.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">AMENDMENTS AND WAIVERS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 9.1. <u>Without Consent of Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Company and the Trustee may amend or supplement this Indenture or the Securities of one or more Series without the consent of any</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Securityholder:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to cure any ambiguity, defect or inconsistency;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to comply with Article V;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to provide for uncertificated Securities in addition to or in place of certificated Securities;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to add guarantees with respect to Securities of any Series or secure Securities of any Series;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to surrender any of the Company&#8217;s rights or powers under this Indenture;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to add covenants or events of default for the benefit of the holders of Securities of any Series;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="25" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to comply with the applicable procedures of the applicable depositary;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to make any change that does not adversely affect the rights of any Securityholder;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to provide for the issuance of and establish the form and terms and conditions of Securities of any Series as permitted by this Indenture;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(k)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 9.2. <u>With Consent of Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">9.2.1. The following types of changes may require specific approval of all of the Holders:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">change the Stated Maturity of the principal of or rate of interest on a Security;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the principal or any amounts due on a Security;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the amount of principal payable upon acceleration of the Maturity of a Security following a Default;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">at any time after a change of control has occurred, reduce any premium payable upon a change of control;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">unless otherwise described in a supplemental indenture, change the place or currency of payment on a Security;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(f)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">impair the right of Holders to sue for payment;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(g)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">adversely affect any right to convert or exchange a Security in accordance with its terms;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(h)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reduce the percentage of Holders of Securities whose consent is needed to modify or amend this Indenture;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;reduce the percentage of Holders of Securities whose consent is needed to waive compliance with certain provisions of this Indenture or to waive certain Defaults;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(j)&nbsp;&nbsp;&nbsp;&nbsp;modify any other aspect of the provisions of this Indenture dealing with supplemental indenture, modification and waiver of past Defaults, changes to the quorum or voting requirements or the wavier of certain covenants; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(k)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">change any obligations the Company has to pay Additional Amounts.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">9.2.2. Any other change to this Indenture and the Securities shall require majority approval:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if the change affects only one Series of Securities, it must be approved by the Holders of a majority in principal amount of that Series; and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;if the change affects more than one Series of Securities issued under the same indenture, it must be approved by the Holders of a majority in principal amount of all of the Series affected by the change, with all affected Series voting together as one class for this purpose.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="26" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Holders of a majority in principal amount of all of the Series of Securities issued under this Indenture, voting together as one class for this purpose, may waive Company compliance obligations with respect to some covenants in this Indenture. However, the Company cannot obtain a waiver of payment default or any of the matters in Section 9.2.1.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 9.3. <u>Compliance with Trust Indenture Act</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 9.4. <u>Revocation and Effect of Consents</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security, even if notation of the consent is not made on any Security. However, any such Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the date the waiver becomes effective.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any amendment or waiver once effective shall bind every Securityholder of each Series affected by such amendment or waiver unless it is of the type described in Section 9.2.2. In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second immediately preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those persons, shall be entitled to give such consent or to revoke any consent previously given or take any such action, whether or not such Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 9.5. <u>Notation on or Exchange of Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company or the Trustee may place an appropriate notation about an amendment or waiver on any Security of any Series thereafter authenticated. The Company in exchange for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section 2.3 new Securities of that Series that reflect the amendment or waiver.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 9.6. <u>Trustee Protected</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in relying upon, an Officer&#8217;s Certificate or an Opinion of Counsel or both complying with Section 10.4. The Trustee shall sign all supplemental indentures upon delivery of such an Officer&#8217;s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental indenture that adversely affects its rights, duties, liabilities or immunities under this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE X.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">MISCELLANEOUS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.1. <u>Trust Indenture Act Controls</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If any provision of this Indenture limits, qualifies, or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="27" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.2. <u>Notices</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in person or mailed by first-class mail (registered or certified, return receipt requested), facsimile transmission, email or overnight air courier guaranteeing next day delivery, to the others&#8217; address:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if to the Company:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Pyxis Oncology, Inc.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 36pt; text-align: justify;">321, Harrison Avenue</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 36pt; text-align: justify;">Boston, Massachusetts</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt; text-indent: 36pt; text-align: justify;">Telephone: (617) 453-3596</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">with copies to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Sidley Austin LLP</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">787 Seventh Avenue</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">New York, NY 10019</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Attention: Asher Rubin, Istvan A. Hajdu</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Telephone: (212) 839-5599</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if to the Trustee:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">[ ]</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Attention: [ ]</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Telephone: [ ]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">with a copy to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">[ ]</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Attention: [ ]</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt; text-align: justify;">Telephone: [ ]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any notice or communication to a Securityholder shall be sent electronically or by first-class mail to his, her or its address shown on the register kept by the Registrar, in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Securityholder of any Series or any defect in it shall not affect its sufficiency with respect to other Securityholders of that or any other Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If a notice or communication is sent or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Securityholder receives it.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If the Company sends a notice or communication to Securityholders, it shall send a copy to the Trustee and each Agent at the same time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding any other provision of this Indenture or any Security, where this Indenture or any Security provides for notice of any event (including any notice of redemption) to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its designee) pursuant to the customary procedures of such Depositary.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="28" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.3. <u>Communication by Holders with Other Holders</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Securityholders of any Series may communicate pursuant to TIA &#167; 312(b) with other Securityholders of that Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series. The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA &#167; 312(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.4. <u>Certificate and Opinion as to Conditions Precedent</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;an Officer&#8217;s Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.5. <u>Statements Required in Certificate or Opinion</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA &#167; 314(a)(4)) shall comply with the provisions of TIA &#167; 314(e) and shall include:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a statement that the person making such certificate or opinion has read such covenant or condition;</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;a statement that, in the opinion of such person, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.6. <u>Rules by Trustee and Agents</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">The Trustee may make reasonable rules for action by or a meeting of Securityholders of one or more Series. Any Agent may make reasonable rules and set reasonable requirements for its functions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.7. <u>Legal Holidays</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">A &#8220;<i>Legal Holiday</i>&#8221; is any day that is not a Business Day. If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.8. <u>No Recourse Against Others</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A director, officer, employee or stockholder (past or present), as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation. Each Securityholder by accepting a Security waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">Section 10.9. <u>Counterparts</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">This Indenture may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="29" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.10. <u>Governing Law; Waiver of Jury Trial; Consent to Jurisdiction</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>THIS INDENTURE AND THE SECURITIES, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the &#8220;<i>Specified Courts</i>&#8221;), and each party irrevocably submits to the non exclusive jurisdiction of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The Company, the Trustee and the Holders (by their acceptance of the Securities) each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.11. <u>No Adverse Interpretation of Other Agreements</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">This Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company. Any such indenture, loan or debt agreement may not be used to interpret this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.12. <u>Successors</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All agreements of the Company in this Indenture and the Securities shall bind its successor. All agreements of the Trustee in this Indenture shall bind its successor.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.13. <u>Severability</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.14. <u>Table of Contents, Headings, Etc</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Table of Contents, Cross Reference Table, and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.15. <u>Securities in a Foreign Currency</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than one currency, then the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined by converting any such other currency into a currency that is designated upon issuance of&nbsp;any particular Series of Securities. Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, such conversion shall be at the spot rate for the purchase of the designated currency as published in The Financial Times in the &#8220;Currency Rates&#8221; section (or, if The Financial Times is no longer published, or if such information is no longer available in The Financial Times, such source as may be selected in good faith by the Company) on any date of determination. The provisions of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="30" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">All decisions and determinations provided for in the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Trustee and all Holders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.16. <u>Judgment Currency</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the &#8220;<i>Required</i> <i>Currency</i>&#8221;) into a currency in which a judgment will be rendered (the &#8220;<i>Judgment Currency</i>&#8221;), the rate of exchange used shall be the rate at which in<i> </i>accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture. For purposes of the foregoing, &#8220;<i>New York Banking Day</i>&#8221; means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or required by law, regulation or executive order to close.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.17. <u>Force Majeure</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 10.18. <u>U.S.A. Patriot Act</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="31" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">ARTICLE XI.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">SINKING FUNDS</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 11.1. <u>Applicability of Article</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The provisions of this Article shall be applicable to any sinking fund for the retirement of the Securities of a Series if so provided by the terms of such Securities pursuant to Section 2.2 and except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series is herein referred to as a &#8220;<i>mandatory</i> <i>sinking fund payment</i>&#8221; and any other amount provided for by the terms of Securities of such Series is herein referred to as an &#8220;<i>optional sinking fund payment</i>.&#8221; If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be subject to reduction as provided<i> </i>in Section 11.2. Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the Securities of such Series.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 11.2. <u>Satisfaction of Sinking Fund Payments with Securities</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company may, in satisfaction of all or any part of any sinking fund payment with respect to the Securities of any Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to the terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been previously so credited. Such Securities shall be received by the Trustee, together with an Officer&#8217;s Certificate with respect thereto, not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption, and shall be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly. If as a result of the delivery or credit of Securities in lieu of cash payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of a Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied to the next succeeding sinking fund payment, <u>provided</u>, <u>however</u>, that the Trustee or such Paying Agent shall from time to time upon receipt of a Company Order pay over and deliver to the Company any cash payment so being held by the Trustee or such Paying Agent upon delivery by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash payment required to be released to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Section 11.3. <u>Redemption of Securities for Sinking Fund</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer&#8217;s Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by delivering and crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein specified. Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer&#8217;s Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund payment date the Securities to be redeemed upon such sinking fund payment date will be selected in the manner specified in Section 3.2 and the Company shall send or cause to be sent a notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in and in accordance with Section 3.3. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4, 3.5 and 3.6.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="32" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the day and year first above written.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">PYXIS ONCOLOGY, INC.</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">&nbsp;</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">Name:</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">Its:</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 331pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">[ ], as Trustee</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">Name:</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">Its:</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="33" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ex_893455.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html><head>
	<title>ex_893455.htm</title>

	<!-- Generated by ThunderDome Portal - 11/26/2025 1:36:17 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<div><img alt="sidley.jpg" src="sidley.jpg"></div>
			</td>
			<td style="vertical-align: top; width: 74%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">SIDLEY AUSTIN LLP</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">787 SEVENTH AVENUE</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">NEW YORK, NY 10019</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">+1 212 839 5300</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">+1 212 839 5599 FAX</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">AMERICA&nbsp; &#9679;&nbsp; ASIA PACIFIC&nbsp; &#9679;&nbsp; EUROPE</p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 288pt; text-indent: 36pt; text-align: right;">November 26, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">321 Harrison Avenue</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston, Massachusetts 02118</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Re: <u>Registration Statement on Form S-3</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ladies and Gentlemen:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We refer to the Registration Statement on Form S-3 (the &#8220;<u>Registration Statement</u>&#8221;) being filed by Pyxis Oncology, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), with the Securities and Exchange Commission (the &#8220;<u>SEC</u>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), on November 26, 2025, relating to the registration of up to an aggregate total offering price of $350,000,000 of:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">shares of the Company&#8217;s common stock, $0.001 par value per share (the &#8220;<u>Common Stock</u>&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">shares of the Company&#8217;s preferred stock, $0.001 par value per share (the &#8220;<u>Preferred Stock</u>&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">warrants to purchase Common Stock, Preferred Stock or Debt Securities (as defined below) (the &#8220;<u>Warrants</u>&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(d)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">debt securities of the Company (the &#8220;<u>Debt Securities</u>&#8221;);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(e)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">rights to purchase Common Stock, Preferred Stock, Debt Securities or Units (as defined below) (the &#8220;<u>Rights</u>&#8221;); and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(f)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">units (the &#8220;<u>Units</u>&#8221;), each consisting of two or more types of the securities listed in clauses (a) through (e) above.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Common Stock, the Preferred Stock, the Warrants, the Debt Securities, the Rights and the Units are collectively referred to herein as the &#8220;<u>Securities</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Unless otherwise specified in the applicable prospectus supplement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;the Debt Securities will be issued under an indenture (the &#8220;<u>Indenture</u>&#8221;) to be entered into between the Company and a trustee (the &#8220;<u>Trustee</u>&#8221;)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;the Warrants will be issued under a warrant agreement (the &#8220;<u>Warrant Agreement</u>&#8221;) to be entered into between the Company and a warrant agent (the &#8220;<u>Warrant Agent</u>&#8221;);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;any Rights will be issued under a rights agreement (the &#8220;<u>Rights Agreement</u>&#8221;) to be entered into between the Company and a rights agent (the &#8220;<u>Rights Agent</u>&#8221;); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">(4)&nbsp;&nbsp;&nbsp;&nbsp;the Units will be issued pursuant to one or more unit agreements (each, a &#8220;<u>Unit Agreement</u>&#8221;) to be entered into between the Company and a unit agent (each, a &#8220;<u>Unit Agent</u>&#8221;);</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">in each case substantially in the form that has been or will be filed as one or more exhibits to the Registration Statement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: center;">Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="sidley.jpg" src="sidley.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">November 26, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Page 2</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We have examined the Registration Statement, the exhibits thereto, the certificate of incorporation of the Company, as amended to the date hereof (the &#8220;<u>Charter</u>&#8221;), the bylaws of the Company, as amended to the date hereof (the &#8220;<u>Bylaws</u>&#8221;), and the resolutions (the &#8220;<u>Resolutions</u>&#8221;) adopted by the board of directors of the Company (the &#8220;<u>Board</u>&#8221;) relating to the Registration Statement. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and others, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Based on and subject to the foregoing and the other limitations, qualifications and assumptions set forth herein, we are of the opinion that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;With respect to an offering of shares of Common Stock covered by the Registration Statement, such shares of Common Stock will be validly issued, fully paid and nonassessable, when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to the sale of such shares of Common Stock, if any shall be required, shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter, the Bylaws and the Resolutions authorizing the issuance and sale of such shares of Common Stock; and (iv) certificates representing such shares of Common Stock shall have been duly executed, countersigned and registered and duly delivered in accordance with the applicable definitive purchase, underwriting or similar agreement upon payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof or, if any such shares of Common Stock are to be issued in uncertificated form, the Company&#8217;s books shall reflect the issuance of such shares of Common Stock in accordance with the applicable definitive purchase, underwriting or similar agreement upon payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;The issuance and sale of each series of Preferred Stock covered by the Registration Statement will be duly authorized, and each share of such series of Preferred Stock will be validly issued, fully paid and nonassessable, when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to the sale of such series of Preferred Stock shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter, the Bylaws and the Resolutions establishing the designations, preferences, rights, qualifications, limitations or restrictions of such series of Preferred Stock and authorizing the issuance and sale of such series of Preferred Stock; (iv) the Company shall have filed with the Secretary of State of the State of Delaware a Certificate of Designations with respect to such series of Preferred Stock in accordance with the General Corporation Law of the State of Delaware (the &#8220;<u>DGCL</u>&#8221;) and in conformity with the Charter and such final resolutions; and (v) certificates representing such series of Preferred Stock shall have been duly executed, countersigned and registered and duly delivered in accordance with the applicable definitive purchase, underwriting or similar agreement to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof or, if any shares of such series of Preferred Stock are to be issued in uncertificated form, the Company&#8217;s books shall reflect the issuance of such shares in accordance with the applicable definitive purchase, underwriting or similar agreement upon payment of the agreed consideration therefor in an amount not less than the aggregate par value thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="sidley.jpg" src="sidley.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">November 26, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Page 3</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;Each issue of Warrants covered by the Registration Statement will constitute valid and binding obligations of the Company when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to such issue of Warrants and the Common Stock, Preferred Stock or Debt Securities issuable upon exercise of such Warrants shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) a Warrant Agreement relating to such issue of Warrants shall have been duly authorized, executed and delivered by the Company and duly executed and delivered by the Warrant Agent named in the Warrant Agreement; (iv) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter<b>, </b>the Bylaws and the Resolutions authorizing the execution and delivery of the Warrant Agreement and the issuance and sale of such issue of Warrants; (v) if such Warrants are exercisable for Common Stock, the actions described in paragraph 1 above shall have been taken; (vi) if such Warrants are exercisable for Preferred Stock, the actions described in paragraph 2 above shall have been taken; (vii) if such Warrants are exercisable for Debt Securities, the actions described in paragraph 4 below shall have been taken and (viii) certificates representing such issue of Warrants shall have been duly executed, countersigned and issued in accordance with such Warrant Agreement and shall have been duly delivered in accordance with the applicable definitive purchase, underwriting or similar agreement to the purchasers thereof against payment of the agreed consideration therefor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;The Debt Securities of each series covered by the Registration Statement will constitute valid and binding obligations of the Company when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act and the Indenture (including any necessary supplemental indenture) shall have been qualified under the Trust Indenture Act of 1939, as amended; (ii) a prospectus supplement with respect to such series of Debt Securities shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) the Indenture shall have been duly authorized, executed and delivered by the Company and the Trustee; (iv) all necessary corporate action shall have been taken by the Company to authorize the form, terms, execution, delivery, performance, issuance and sale of such series of Debt Securities as contemplated by the Registration Statement, the prospectus supplement relating to such Debt Securities and the Indenture and to authorize the execution, delivery and performance of a supplemental indenture or officers&#8217; certificate establishing the form and terms of such series of Debt Securities as contemplated by the Indenture; (v) a supplemental indenture or officers&#8217; certificate establishing the form and terms of such series of Debt Securities shall have been duly executed and delivered by the Company and the Trustee (in the case of such a supplemental indenture) or by duly authorized officers of the Company (in the case of such an officers&#8217; certificate), in each case in accordance with the provisions of the Charter<b>, </b>the Bylaws, final resolutions of the Board or a duly authorized committee thereof and the Indenture; and (vi) the certificates evidencing the Debt Securities of such series shall have been duly executed and delivered by the Company, authenticated by the Trustee and issued, all in accordance with the Charter, the Bylaws, final resolutions of the Board or a duly authorized committee thereof, the Indenture and the supplemental indenture or officers&#8217; certificate, as the case may be, establishing the form and terms of the Debt Securities of such series, and shall have been duly delivered in accordance with the applicable definitive purchase, underwriting or similar agreement to the purchasers thereof against payment of the agreed consideration therefor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="sidley.jpg" src="sidley.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">November 26, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Page 4</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;With respect to an offering of Rights covered by the Registration Statement, such Rights will constitute valid and binding obligations of the Company when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to such Rights and the Common Stock, Preferred Stock, Debt Securities or Units, as the case may be, issuable upon exercise of such Rights shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) a Rights Agreement relating to such Rights shall have been duly authorized, executed and delivered by the Company and duly executed and delivered by the Rights Agent named in the Rights Agreement; (iv) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter, the Bylaws and the Resolutions authorizing the execution and delivery of the Rights Agreement and the execution, delivery, issuance and sale of such Rights; (v) if such Rights relate to the issuance and sale of Common Stock, the actions described in paragraph 1 above shall have been taken; (vi) if such Rights relate to the issuance and sale of Preferred Stock, the actions described in paragraph 2 above shall have been taken; (vii) if such Rights relate to the issuance and sale of Debt Securities, the actions described in paragraph 4 above shall have been taken; (viii) if such Rights relate to the issuance and sale of Units, the actions described in paragraph 6 below shall have been taken; and (xi) certificates representing such Rights shall have been duly executed, countersigned and registered in accordance with the Rights Agreement and shall have been duly delivered to the purchasers thereof in accordance with the Rights Agreement against payment of the agreed consideration therefor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;With respect to an offering of Units covered by the Registration Statement, such Units will constitute valid and binding obligations of the Company when: (i) the Registration Statement, as finally amended (including any necessary post-effective amendments), shall have become effective under the Securities Act; (ii) a prospectus supplement with respect to such Units and the Common Stock, Preferred Stock, Debt Securities, Warrants or Rights, as the case may be, included as a component of such Units shall have been filed with the SEC in compliance with the Securities Act and the rules and regulations thereunder; (iii) an Unit Agreement relating to such issue of Units shall have been duly authorized, executed and delivered by the Company and duly executed and delivered by the Unit Agent named in the Unit Agreement, (iv) the Board or a duly authorized committee thereof shall have duly adopted final resolutions in conformity with the Charter, the Bylaws and the Resolutions authorizing the execution and delivery of the Units Agreement and the execution, delivery, issuance and sale of such Units; (v) if such Units relate to the issuance and sale of Common Stock, the actions described in paragraph 1 above shall have been taken; (vi) if such Units relate to the issuance and sale of Preferred Stock, the actions described in paragraph 2 above shall have been taken; (vii) if such Units relate to the issuance and sale of Warrants, the actions described in paragraph 3 above shall have been taken; (viii) if such Units relate to the issuance and sale of Debt Securities, the actions described in paragraph 4 above shall have been taken; (ix) if such Units relate to the issuance and sale of Rights, the actions described in paragraph 5 above shall have been taken; and (x) certificates representing such Units shall have been duly executed, countersigned and registered and shall have been duly delivered to the purchasers thereof in accordance with the applicable definitive purchase, underwriting or similar agreement against payment of the agreed consideration therefor.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt;">Our opinions are subject to bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting creditors&#8217; rights generally and to general equitable principles (regardless of whether considered in a proceeding in equity or at law), including concepts of commercial reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief. Our opinion is also subject to (i) provisions of law which may require that a judgment for money damages rendered by a court in the United States of America be expressed only in United States dollars, (ii) requirements that a claim with respect to any Debt Securities or other obligations that are denominated or payable other than in United States dollars (or a judgment denominated or payable other than in United States dollars in respect of such claim) be converted into United States dollars at a rate of exchange prevailing on a date determined pursuant to applicable law and (iii) governmental authority to limit, delay or prohibit the making of payments outside of the United States of America or in a foreign currency.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">For the purposes of this letter, we have assumed that, at the time of the issuance, sale and delivery of any of the Securities:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Securities being offered will be issued and sold as contemplated in the Registration Statement and the prospectus supplement relating thereto;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="sidley.jpg" src="sidley.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">November 26, 2025</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Page 5</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the execution, delivery and performance by the Company of each Indenture, each Warrant Agreement, each Rights Agreement and each Unit Agreement, as applicable, and the issuance sale and delivery of the Securities will not (A) contravene or violate the Charter or Bylaws, (B) violate any law, rule or regulation applicable to the Company, (C) result in a default under or breach of any agreement or instrument binding upon the Company or any order, judgment or decree of any court or governmental authority applicable to the Company, or (D) require any authorization, approval or other action by, or notice to or filing with, any court or governmental authority (other than such authorizations, approvals, actions, notices or filings which shall have been obtained or made, as the case may be, and which shall be in full force and effect);</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the authorization thereof by the Company will not have been modified or rescinded, and there will not have occurred any change in law affecting the validity, legally binding character or enforceability thereof; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(iv)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Charter and the Bylaws, each as currently in effect, will not have been modified or amended and will be in full force and effect.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We have further assumed that each Warrant Agreement, each Rights Agreement, each Unit Agreement, each Warrant, each Right, each Unit, each Indenture, each indenture supplement to the Indenture and each Debt Security will be governed by the laws of the State of New York.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">With respect to each instrument or agreement referred to in or otherwise relevant to the opinions set forth herein (each, an &#8220;<u>Instrument</u>&#8221;), we have assumed, to the extent relevant to the opinions set forth herein, that (i) each party to such Instrument (if not a natural person) was duly organized or formed, as the case may be, and was at all relevant times and is validly existing and in good standing under the laws of its jurisdiction of organization or formation, as the case may be, and had at all relevant times and has full right, power and authority to execute, deliver and perform its obligations under such Instrument; (ii) such Instrument has been duly authorized, executed and delivered by each party thereto; and (iii) such Instrument was at all relevant times and is a valid, binding and enforceable agreement or obligation, as the case may be, of, each party thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;text-indent:22pt;">This opinion letter is limited to the DGCL and the laws of the State of New York (excluding the securities laws of the State of New York). We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Very truly yours,</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Sidley Austin LLP</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>5
<FILENAME>ex_893454.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html><head>
	<title>ex_893454.htm</title>

	<!-- Generated by ThunderDome Portal - 11/26/2025 1:40:22 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 5.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<td style="vertical-align: top; width: 25%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<div><img alt="sidley.jpg" src="sidley.jpg"></div>
			</td>
			<td style="vertical-align: top; width: 74%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">
			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">SIDLEY AUSTIN LLP</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">787 SEVENTH AVENUE</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">NEW YORK, NY 10019</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">+1 212 839 5300</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">+1 212 839 5599 FAX</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

			<p style="font-family: Arial, Helvetica, sans-serif; font-size: 7pt; font-variant: normal; margin: 0pt;">AMERICA&nbsp; &#9679;&nbsp; ASIA PACIFIC&nbsp; &#9679;&nbsp; EUROPE</p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: Arial, Helvetica, sans-serif; font-size: 7pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">November 26, 2025</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Pyxis Oncology, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">321 Harrison Avenue</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Boston, Massachusetts 02118</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Re:</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Registration Statement on Form S-3</u></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Ladies and Gentlemen:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">We refer to the Registration Statement on Form S-3 (the &#8220;Registration Statement&#8221;), being filed by Pyxis Oncology, Inc., a Delaware corporation (the &#8220;Company&#8221;), with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) as it relates to the registration under the Securities Act of shares (the &#8220;Shares&#8221;) of the Company&#8217;s Common Stock, $0.001 par value per share (the &#8220;Common Stock&#8221;) with an aggregate sales price of up to $150,000,000. The Shares are to be sold by the Company pursuant to a Common Stock Sales Agreement dated November 26, 2025 between the Company and Leerink Partners LLC (the &#8220;Sales Agreement&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">We have examined the Registration Statement, the Company&#8217;s prospectus dated November 26, 2025 (the &#8220;Prospectus&#8221;) relating to the Shares, the Sales Agreement, the Company&#8217;s certificate of incorporation (as amended and restated, the &#8220;Certificate of Incorporation&#8221;) and the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the Sales Agreement. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of, certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">Based on and subject to the foregoing and the other limitations, qualifications and assumptions set forth herein, we are of the opinion that the issuance and sale of the Shares pursuant to the Sales Agreement have been duly authorized by the Company, and such Shares will be validly issued, fully paid and non-assessable when certificates representing such Shares shall have been duly executed, countersigned and registered and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof or, if any such Shares are to be issued in uncertificated form, the Company&#8217;s books shall reflect the issuance of such Shares to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof, in accordance with the Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">For the purposes of this opinion letter, we have assumed that, at the time of the issuance, sale and delivery of Shares:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(i) the authorization thereof by the Company will not have been modified or rescinded, and there will not have occurred any change in law affecting the validity thereof; (ii) the Certificate of Incorporation and bylaws of the Company, as currently in effect, will not have been modified or amended and will be in full force and effect; and (iii) the Company will have sufficient authorized and unissued shares of Common Stock from which to issue as the Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">This opinion letter is limited to the DGCL. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Arial, Helvetica, sans-serif; font-size: 6pt; font-variant: normal; margin: 0pt; text-align: center;">Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="sidley.jpg" src="sidley.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 2</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">We hereby consent to the filing of this opinion letter as an Exhibit to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Very truly yours,</p>

			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Sidley Austin LLP</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 252pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ex_893453.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html><head>
	<title>ex_893453.htm</title>

	<!-- Generated by ThunderDome Portal - 11/25/2025 7:44:46 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We consent to the reference to our firm under the caption &#8220;Experts&#8221; in the Registration Statement (Form S-3) and related Prospectus of Pyxis Oncology, Inc. for the registration of common stock, preferred stock, warrants, debt securities, rights to purchase common stock, preferred stock, debt securities or units, and units and to the incorporation by reference therein of our report dated March 18, 2025, with respect to the consolidated financial statements of Pyxis Oncology, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ernst &amp; Young LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Boston, Massachusetts</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">November 26, 2025</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>ex_893452.htm
<DESCRIPTION>EXHIBIT FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-426">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-427">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-428">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-429">0001782223</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-430">Pyxis Oncology, Inc.</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-434">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-435">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_3" id="ixv-436">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_4" id="ixv-437">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_5" id="ixv-438">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-439">0.0001381</ix:nonFraction>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_3">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_4">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_5">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_6">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_7">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001782223</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-25</xbrli:startDate>
              <xbrli:endDate>2025-11-25</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-518">S-3</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-519">Pyxis Oncology, Inc.</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-520">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-521">Common Stock, par value $0.001 per share</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-522">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-523">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-524">Preferred Stock, par value $0.001 per share</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-525">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_3" id="ixv-526">Debt</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_3" id="ixv-527">Debt Securities</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_3" format="ixt:booleantrue" id="ixv-528">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_4" id="ixv-529">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_4" id="ixv-530">Rights to purchase common stock, preferred stock, debt securities or units</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_4" format="ixt:booleantrue" id="ixv-531">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_5" id="ixv-532">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_5" id="ixv-533">Warrants</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_5" format="ixt:booleantrue" id="ixv-534">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_6" id="ixv-535">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_6" id="ixv-536">Units</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_6" format="ixt:booleantrue" id="ixv-537">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_7" format="ixt:booleanfalse" id="ixv-538">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ix:nonNumeric>
          </td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_7" format="ixt:booleantrue" id="ixv-540">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-541">350,000,000.00</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-542">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-543">48,335.00</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-544">350,000,000.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-545">48,335.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-546">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-547">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-548">48,335.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_7" id="ixv-549">(1)	An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.
(2)	Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.
(3)	Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $350,000,000.
(4)	The registration fee has been calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended.</ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>pyxs-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:11AM UTC 2025-11-26--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:pyxs="http://pyxisoncology.com/20251231" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://pyxisoncology.com/20251231">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pyxs-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://pyxisoncology.com/20251231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="pyxs_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pyxs_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pyxs_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="pyxs_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>pyxs-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:11AM UTC 2025-11-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://pyxisoncology.com/20251231/role/statement-document-and-entity-information" xlink:href="pyxs-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://pyxisoncology.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>pyxs-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:11AM UTC 2025-11-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="pyxs-20251231.xsd#pyxs_DocumentAndEntityInformation" xlink:label="pyxs_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="pyxs_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_DocumentAndEntityInformation" xlink:to="pyxs_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="pyxs-20251231.xsd#pyxs_NotesToFinancialStatements" xlink:label="pyxs_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="pyxs_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NotesToFinancialStatements" xlink:to="pyxs_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="pyxs-20251231.xsd#pyxs_NotesToFinancialStatementsAbstract" xlink:label="pyxs_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="pyxs_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NotesToFinancialStatementsAbstract" xlink:to="pyxs_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="pyxs-20251231.xsd#pyxs_NoteToFinancialStatementDetailsTextual" xlink:label="pyxs_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="pyxs_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pyxs_NoteToFinancialStatementDetailsTextual" xlink:to="pyxs_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressAddressLine1</link:label>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressCityOrTown</link:label>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressPostalZipCode</link:label>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressStateOrProvince</link:label>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityExTransitionPeriod</link:label>
    <link:label xlink:label="dei_EntityExTransitionPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>pyxs-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:11AM UTC 2025-11-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://pyxisoncology.com/20251231/role/statement-document-and-entity-information" xlink:href="pyxs-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://pyxisoncology.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pyxislogo.jpg
<TEXT>
begin 644 pyxislogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
M   *    &@    !'<F5E;G-H;W0 _]L 0P '!04&!00'!@4&" <'" H1"PH)
M"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ
M_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@ 50"L P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]]\1:[!X
M;T"ZU:\CDDAME#,L8&XY( QGW(KSG_AH#0O^@3J/YI_\574_%?\ Y)?K/_7-
M/_1BU\TZ%I3:YKUEI:2B%KN98A(1D+D]<5W8:C3G!RGT/-Q=>I3J*,.I[=_P
MT!H7_0)U'\T_^*KH/#OQ<\+^(;M+5)Y;*YD.$CNU"ACZ!@2OYD5P1_9\O]O&
MO6Y/;-NW^->=>*O"&J>#]26SU=(_WB[HI8FW)(,XX_P-:*CAZFD'J92KXJE[
MTUH?4GB;Q!%X9\/7.K3VTUS%;@%T@ +8) SSV&<FN(TKXYZ!J6JV]G+9WEH)
MW">?-LV(3T)P>!GO3OA#XFD\6^$KK2]9*W,MB!"Y<9\V%E(7=ZGAA[XKR'XC
M>#G\'>*)+>-3]@N<RVC$Y^7NI]P>/I@]ZSI48.;ISW-JV(J*,:M/8^J5(9<@
MY%!.*\M^#7CK^VM*&@ZB_P#IMC'^Y<G_ %L0X'XKP/ICWK0^+'CK_A%M#^Q:
M?(O]IWRE4]8DZ%_KV'O]*YW1DJGL^ITJO!TO:="#7/C9H.BZU<Z<+2[O#;OL
M:6'9L+#J!D]CQ6@OQ0LW\#'Q2ND:B;07'DE-J[L?W^N-N>,^M>">"/"=SXQ\
M216$/RP*1)=2Y^Y'GG\3T%?4BZ+8)H/]CI;(MAY'V?R1TV8QC\JWKTZ5*T=W
MU.?#U*U9.6RZ'GMG\>O#]S>PP2V%];I(X0ROLVIDXR<'I7J*,&4,I!!Y!!ZU
M\D^-?"T_A#Q1<:9,2\7^LMY"/OQGH?KQ@^XKV/X*^-1JNC?\(_?RDWMBN82W
M_+2'@#\5Z?3'O3KX>*@JE/8G#XF;J.G4W/5<US>O>(S!J%OHNE%9-3NFP.,B
M!.[M^&<"J'CGQQ%X=MS:V3+)J4B@JI&1&#_$?Z"L3X5Z7)=37WB&^+233,8T
M=CU[N?SP/P-<RA:/,SZ:C@W'#O%5?AZ+N_\ (]+5=D8!).!U/>O+KSX\:)9W
MT]LVEZ@[0R-&6&S!(.,_>]J]4/0U\;:W_P C!J/_ %]2_P#H9K?"THU6^8^=
MQE:=))QZGU[I.HQ:MI%IJ,"LL5W DZ*_W@&4$ ^_-0:]X@TWPWIKW^L7*V\"
M\ GEF/HHZD^PJKX*_P"1"T'_ +!UO_Z+6O!?C)X@N-6\=W%BSG[)IN(HD[;B
MH+M]<\?0"LZ5'VE3EZ&E:O[*ES=6=EJ?[05K',4TC1)9T!XDN)A'G_@(!_G4
MNE_M :=,X76-'N+4'C?;RB4?4@A3_.L#X>_!^W\1Z''K&NW<T<%QDP0VS ,0
M#C+$@]P>!^?:I_$_P'O+53/X6NS>(,DVUR0LGX,, _CBNIQPM^1G&I8MQYUL
M>Q:#XETGQ+9BZT6]CN8^C '#(?1E/(_&M:O+/@UX%OO#EO=:KK,4EM=W8\I+
M=CRD8.<D>I/Y >]>IUPU(QC-J+NCT:,I2@G)69QWQ7_Y)?K/_7-/_1BU\]^
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M9GUN>E?&VM_\A_4?^OJ7_P!#-?8-K=17MG#=6SAX9XQ)&P[J1D'\C7Q]K?\
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&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sidley.jpg
<TEXT>
begin 644 sidley.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M'C<T9 ((!_H/45_))_P32_X.VOV2OVPOB)X9^!G[47PXO_V./BMXNU*U\/\
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M1_$#2O'<7CCQ#INIZY'X3U'^WI=!UC7=(M-$738S?2W=IX!_P0&_X.)?$?\
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M;75YIEOXR\$6/C/3=92>)I9-%\3:'/<Z;/#IE_=6<_T?_P %0_\ E;X^ O\
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MRS:OH?AGQ??_ !+U7Q1H^EW#Y-E:Z_?^$_#5QJOD!)+LZ)IZ2NT< 2O]"J@
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1WD[A YK^LZBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PYXIS ONCOLOGY, INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1160910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Harrison Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">453-3596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001782223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Nov. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001782223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Pyxis Oncology, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Nov. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Preferred Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Debt Securities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Rights to purchase common stock, preferred stock, debt securities or units<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Unallocated (Universal) Shelf<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 350,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 48,335.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">(1)	An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.
(2)	Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.
(3)	Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $350,000,000.
(4)	The registration fee has been calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Nov. 25, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 350,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">48,335.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 48,335.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>9</ContextCount>
  <ElementCount>39</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="pyxs20251125_s3.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pyxisoncology.com/20251231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ex_893452.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ex_893452.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ex_893452.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pyxs-20251231.xsd</File>
    <File>pyxs-20251231_def.xml</File>
    <File>pyxs-20251231_lab.xml</File>
    <File>pyxs-20251231_pre.xml</File>
    <File doctype="S-3" isOnlyDei="true" isUsgaap="true" original="pyxs20251125_s3.htm">pyxs20251125_s3.htm</File>
    <File doctype="EX-FILING FEES" original="ex_893452.htm">ex_893452.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pyxislogo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>26
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pyxs20251125_s3.htm": {
   "nsprefix": "pyxs",
   "nsuri": "http://pyxisoncology.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "pyxs-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pyxs-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pyxs-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pyxs-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "pyxs20251125_s3.htm"
     ]
    }
   },
   "keyStandard": 18,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 27,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 18
   },
   "report": {
    "R1": {
     "role": "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs20251125_s3.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pyxs20251125_s3.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressAddressLine1",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressCityOrTown",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressPostalZipCode",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressStateOrProvince",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityExTransitionPeriod",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pyxisoncology.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    }
   }
  },
  "ex_893452.htm": {
   "dts": {
    "inline": {
     "local": [
      "ex_893452.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/ffd/2025": 12,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 8,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 43,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex_893452.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex_893452.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "4",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex_893452.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ex_893452.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>27
<FILENAME>0001437749-25-036389-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-036389-xbrl.zip
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M"1A$,S+BKDTDLRD>'5+_/Z30UBB0D0DD'NZI"DQT=X3)2-"+D;JAN66((Q&
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M1:O"JROQ])WBY #Y\ /][@U"0/=+1/\%4$L#!!0    ( #!'>EL#!4["]A8
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M ?Y@']W(\#V18?^.RC"@GQ1^R]#J)T4*Z"53X,4H4(_5I)'%*>"F8>["E2V
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M%)Y"H*J'B<8;2M0Z^]L8P0XCV$FQC;%K&#MPC$ N9#8QUBX0RCE4:%F=-Q!
M"_BBMDWK$-IS\37.#T:7I]*W_LT2IA "7]WD=K5SI"RNZ]([1*QS6OBIR%%X
MH2$2>Z-5[1>[H\+9JVKLZ+5#H88T+IELAX50U8M"&'D9E'K'+[H'54\[_NG5
MNVJ@)PJ62(9VH&"T#9G2 &8%_++R2KNK$$;K#_-(6L8K^)C+*,MO!=]8=+%L
MZ=PDV-F FS7!S6;W<[/[N=G]O+W=SX.'N3UYT.G8G*)W098"U:Q-JES#;T%]
MG,L<C+CR.LA6#V$ I-P!1X[+L+:+Q.Z=TT&&L4E*@[#7/NM(1A=M*!E# $JI
MCRG>Q@3;#F[-@^&LD4-;V?OK($@K#G2]7H,)%>JS@$_+HKLY5X&0[;=7TF^I
M=J?-C6^,WO$7;L4S.QZ>> S+7JX9C504D'H'1)-@;A9<DTFFS6Z7JL&U(\+^
MLBY[G-( 23))5!&)-0^)<.WX@1_IIW*H.  X#! =3R:LI\[8- 0CYY]%A!W+
M%7MN/8RRI//^TLY7[;WUG,N2WA^KLW7MO6N7B];:$J]KQ56VR-LJW84ZI'>G
M7I.BUEZ^.1_M@80W'R\,;S9.@E:#FQM$X)I(>]ZGN^\2*8 -L >'MAM+1D?.
M[*$';)X._3B=E%6:GKO)0E<!*&7DH,[P6XV$EG.]1GA@22F$-NW8=,DBD^]E
MU'2'&JZUC)O:9C@FQP#C*2*=9EYIBSUKB#W,FJ%ZX4 U;Z5 9ITW/%/EQ8'V
M/%^V"I7E:9>)!CYK]-20<+I2GW/+-%66>#E32OKI6 :HU4TZBXX^5=+Q&B%H
M.IY (T$R7YUB=EH*T-S>^!;:Y[5$&U60RL7BCGO0-;-MG!HT6$>U-KFHGNW7
MVGBTB#J@7"OG33I0  CH3&850] )@[T6+*T?6@NI-Z3;Q+6U&JK +#$#J!#Y
MAL4M!M+E\=49ZI7I?*ZH&O:6X,PC_=5!SI;=G6NBFM>F$'"'[2I+QS,GN$DT
MIGP.U/)664_+6>!M(.DF*+T)2F^"TM]84/KQPPQ*'UXUAU0?QUXG9]0]97Y_
MW=.K^(.U0BQ7+!?5;M671+!UU[<8OZZ7#VBZ1QUC_+HQ:[?>0#5D71_P;4>L
MUTZ<71RJ;O##--GJ57<[TJJ=:LQ:MTT<%@:MM3;Q50/8JP_CJT>S5Q_*U4+;
M2X=RI;%H?;/"")XL"JYKQ^]R>6Q]D0I8,7VIP^EH%?<E_DNWF[%R)W?<';E%
M2/+DJI!$U3]9!Y$X%5,V@,0%)+H4W)7PB%?N?X$A/-.YJ:W0A"B@:IIP A?@
M!*K%X(SB]J!)Q*HE<!9LK+</]>LBE+)R3A6?5 ?MW2]TH@C]Q>"$FJEB$]7R
M;4.3E4?QU9')RB.I5II<,H2#M1#)RF/X&N!(7EYA($;?K=#_X>+^%31:BHP6
M:)XU\KJO&_!\>2AW@Y":".GQ(8WCMR(M3]YC%HQSWGK(H\]ID>0^JK\(M.Q,
M1/@9F)6.>23_YDI)3G'/%=1N,?78*.4%,!RI#'2=B;G:(W4N Z2)LI$^G* .
M;QN.D5YW#2/:%P5*X+L/TB.Q@(79A= E_L;J8$4X-SN;^@+# ["Y+I4*^$ F
M:*NW,&T\#4)=*0$P%PW!*>V 8H@ QP?AT-6QJ*4Y#2?'46X;P$'CBF&*B2J*
M@+8/HR)DUG@61]@]EA3PV#B.P>)QE&H<)WQ*09X!'SIGV0&O99("+!&?<:")
MKN^%ID95@O6K.[*8)_]G$2G41N411KO,X2E5#L-R' Y;$6!6]^I@1D ("1H
MX90^.,RH>!QG?Q;!F%;-B.K$10(6,Y_R,6F0*# H D%7D>8N<"![0JH&^A@
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MGC]EFPL[J7PK@_B^5P:78F]3EF*]-PDNQ;/VI4BSZSR<@\&45^JV\3T<KAN
M_O2 RW24E;S9=6RF&8UY3!OH>7<VT%==F?7?3R^ZLS*/^I09;\HZK/>68#OL
MV>XN[(TN+<@]H!/6X$V[MS&^6<O0>U^'J#OKL$'&E=97>UW25WL[=V"S7?-M
MTB%UA?PTCW5?=$E=W6T=UGL_:/WTK$OZZ=5=]-.:[XMQQP*+C_FDZ%9<\?'N
MB:C?$VOPHK@2DPU9AO7>$/K0?MZE0_OYSMZ 6,<>[>;HD&NQ01YXQTX/9(9\
MM#LDZI1)=;>E6/]=L215NP8#W.BD7X=LK$TZ1E1WEN516UG3[JS#!FT/[9*\
MZ))+\FKG\:8#.^2,O+J+MEKO;=&E-,=CW@T=LJGNM QKOALZ9$.]W-E]M'ZX
M/JQ?=NFPWGO,Z$(J)]@:=F<U8'M\LSKO!UJ-GSNU&H\7*=(A2_;ESATZ:*WW
MIM!GQJN.E3Z]?,08JFY5/KU\Q(F-#NFHO<?K;6L=];I+=BWRM*T)9\2]+,I1
M5JH?@O/+N CR]I+QXC),DB#-R@%Q@(3I(IA7^3PKU" 8JV""'.D3Y-F'/["G
M!%9;EY?*%I?OK!I_SZO1\VK<DE>#?I\1G[*:Q+3U0);"I%!/L-0__"Z<SY-%
MF?WT9*X_J,KLN_E%6LU^>E*4()OR^20NYDFXH,]WY3.4LS2<P2UK$NE\CU()
MOT#YX _A#C(EH7PRS]4T_O33$_F3GNH]IZBF[@4XE323/SUA4:K-Q;>A$WF@
M9UK^B3I5@R&J.%E\ M5TG*)T7BP&H%6BG4$0!@<J":]#^&64@2[*665M_>-O
MK_?VGK[Y,<:.K'-053_^,WY+'^Z^V1Z02OO?_Y?^Y_^X%TOO./?BE4KK6\S^
M717]*(PN23\O@A ;6Q0XV],L2;)K)G="G3U6*8BO4>$9]<&0'\'<Z<O4OZLP
MH4]@XIG2PO^A;G\K?[HDUT51P4J#PE%X+UC;;W)./! 9R5 X*@\?X;L=C'XY
M/#H\/SP^.@N&1P=(FG-\>G)\.L2/@I__#$Y'OXQ.1T?[HPZ^N_<$P^.VL[L3
M_%B]/0!13[FK+JQK]?9;O]_7YTO[%^C#>+J I_\H*O'IF^&$.PG#SA_.L(58
MX>C+8*;"M"#C,+37A7Q=<'T9@_)!;9WK!K&@6-1X@8UAQPOZF>@(4/&L&Z(X
MC_!T#=,(WJV8JRB>QO+#. U8$^$_!\;VC"=X,U0XHOV14C]7^%O23!$X%B%\
M5(:?4!/-T(:=!+"P6EVM> II._L>V37RX,&#BPH^D=^O/C-6T01]Q05;&W$!
M,P=="?=4Q47 9;'S/(=I@P6PTB-'#G\\ 5&)RH3$)$[-7V@$YG!RX1+ -_I/
M1<L/'X@ 9;,9W$.^9=Y,6JWZTW>PZ0*)C?@U<F[!V30Q.WT0R'O)_?0;;<5I
ME%3(@3+@1X ]DH-M4L97BEZ+>W[@W4&#SHK:;7C0^F8H8_+]TG=PK)DBJ%"
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M&NXS,8K F8N00]N3(,H1G(G>PCQ1DPMT9SSD!'BW\'10W>)+P>5*S>BOL.2
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M/?/5H W*MVC#\K']@U_^CEE4,Y :^*!?X^5KO/L*39Q">V%1#<1OX)<.$E'
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M#TU1F\!W#([-%K.\>/IWO3O+#&N A86$*5!P6:G@ET*W;I4PWQ(I7+90V.
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MWQ>,_PV>&3HRAR?$ #^XS*[1G."_F50P->-Q,3K.J/!/;U5X28AG78BG5]Q
MH_';)D@LA<8KDT$!\RV_X/(_>!>D! Y\#=&?>]ZY1[9D4F3-2*_A+E,>TVJ4
M?:?5.PJ2PS<UYXUI<3W.=Z**Y#N=7FX^$R0VBI''CKA?+'G:K:4SS1J_9;@(
MW)<ZCXHPBI810KP<]+VZ\G63A'LM0T+AZZBE.@G?SA-_N)HT)EL(,-?6-%AR
M_-,INBQ\2E_R!J]R#%<4=ST/C+Y=/FM$&3:]^7SP;N?*RE)162$I_%[4OF2U
ML> X)3A Y[%O3$ UN-'@\>^R9+AOO"AM<*-YL/2FS1?U/!TC@,;CX1.&CA74
M@];@@.O=-^HUG*?A5AVAE+%(845@/6Z]G:?$C62MMXK;E>G.=[<T50;ZI"0:
M4+8=!I2O-A!&CQ&5U.,*2C]0S=,X!\N" 3N]$#C^\ ORA[W5D/AM\![.-O(:
M2"1ZQWB)8RR&.,N]+]8N!->+FH<7.6<(\/SA9)D8P]X-N.P9UP)/%/SYP*!I
MA'K:<9"D]W/]2*RYY%E>,ZO1MZ>5OE2)@2EXP]"/U/ZQ2_,CQ2J6Z\<G^ZV%
M ]!MC1DM@=C96KI$3X:,?R)U4#(DQXV=A1\U/I8/>Q[83O#')2*)G#.;[X"M
M$N.TJJ=74;/HU0N#^AZ8D_E7GYRXK!D)_OGD>G-?Z?8?T(\W4T_QR\Q?PL:"
M;=7QW_X!:F&H=>SJMIN+2\E%I-O8Y(XAB,=ADP-[^[MC/HDBFNY@!_C. AY3
MNI,"$S<EPL)<J'E(_B$GP8BF[&[;H'WF:R.3J2?(6IA^S*MY&5$=2Y9?A&G\
M/\86) !;F+-7I28FY>N$-)Q9:$OQ&\NE==^M<X[L&QY=+^GH\E<]> <&1D\>
MORS'3F$/%#5N%,P,C2#X#-3 J D6'(68T1T3?@0SP%Q<P)L>ZUD4Y@>I8"X(
MKT*0?,G=Q*4;0"O<Z)&W_]P-NCK4QX.VK1D94L&;"YLC_^-ONR]?O0F>[>YM
MA=M&&9D3A7O8E6X$<M 68]-Q,-_Y U6>P%0@#70:3,(%PN>FF3[HS8&G-?-$
MZRV=/!<%3,L;%JT'#_[>.?="FE3B)Z0[\*+@+6U\EA_3=CNS:G+F#+[B:JS?
M9GH,N?E7#YB;?]7GYOO<O#T[7]'9^;XJ07T3]OL *0FS!?[S'6IY5!=G9990
M:YV^*4L3G;\(9GKV/$R]F_!K,]3]LX?Q7LH$SFJ8XV6H-PR;ZF0A)6:(J"=(
MX6W-6$3[$YC ;6XPA5/F(X;HTBR7VN Z@S]\.%8A%QT'K*WH**66\S-,UJ0J
MJPHX:QQ05R\8;]D <;'Y-EM: [?4%WPKWG;0^SK%68"/44P%AB<+.L&=6D4,
MUTVRHA"7?EI:CT=$@ "J,=R9^86,9%!%HIJE^,<X8P.C7ET*+A&9 _S4&8Z)
M/;*R4,G49$0U\INS%Y=A/DLH%8J":_H'A>-""?#9#[0[?J,?>]1&5$OY0F0'
M&.+HP7C%SF6:W[G5Q'.WF8> ;T+>;[,-9R%L(&O[3KD&&!>:>R8EL:KJR0.M
M79.,&9$+3[DB<T"_?;_U]DTYXFR6;6;/QYM74$04?!0F%B^PL+(JN9,=?5KC
MR/$%%<0&-](D+J)<:<0Q2A,(8DCKCM%K65-'4 842?(V2[^4;S]H\$N]6YJW
MQYSB)S&-_#5Q(WBU "@VLIP%9*I'L83THDPCTLOPDV5O:..Y= OZXQEF*G6-
M!D>52BFX,&J6[J0^S56*[ENM7]54B78P%_C8@&U=]\\U.[E"#[J7DK<CU-@-
MM>L$#:7"VR_&MM)2U_6W4!)\HF!]>!F7?"39TC G!8JZ&J,O5"9K\NP-HAA-
M0Y#E)M9QZT&,E1>N5BF<8Y'BYN%H.RS W1LX<1CLG^/TO\2/G AL2VF[UT)S
MGF=P\M#;E4H'<;0E9,(\*])XDPK[ _*"H S3YNV%F*)\;I^.J2^BF/TD>!$5
MB-K5G(,)1)BC+;'%J,%-*64MV\Z2:"0R]LM#VA]=3E6/;^>*4!R:WM=1EI]S
MCJYEM.D;>NJOR5,_]HIG>G^\L0-<O>',E:O@<"=HI>4&FMO*M+4#(&VP.1.#
MY4\1&A.)DI310#[UW+R8K^<KDU";%7@=7%%%AOF8(18V<1H&OR;9V+8G! ^,
MN+J:P\+P?82ME<FT,:!-1PUX#7EXB&!8QF-=6>QJ"(Z3][Y /<;CQ75$NRW#
MI;VB/"8<GX72#<)=.61& '<)!9])/98PN*\]_2Q?B! 93(!YM#L>G;=L]8'[
M!9183"TOWIX4'ZQ,6J\NKMD6R@UQ-][K_N?-&F]3&$!I9]]SJ+MP5/X@3*J9
M5"US1_622BD9=!A.2WX;R3[5[^#3F)%LMH@FWJD&WY@Y@LS]"'N!:D"#3:\U
M[>A1BE+"4[5#QAKJR.X$/IJ0KIF;(.Y<761ES+P*6-D01H;"S=Q^)W"(1R:9
M8LV];&7'*@JK0GV&-!O^&(<X9&M<E4&AE*/LOH=;)]GU=B\5&#-R&W.Z;/!.
M$31K<4VWW-86.6LU\!B(@X!EQJ%(TG@@A0G,. +NX_^(E<$EX?1/#K0R%9E8
MY-<A)0^,\V3Z\#5&$P8'<1'17T8.."AK ]O46*\I= T$MOT-A8*]1M#VV:48
M+/04+C@?-R)FD@@G+U>$5\*KO +L(U. -Q3::N,V8YUIHG+/C3;:6C]]"6MU
M+^>.0_(].23G"#BH\D7OC=Q1(^2J)82_W'H@A8",3Q71]\5?3R\,ECTRNTZM
M!U(#XB\]2*RBB L$]>43=/G%G:)-;E"E6D]DTZ43Y^=CJ(ZSE=G&+X^[LZ;,
MTJ3.+F)FA0N^VA@UZH59']/L6AJ"9#*9YCW@$V>"UF_W/ :8S>L'A-F\[F$V
M/<S&GI78414/2\ZZ]J=E2Z*. B,3V)E8:W35Z*$$9L9D4<NPUU-T<VS$GM\*
M1%.VK(0V&&O,=VV+YBCN:HPF+Y9')0L=S--T9^VO@WX4#I>.<)HK*9V\-(70
M/ !B#R9#(9QCVB2G Y;.RY8Q[01_Q'"TP<VKU*! *209+MJP$,MFZR9<1,ML
MMK_G$N2"MMAGVNAV04S+7XX%!,Y)?2T2E9HKB_K2&!8QET2EC>12@VA;WZ'?
MF*X2VR4EMN_$LWOEU0@)U2M_-%3/[Z7D;KAZDJ!.EJ$WJ!?"%,AZEE\CD5P=
MLNZ3X36AB+.5'"1.2PJ;O^-1^2J51TW)E"6/H_W<N.W ]A&O)0O=>7"2E)(M
ME))IG7IQGNDR8;)+A5D1^ _F,F-2:.1CN6P*(_V2PZBL:\%MGUQ0-Y:.W&B#
M-]8:D(V4J"XJUQ#_&AV35S"F:069%=:!(HC R#QYG^)Y$3-=U#R,)X$]'!N8
MTZ:0];O6T6Q[I-FDX1I,WJ'$P7O]YN90M*Q*.67!57E.?M]/8K;7?IHJ/]V1
M=V)F7?\<U$-2(7;4 R3,,2)02A(T":\'@>XRJ^MO;)JD_:YR/Z:J1!ZXC$S+
ME@(8)UU"KX)6'FYB5+Q(3!$F6L.@->/O9-',\2=7$9FJ(+=,:"<8ZMJBW:=>
M:1$9+LT'M9EQA4I;]/_$X4_RZN+\EPL-#I>"NB51**Q\>*/,R0_FFN7@@#"J
MI::>FX>+EO71,2S.S3'\1,A'^BWH*BON2N%#!'I'TC;F@0G:%7=;.*)KDQ0,
M6PBOPYLIKV_@B!:(N>:^7M81V T>>@VM.8@)6BEAX#!6>^=EW:=TB88:,F!V
MI.E!MK")F#JHQ.//Z27G[; Q0R[7LQBQ:%I)]!J)MF2Y)"CNS'HKH6']_IA6
M#Z@-NK)FI;W)@'$=RR\P-W8^(CEE';KBAUG>,F:)Y=.U^K<T1/@$:<+@^]K5
MC4>T7]L+%ZLE-C/?*?#@)EH5P837Q:(.;C5J IU!9&Y3!-6HQ9Y8221)=BWI
MU]D/_;0+]]3Y;X=GP=EH_\/IX?F? ?P;]OJ[XY^'[^R'?QS"14?!^6^CX/UH
M>'1X]&MP_ O]>7AT,#HZ_W Z"GX;G8X.CRA<'YR.?AF=GHX.@O/C8'AT@#<]
M'?UZ> ;?P8=RIZ/A^Y&^S<'HY/CL\'QX^F=P? H#.#I^?W@T:OD:#*;Z<$?_
MO?_;\.C7T?#G=Z/@%_BY?'DX6O7487 R.CT[/@J.X=-3^&IXU#*2P_,S.Y:C
M=W_JN[P[?']X#C?=/SS=__#^['QXM ]/.QB=[9\>_FP?9F9G0-/P?O@GW.T\
M^'D4G)\.C\YDDN %1B?GP1!G_H_?CN$M?OZS/A:<R.6S,L!?K/@>?]XRS4?\
M[LM_!A<UAT*__#,X^[#_F_DI#0\^@5DX@^]7+"?]K/W:':$\6[N=^1@2?-\_
M8(+O^S[!UR?X#E-3JC/ U 0V7]/Y!+%^$,;+=+;: ]9TR0?G^X;'.2YJMMB
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M<CKS3!D=5^A:0X"@ !-A]R/JR@E(>M$6-;Q-4).9:5TP;S9&-GA-U!J9Q7"
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M)D\2-Z_'\ML[19C/3*L(#NFW!?MO#//;Z+Z-;Z[?<C\*&.CN0\) =WL8Z.;
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M^A,]I8[#YJBJFZJV9LFB>ZEHE1>7NKN$\-#)!:,GC(M!C0$L')R EM25!47
MW"H;"^][#?H;%E)293ANJ21SB,YXHIR^S'7X+PSN7QE!RN\*_B4]5(/_KH8C
M#TC%8LN).)T(QP4<[DV50]X6IMP1A_+OBI%_,==!-TKT/L=[<(XZ(N+*TN]J
M:S#W.CBU;/@F[-NMLD'GA J?G,ZYX)+@UAZWZ-::= WT;UN.Z24]?4'E/>OW
MM3>2(Z%1RZTA*0T;-3D+,;RQ9)4N74\,8ANSQN22<2. )2/XL[2?ZR5FO6YM
MD"3*$.5AA?BX5).4N"5A/YU5N*U1]8U2(N6FK0<[0S3$#AKY_0S?S./.=-_3
MS9FJNU1."HW$9U904LDD*1)SR9+J2<M&J1\IE912"M12-SE8Q[!AGS-XQ 6(
M2S=!K=^?LP.$AT2'9N0(G/:YL$<GU]WC9EPBU[KMI6;IC=./Z,1,*];6*//6
MEB<-SPS*I-+%QS+Q'ML7O$^I?0X]",8"!P%&.OP:_R09<)QIHF9.*T3C'5('
MT@P\OT$;!KOFR=:"<>SI7E]FB2$@H)!D[:B&T=' =%S+\>7((6_U_I@CNJ5S
MCJ-%?4/!4"MI%FK%YBYS+=1-#K#J<ARG_W3W&SL25LG$L(WH'"*<-ET<I3T<
M][UKSA!37<,S)\SGSE<CGQ;W+JQR#BF9B*AY#;]3+)JAN?!H%M+64GV:JU1Z
M'$;&":BWJ2.07%J(LYNKL,@8NJQ_/D#:JG&5%XJ;_=%$8 N<R!99&WE!7R*\
M,-=%3 G8>VCU'(&["Z=AG!0:*<[Q+EINDO_RDF(IM$?%GIVQ['O3GM+,9]?,
M=*8U:*E#CA2PE;Y&FB > S^Q:9E( 3%.GQ$5N2(!T7L^\GQ(9JD#A5QD9C-S
M.);O"C<HL+F0TH%J<S]X23?N-HVQ Z1$WPQ1'.]+"Y-O [I)$)6#1T2-AOVH
MYBTZA,60AF\C>O#Q! ?"X1ROO:@)[TNE-??-,G&>,3>\P@"P0U*+>*06.-/M
MACBPQ$QP3E;A6C96^M8;IBWAT![X;:>OXJ0#BT-<.,3.WDZ23<'U&C%H<$4R
M+Q),>S3/2DTGK"45KZ;@E.Z:K?2?S3/2'Y]+TZ2#D>$<)2K'[$/;GC0E)'K(
MFF)9S4"V89LP( ;[G2X9KDDI\2!)_$A(]6Z7_$ND?^'ZYH9W \4;>SLPD5!:
MYQ^4SG.Q,2D,_Z/7PTPW+],M5)D_PQVIZ3H\IP;,L%'7D+#W493#/'_(<ICG
M?3G,VI7#/- S;8":>X=J18;]K'[!CN8G>99-23_N8X_*#4.9+#T$4\,Q2V:'
M0ET;+;0^U8 I; .$!F&1)5?X_<"%I0Y@#VA$%!K[T@M(O@OS')O"LT>.!E)1
M\K_11S#<QSK-W68OYBJAKB+UK.-R6ZB.O,AOLJGTJ>G?BW^'C;1M2;![2&[%
MN1@*U!)\:LX\/\'8A(+PZ4I^:PL&A(]BXM$4ZYHMRG$[-. :SS^R0%:,QC_7
M*?LHV>N%\=)3WX'0LV9]WZ;_RAS1Y+(Z/,.FCS@9"#,ZE#%'/98H/)I<Q/N<
M-FQY]Z4&_?9<D?6 S3"-)2>!C@0U]Z+NNWKEO"")%P#V@AY,M.JA7USRLYKH
M"MB('NULF7DXE_YEDRRJQ*<W4*N4Z*VI_0)UNHT+[0TQ(!MN:%A$Z1WJ,0#8
M:B:^0 :C]Z(/$6U@S%/-] Z1II;S]-+0JZ&]*!JS=H+<1\H?7P:( G8<DF#N
M/3JZ:;M(>,*<LN8DU$<.Q2NHD0;_Z4 $93_*OI]0L[LQAF%T**6/F:\N4I,0
M;Z2AZ0,'AF[1YP:0;F'H*"/_KD!%YQJ4SJO7@*;'SG*U&5!QH;N0@\!>9CGU
M:<2>Y,C3R+H,UQ:I4CPJWZ(.*]6!97*]KTQXO&E@"+&0_CW<68@%_=M/8IB*
M,EGHZT2O#G3<LO'XA3[.*%A>/N@),+#1>B=\SADE=Y1<**#]D5<[KWHW _LS
M(5>[IH?'0!G#'8W-:,.E1D:]6?6^X(ZZ6L+0IH@B->?PT22;4\)EK.#64^W(
MB)13C"CA*M%;.BK\,.NJ,+A,)SJ:7H8-TCG/E8RZ1**6ON%55JH6\XNM'?^.
M[IZW6_V!6U \YL#5BX<,7+WH U<="5P].-[R12.<)9!*CF,5P1]2.G"2%7#0
M%9).LXJICW1Q%0#(G*.;;?]%,7!;&QZ)3G>TO'BT)ALY<;,@#?B^+NN@0(JW
M/F1'-&N$3*1J4CE][)"D(!7B^%I8C,\ASN[;;I)^4,4D9!OC,\?O&!0! J$;
M.=\;\KWZD6#'9501!E>99"S=?2 U%Y3L+'2GZUIDZ>%LN+&R):6AN,%+L2>U
MU?%/9J?;F7EC4\\A\]$G79?JM9=<'CJ?)UB$K:M#J3)&P.4T>3U,O*;&M#M/
MG4BU'Q_I&:MO<)?MW:L<,CL_Q!6P19"V]1*9%0.-1)H($FE"2"0P@5IJE<0[
M=!,*)EX@"TS;I3G^C OP&X%*)[XLD#+4/ECH[\)&ZN%)JOB12Z2<PR0X=),:
ML,739$&U=$P&0Z%/4R%98%%MZIKN\(MII2]</S;\;RJ4O\1Y ;\^SQK ^R2Y
MO9_\9BU#I=]:76;II&UF\4\]LQX 4H+X/LI12EU=0.(MSK;,HC><,](Y]W@C
MFT//:*&!G*V(O14+:$[EY4HZ5U)_)^EW@^;#QQAU!W-P."7.KNBX&;+/0G4.
M IL62Q:]D+54'L6YE;&^?_5JN^45V2WOXEFL#Z&4R]TVS,^Z986FA*OJ)2<^
MC,[)2MN:3**A,$A2S_<9V#"WES!N@/=\=V[@:K0&U[V.RG/+=W$C-'V<B?HR
M6,SV'M*M*==NX>^6XJ/XD?L.=8FQHZ9!V]1?/5562P%B!E ><6.^[WX3ZZOR
M>RV#_E8CI8-.=M$E%8>KJSBK"K!$F>*CO33_W/':'6#JS7C7>D3"JWQ_T^?Z
M;L@:KVK!]=F$.)_5HZT.[=%RD7,2L2X8GGIUD<"^)4CBUQ":EC"1OJ_MRK9V
M*G&=NA&ZVQH.&"T:M'S9=*J$B,E=,81:S%(Z/?.@T"<I!LP*HIS)FPE3I\B!
M2G@&MGX'3>0D#L=QPM+$9OV,CEXDJTF%5ZKFY%/V;C:'7QJJ/"%A("E;OT7O
MS\&5$CKIRCGH"J'#RRG19:J60 -N;K46'X@#HP 9P#5E:]1N)CQ4L5I*,Y^Y
M)F<MDFZ=Q_X(_'R&T#03P =C/S&#CRU1T])1(_5#R^^D6M=ODRHW'4A?/OT.
M&T + T-+0]2OQXBT?DKNP9>96HSC)-%17Y19-N%ZUW2B4V*<*$IL=8^J+0O.
M*M,(6BX.% 3^C-TM@]OP^]W28H \92F%DV;(OJ6WO5[S5J=2TFA2@'<-MZ$2
M.1C759R7%=YE(%CK\ J4 L.6!MK_E P6B8.7*$14!P%#*$D%'XTYS*7(454M
MR!"!FON#UK5*3 <F?Q1*?70^M+&SW(NJ7:E\^8U;:J!X0MK2GF@E$)[&+U<4
M\(ZI6L1%T=XT;%<)N[5DU7 =_,%,M0N.R1^\FC=6'SY9$G1Z34&G#Z@SN:0;
M)ON4U@^F4L\JK.^I@#Y/O$CHH41"-RQ"M0*,AGK&Z'FO(%!V>*/V<%!37%XT
MRU$U9J,[%-;AF-BJ=7S>641".FJD[E*&NEKTWF.E=./@"QW7-TPN-?Z$1;U.
MGWB6)_9Z6V\2UV_-Y*Q\?YWA _] S>:<L)='VX\H5;BM@</6KBHJ![C94@SJ
M0D0'EG))M"=/-9/<"H^;$(MKG(5&!OH:</WD_E&@Y%X^)$KN98^2ZU%R[0?D
M]W1 GH)VS"SEYJDMGS_%L/WF@>$^@SBDE4F8_"\'/E:#H+5:E)E)DK1"ZHQ"
M=^YCO#RD1^!8-9<\AF.X/$.@N,[","Z,[&3[*X543H0G#R=8K:J21BA,3&E[
M( PX;:X;?OATYLB4,_Z7PP"A'Q$N*5P<N+E3OTI4^RZ^7S+&HQ*E%4'P^'3N
M2$2%.S9;+6\14Q9JAA:*P- +&V?5#X"9H5!(:(&.?#N6_'I%7?NP].QS$2IB
M M'-:J[7A&?>BD:_J99HIMVGK)J:NBC8KV85ES;W:JDQDA&[H-CBP%0Y+VTD
MPY;G/ FU*>EQ;L^J,DY"PJ5,L)PJ6^ _$^0UP4AZF24JK6%A;/N75P/< 775
M9@M9I&D"H<;H^P(+G!O!>]8_[H:+"QLP898@\+J3JI#J;2?E[#^;;6)66/R5
MV>8+#;GU.<SFJ+K*TA -$0HV,L*G=:"E"\N\&$SC(1R+LPH(AI9FUZ22C192
MG^*"T,EAR=Q&5+*B_EU)Y,(L*O=Q :-'Y;JL'1R()//(6]NF7]+O/@# N <W
MSP$F4H7P&=>1TAU$A[9R)%+[Y=#IU,;6;^-EBG"7%.&!2D*2@..9D':#/Q[\
M@>3G>:\&VR T$SUCF9ZQ9O,'OSC,CT](MQ'#E=2VH:@)!L5S=7^09B<.VEH.
M=;IURYT;26F>(8 C5OO<\^T;=^8.76$$RD$5$44SA0!C!R]NTW.FNXD':N;
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MFVN/-V7M=E)_R#^.YAO,PK22 !_/ 8'87X>ZFJVH1WLXXZ^A)(X]$&X/R"C
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MOQE'4_&5>9@6,\[*SL*8:$V84-:3;=U'/<Z#-)R)^@TG$V*I*1 ^I,+<-@-
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M4<8M[[2E@0W8M>NH<\\F<%L&"7@C9?!,4G^>\3)Q$'YHGV3HOCNBQL[29U.
M+K6)^$U!=/T8;/.M;;JF[>7J1 &&D\PU]6_YK!MG-Y[^L':BVP/<;^#HZ0C
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MKMY]+:E6C8]27]<2K%V/SETS';&]=?H.YAM>[3BZRNJ>R>&EZ6K)0]9WRYN
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ME4Y.H#9@!A[84%'Z)8,S&ZTM5 UY0'\X;8'PV=?Q)*93F*SQP-!1WDE-VD;
M\\" #^HN=9N[ T,33,K>$  5?Y@KJ0^9K(]R,&FF#57T''08J8/8$)Y>QM)
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M?68.9^P FX3:W#7E<L%G!9\#!<&I1.PUGPV>2Z#>A7$_26H@T1[\LWFJ>?/
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M4U;-\-'A<PWK;TRQB[^."W-T8]J'[!C?0UMM)G07:+OEH9.CX &@'L(D4R&
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M2OB/218N8;&ORWGRYO\#4$L#!!0    ( #!'>ENA=*3O=K(  %T5!  -
M97A?.#DS-#@S+FAT;>R]>W/;UI8G^O?TI\!D9GK$*DB19#M.XIQ4*;:3XSF.
MX[9][NF^MV[= DE00DP"#!Z2E4]_UW/OM8$-BI3D.)'55:=C222PG^OY6[_U
MW5F[6G[_W5F>S;__M__V75NTR_S[_,/_]_4W#QY^_>  _OK=E_S+?_MO\/?_
MOK^?_)27>9VU^3R97B;OSKIRGM?/JE6>O*[J-ELF^\G1T9?'7WUY?'C\*#GZ
M]L&C;P^_25[_G.SO?__=*F^S9':6U4W>_NV+KEWL?_V%_+;,5OG?OEA4]2IK
M]^=YF\_:HBJ_2&95V>8E?+K-E_GZK"KSOY75%]__VW=?\J"_FU;SRZ1I+Y?T
M];+=;XK?\V^3H\-U^R2A7RRR5;&\_#;Y]]^ZJGWRKECE3?(JOTC>5*NLY%\^
M2=;9?%Z4I]\FAT69'!X<%>639-;5355_FV1=6SW!=Z[U1:NL/BU*^/#Z0T(O
M:O,/[7ZV+$[AEW5Q>J;OOM9@8$WPL\&L]'O_N_>5_YTF])LT:?*Z6 Q>"\^:
M?O_\PUDQ+=KDZ.#XNR^GWW_W)7X(_K/^_M^VG=0R7_R)YO3OY;19/QF9AWWV
MX-%/_+-H!O3C>5876=E^6^+Q6SZ1A< _^U>-OZ/WBFW>8%9V!J<[K\-WPI:]
M_J__?/$V^>75TU]>_O+3?Z7)BU=/#WCO_LB!O(6["H^L%LG3:K6JRN1M6\W>
M_[%CV/N?AP>'AT=P0^OD/%MV>;+.ZZ3!D4T^]=;_98_7=]WW;T]>/G^;G/ST
MYOGSGY^_>O?=E]WW5QVP^R7%)67Y'KSR576>KZ9P+(^_2A/4?)]ZAG_250S>
M\/+Y\S<O7OTC>7WRYMVKYV_>)B]?/OV8[SMZ %+DY#PO082 1&O/\N1D!0IF
MEH&F>?1=T[FWGN=U"[]>RH:WU?K)LBCS_;,<M_[;H^/#_P7/:\^^^Q*^]'WR
MX[*JZH\Y<OSF?U7U^S31?X$>/#SZYE.?@+_$*<OF!3P@*^=HNH(IN\K+;__J
MDWI]^:%HDE_*6;6L3B_!.BAG!VF2)<_R978!BA',YGI=@9D.-G2RAR?]W__'
MU\?'AT]8](,R7V?EI8I\^MO1DTF*UO:BJ%=-4K2P9*=UCJO5XA/@=<$C3O2/
M_8<D%T5[EKS,X6*5[Y/76=V"O]#@W8X,Y.0T\@282 ,FWW)9731_X9U"&]K^
MCU5( ?X2?/3!5RR2#G@$P_\/B_.B:;JLG.5T=M]F2Y):;)'ADAV ]Y4GLI6\
M60T(M:Q-DT5=K9(61IZT%?]WWL%VG)+, W-@Q?(/]M1M8YK 2=$_\W5INNFO
MX(;1,\[P2)7S @]4 V9Y"QM4PSZ?Y75>E"F<EV25728%#)G'V^3+)7RMKKK3
M,Q:UN-5LMI%!.6.#LD&#,DW&;;Q49;7.-'J<C6W:/TR]:2R+5=%F_7F T_>6
M7<[DT=YL$GG)ZV4VX]O@M\"^Z"!Y5;5X]IL6YH^+#8.%-<95=PO8UEE]2?_(
M0)_,W?+AGV'N+4HJ_!U\@S:4]A.7:KTLZ"C0Y0JG$<Z"=E6G<J2;FIW"TT[!
M:T].ZZJ!B<-I:I(UZ#XZ5/VY\6MQ0Z<Y[^F<-[5:SA/R^'NG)W+B8//@!$QS
M>C]\,4_@P6M8=?!$ET5[V=O6E%Y [PU."SSC+#O/D[)*JBEH8YXR3!06L91I
MTJ(TW>S,K!3?CL)>H4:N4&2V_6-Z4?#8\\4"W@&S7W<U/LF=HC?Y:=&T(F#?
MPD:(H 3)-<\7M+?3' 38!+\ #UH42XZ8V)/L-A/V"^YGJWKJ^8?965:>T@=7
M,(51(2Y_'(A@6DIZ[SR?+6&.<YE) 2OI!R%?AZ5?MF>T F7%)U8/DM]@MYVP
M[C!Q.A$-;.EO7>$DB\X+7JV"X'*PV@=_78G.;[!2]RS#6Y2O:8EQU>G@X&:G
MN(;9#/3P/+RXZ[HZ+QH2/W(#S.Z?@)R"WQY]\^ !:<$,%FZ>S_5RP!WJEG)(
MX#YW2Y%C+<H,OI=[8!(L>:>7ERQ8@E,3OFPH+=TXS=G+\&7^N#?NN,,//\(*
M)6_W'^!\9\N.!-]>!D<PF68-S;99PW Z,+'K',?+\G &%C:(0)!=.AS[ 'V_
M"O543K.(HJ&P"2\6+]?%63%#D:BF$,P8/E;G"U@KW)%Y->MP%HV7.G9;^<96
MM=_2:^VHN\M^:Q]^I*VUKXK85/#@O2ENC-\3$)KK]5(N./RJ6*#7L[P,M@K?
M,Q29F_<C%)>!((EH5C^>MVX\ YDF(^F=*CDT+(U0@^(:DRJ(']G0:.*M[>JR
M:,[T!:0 4E2H2=>XDR6_G57K(G?;?,.Q)'+J:,7 @)KFH+[@Z4Y4TSGQ6^05
M2'3%#O"LY6!K7N"1<18'&)U)A:?HHFAR$=@46AT?F+V**/7]3>%+H=.CLPES
MA*4RUVP>7K-6;1P\@.:YL/Q%R?%^?+FWB?"6V1E&="J8= U,!-VY2QE33&[9
M4_@&;E?R\/@A7@&U8(:BMX8WP1*H]LRVVL;A:QX<_H#/XA^^.M[T3ECK1LS
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M<EYD!, &TQ!<RLG(S7&'R5N.'0S.#=N&\=55P$,((@C6ST?!XAD>&9YX$1Q
MC6(''J;F-9A[!=G4\ 6ET+QW#GR\6^W%A5AQ=9XUF)2%7Z%I1:ES\))G(%,H
M68NCPI-R45EAZ+:6#&8_"%J \[SIQ0!?B4+CP-UMSKKIP"HMYXHQ\,;_8,_"
M"8_.%X8(8\0GP'=A($9S1..:F+RC*#"ICO%,%#[Y_';V76*::7BW8@N!K@KL
M/\GW^)YLO2SGD^!U9(;!H3;)D>&S\<CG']" +C!8CM=Q)B,!E8OO,2H-/ CX
M3TY6!+@M88J&]B.KEP5,BH7GX&48%SZGK0L2@&Y_W$(,X15A2M5)OR.^_?X
MD)\)BX(_IP0I<E%@D2&(",G+AHT0MD_663%(#MCD7PQ=@G]4_$CTU#FD2!3S
M)-");#G#Q*XDN2('CF5#<,1Z4OF!-R%>M!QR7Z/V[,M=LH#$RL6]+46QV4F7
MXC@;S ME5$A@>[#-!7R_J?)S37J82$1F%D*.[6!E!M+6#F&>+T$ZU4WP)#D_
MP9YHEEQ$:P4/1L--9&S?5)8G](]5?WFS:76>NPP\&JFPC*0WS*<Y+VX$-7Z<
M_PE[(#?A/)<#21!*N%]H4[87=,S=HP9NOYN5^_MP&=+^ R(B@[:.X&75,AHM
M6H%MBJL\@_G6.I7IY1_IZ_XU4Q NM@Q>BP\<]R/++HZ\81@W*9TZOD^!_.E2
M()\@=O-@4^SF[1BZT9J^'-;YI53X2M%X7PO5"'Q$<$>$H,KJ&D:JH-3"HC0B
M &&/'#908?FBD[D6D6 1MZF7NS12EX)ERYG4I QU@[ D:$K$;SI.1?^X',%&
M93[/P<XJID;F.Z-%%,X\5?N.T],^U6"LFHU*/A(#=I-G^!$90AQY\4I(3*^A
MEB =@(@EM.+0$LKK62%@+C0D,;J*5@IL GD?#3KKI/;1SFA1G>)Y3%KQ*10Q
MBPN*H=B9@--\K)8A,/3+!5B)-7QYF5T@T"^*9 MQ;K+TK[)FGOV6_+2LIA@5
MSC%4F_R<U>_S/M2!/QF#A5'8,1XKZ]9Z. >!)[ND?#K\'EZQ<6G<W&#CU!A3
M<A)=G$"J*YPM:@VAS]RM1WPW6L;R5XJ,P.V2=!+^.!;X$TA8 0=^7L 3$!%&
MM2,:=+5?K$H?9<4KC4$_.>4QT>F#U+"B%"/F5=TZDDDNJ,;#S$#XKI]7RVZ5
M[U^0&D:9"L99=II[7'Y4.-$S]3*]@IU^75<SL/.C2+EU=DE7-3QM!\D_61+Z
M(^^O0\\S8CA>U"CEHXXQ-+J",<U#05@.OJ]1,+829@-!T8/:E2XUVHK)2D*@
M K\*H\Z:"XWAI8X>Q:'45M=HO'>.7C2<>G1_V4]4AXT%3-K[+9UR.K;Y!Y"8
M=*AD'V6$*JHM8)F>4 7/T8^OLO=Y#8[#PGIN/IC;6WTC%J(;,>GO!%S!:F0[
MX %E?@I?XS0EJ/8F(_78#&M7QIWPK_;:%MZ:,]8T:S2&ZH^2N)V]F00.7! P
M(O<8G3EPUV9GF%L=#)U Z' MREFQ!CW!ELL&D+%1]-'W)V24PXJ0#]L@@!]5
MF0IJ7_DVO/=.>].=QF/5*\3R8K+Q7KB'V[%)D<PR#->CV .SMZLSQD,$U2]:
MA (O N7;+#I,Z]#>XHCZ:R2QO-[78<6ZFH1KD6G=36V=^YX:$B=>HM+@,O)M
MP,@;!J@7E)Y2YSM^S'KQ*R/SLV0!:JVK0U0U#N$O9;>(S;+9\L@,GC):,45X
M_"+<,A<IXF^$-4_POK_L!?E1S5E%0#!RO)>/-PJR9^>!#LEH*R[!XS9J?"!W
M>=:T2*9D#?[,F_;)D_N;'/UKN*?B'R;B($H<6MS$9,-_T"(D_X6CI0NJ+^6L
M_Z=>HIOAZ>RR/#QB I%L,N8W;_[_[T+!&"A:\5?+(%392^8IL.!6;'O[[+^@
M?0_KAT)?29P0ET/.$-IQQG3_ ]=GXEQXFNI8=>B3Y+OB>XTI?/=E >L*OSBK
M+C @SC^3WF9IY^^4-VLR2@U0E0R<I:(.<LPNSN$E?3,,L\?BZB39O(<"PI^-
M3H[FA-M>BH/ZW*RAUAM;^Z2L[.>MXG*YOEBJ-3O-BK)I!_L@6B8\)KC'(Z &
M!/W.-R(4!%IQ?]^N2I/?1_9WBNP_^$21_0?WD?V['MD?LTJFU[1*(C03*JS4
M88\%EP6\AY^6H'+1LZ(%1D!XZEG5+><A5'C*I5E@OX,!KV]98<P.W#4\A/OK
M#G38S)9UIAL\#$-P@6XQJIZQ% :YLFWV'I06_LFXNB[BZ;2MH!&#(']4?WH,
MV@R];T:N>IW6C[1@_ 2)#V:MQD><]XHA'6=#--ZSX_V*13HP7L+ZGM>6'$ET
MS!<"K1^%TGYR\_PC>3!R*_C]CS9Y,/(#Z& P2MIVZ=WI9PPFN!P+G=Z[-X.D
MH5_ R+WC;.&&4+$DHTQH91@H;OPK,#(T'FRG2U[-,%XEB4#P#^ BV_A]&-GG
MVI"@<MBCDBG4&\>6FUD_@T<,F7S>!2"CM<;7E5*%3AE?W"!VAC&8WK.=:6P,
MP_&H_K 0RL;W(TQ;8HC_UF$ C$>SB>I'P(#S,/Z6M78%A_N"X4H&A'.Q#OA!
M'3L#,)F]@9AS'LW,,,PH2&L$F+70"AS%57/6HA="MO$LE]EUH232"5X9\OXU
MH/<XU#?RS !D9+RIR*L>[YU.Y&TF>D</\;'T9('.%#AZ5>/-^E.$W92XJ!F)
M>9#N8"%QC+%">56?9F7QN^,V4M?/!M$^O>3_\YA <#&LK(_+K5\H<CW-X6SE
M[.SU[F9HG'"XG&I9HA=TFE,:R2;TYAI&QN^FCBMFEFDXF\X%:O1,3(4TR5TE
M$SF![A/QNP?G9U9CA6U@<_B804VOP7J1TS+/+6:"+MN>PT+TC1#"^9W""I;A
M(H2(=CU_^H(PR-!;S@D*$I2<SW(X_ 4=['<U5C2XNR:Y,!RS?(B6[U]@SL[K
M[ (N!SSB*7REFL,ITB*Q$ ?P[%\G3P>2D*-+-%8M^,DX;377<^(S5?TJ( KD
MA<4_$F=('8E0PG8BAJY]%5T7I.Y2JAOD/9WG4LPFV\L_,7\(J0[/@Q>&KTN0
M%5AIPZ,F@87&-)WF\3-L$C[R38D",=@T2!)C"BE#1D!4IUW):BTKW9GAO<[:
M80:/4T&;CH!%0+AE<K1O/!=!19!&AZWT5C7E&6M79V)^NR!>%MG'Z66PQ1(J
M.\UJIX_=G1K3M?XJ$X 3F=\UP\+5G.B,@(_-]4MZ]2A0P=:]C=5%$?'?( 66
MGJ' !3+!MB($;<AE[LF,O: \<I)B]COKEL3@0I\/,T2Z_3<YF['$<?14XEX<
M?_O@,'E]\/.!X:9]BKE"+)=)XS;1GLT)-E0LT\"4&-(UEB)4,,WHR9A$Y#GE
M6\D[0\<KQS0J$C"*JD8>,I+59&QVZ'$%R/+@WM"6D2TT9@ .Q&\_C,NZW"U&
MC$QF5C5,SM/5]<!.8RH<RI,N\XS<>0RAQ_#J2%QRSA6X]%8[%<>F9N+N<%*[
MNO13XC=&WQ8B=1Y]>WC(2GGC(:!!#&37%+>I#F^L'55V#H>!C]M6DFI\U*[2
M99ZO2JP:)1 W*O-@?2/3A2NP8@"[6/)4Z0:6=8J!K0*>/,]6<%=)_^<?T*;-
M;03:9+&7(*:6;"!*(09^N&'"6]US^*$N&@(^=702B5TK3G<ILB!"R'.U)#$F
M+)C&?;#]Y2[6.X6H!55U08$C[RR2H4'(2<(0$,O"E-( =@8'R5.DW%Y(-8I"
M:H88!^5K<-JE4%LL+RO"7;J<O9%H^B',+S1:Q>\Q,QHR,BD$3%#\T#58OM6,
M0<[$M.QYP .5N./,U*DC_]5?@-X6+^BP93IC\7!F[[-34\GLJEG"2XD!*'.#
MCX[A"F\6X?BP8#4"(V!\\D\28X".,;NNL52RZA '%9BK ]XN7V<\W&S>6>=&
MSLR:WZ="=DN%//Q$J9"']ZF0SS45,KM^'."EH?,&2?6+P$63MS >C5\*EFI6
MU#,DB<J(884ED!4T; L*UYRF$#@B+X'+T5Q"L=#@&/C4^'K.(ZB$U.]&G?RT
M%[;SP.(P@"=VZ"C,> /:BY4R0C9%MJ)!0^;6MPI)-*^=5\ME9F'-(\ZJ4;#F
MW8RE-Y:;2VLX#FX*L?&T1WBT[5Q\CDJQP-$U*-2O8R('ER'2>2T"E&V'$#BA
MKQV97I]VGHS ,;\=><9QMA1+R#\@AA&I#,%JP^I&J4C-E?Y(CA$8>"Z+YXF0
M^R\.JDNP1J<^=YR[,>?#SW*6K0N,.!+'_L164N^^V1Z]S<X#[87%V/4,% ZC
M*CNT-8BY@=P2/&_GR"4O#GXX^.J H;$8RRWDKAAGC[ 3UA'VU=O7FU&?TL:M
MX+3"8 +&C@@H7M5,L-3WJ=E"AB7)==PTQ("7H\>-,^"3X,M"1#9%W_GRUFC*
MI=2\==M.#^_=,+WKF:W)"HWS"/\1$G.#M"(Z&TY8@)UM2T)".A>SU%<Q@M]\
M;[?;J5MO N$Q0AY+GFS1%*(7EPH@7-3@8L#',SA7=[$IQ-U)H0CB]ZO1DM K
M+:<WD8K/?_F*SW GA@UG7,%H4"O:> N (YVX#39(S521(5M)C ZOG,NGT#ZA
MR'<X7HDDQAF@'N^M)A.Q >B[8:8X4C<*;Z=LB%62+KU#1Q>&PGQ@UY5J%&XY
MGT3#^)9KC-_&K!I,"5@[JC+P'SK,0;#1QMD4?&AJZJ>DLY)WRO'0]3,F?^&^
M2A\3Y>WX&$QQ%-.)@@CQD<9@8U=YWKKXA*.)X2J8.0L?$\0PI=$:"R(=NMC6
M5FK 6#JA1Z/1='0P3E;.]W7$PM8PTSC'HVMGLF4;F7'.\B!:Y%KR#.Z0XJQ"
MU7V0G)@V"1M\!N%-6Q()_ Q37'ZPN!GF*:%L<\9!R"3/*W-2E@BN .%3U;[A
MR='A_C]Z8!3W,@J2;60L!6'9C"]\F,98R>&"_Y7[)M(V.&R?Y!3AV6]\"Q/G
MH&ULMY3UKA1SD=B;D@[O$SQ(BSWAIN\=3?8^7#5F,<X45BYAWTS*FTZSTVBQ
M*UDFHD=<R%I$*TR%0"_/<"T*<"*1^TDJE+0P/VY26R&#-C@C%1F-P^O'O]7,
MNW7O'*?1@ED5RR&YC2'6/SS:.\7UV=#E@E@;C$TJ1X=F?I8O%V.-+C@3_:I"
MAW*=4,C-7"7'#5L3&P[YZ;666.@M,:\:M*H873XMOGEM/BR_VN'6I9[$@:U7
M->DUM@)C-"%D*54C+)G.0"+^R%HK2^?-\[[E"NHYAS>7,5;:4*8YT#]L4;8T
M+,J;YF)/+1%:F1LSM]LACZ.L4[\GA DZ*#.0C'7LM6&/IC&^SDVD:Q%N!;[8
MCQ[O59NN]-.@]\YVS,A\86@_'3ER$[(C-UI@(P_&'3ZM5(BAJQ%G $]\0GA#
M,XHA9")N\9H\F4LOITJG[H-I:O,1<W':3]I)^A(<N"9?WJ<]=DM[//I$:8]'
M]VF/SRWM(;[[M>&/MHIOQ#!3 N0UDNJ;0CT5@AS6(E]]T(0L8_\SUHZL%7>:
MBT)Z+/TQXCD636,]@ Y_V%M,]HXWV"H^#D O[GFUJ<1V4%;*OQKOMXA!*> ]
M5ZDB(VS"Q+(U-$?&,2\H )AZ @3W*OQ! GH)1[^Q1:;ME+@@!A 9PB+C>M!J
M53 PB D)>A_HM2^B#WE&*OBZ!S1I$0HI=7UIXSZ+PP.5M,PS[I4AY!TNL'8%
M^=<PE(B?E2:*O!#8[@5'$>)37Y@&;T, A5#Y!KV^DBWZ&*1,^-]4&Q0O'ZCM
M6GJ-G*'Q8W?KQXLM47K55LTJKNC9L=?O![&MR3/19HC]"+<ZF"/,J#8QUT;0
M+>3P%BC[$/:LCXY!H27')'T6-:^R72,*,8KT<,M+/A!;2$ ^],:Q>X"G_ X\
M&L.-:A:ZW*ZM1BHGA9#8&C+<)+.TKY[[5^.@XTK;GY6[B)"6;,55T?H';98L
M7G"0()ESS=D&">*ZIBW1JM!M#M-#?,%<RNF2;6/.QOX)!) 4OT>->4FWD',G
M7>)(Q!0V5+.GS4J"(Q$KU6= FC[;/4'E5N"-^#]/*%V,XQ7JP-VE2M!?A];0
MNR>$Q$4MC_$QHH>)QIY4!H,@H#LQXOPXX3MH?^,;^HQX.F'D<3@L>&)/PJ>.
MX%9[1=YP;9XXHH/X<=BT^1]Q[QVUYHZ7_U9,B$\B"9YH"&9\,_Q5+)K^<1![
M:]OEVD(R?J0%NY7%NGO9RVL#OS#_U0NA29SK"I^(BP2'P;?\ QAD6M/8[UAM
M -=X9AAF1/VF)*8\SY7U%9] 'UK$^GUQ^HX&T:]6R+Q'4>@_76O9,H<#1 4T
M;/G9;K(#-L3#1]+&'?'C;?:>0ED"F9><2SC>829GV.[T\%$B+0)T>,;YZ/>&
MFN9,U#87A% RF, =/,KS6T@_%I)+:0HT;?Y/5^;)\5&:'!\>'[G@M4WUPOFL
M"?!]6E<7+2,=,/@<)\MT);-8G!1W<_?Z:>3G^H:?^ T&#G!'FJ:-[6=^D^#,
M%HT$Q6-@A-A6?L,5\0?O.X2=U04MQ%T)V,OE?WMOP?4L<!;4:&OVC0G80?0]
M[/<>-[9B'=?5\:.Q:[Z,F[IH4Q*BW5Y5<\)CB7%_A5\\$%1GWCPCKSI0__B'
M--KYF6>:L?T&CLLZD\Q)58==N-AK'F0979C!K_^MA1+NP_Z[A?V_^D1A_Z_N
MP_Z?:]A_<0N6@LK$N2(1V!5/PURC5'E52JNRB(//'$XI]Q9PGVI@;B /HV&^
M& HT]1K*#U:BCQ(U= +OJO"BA95$!V *B[=/$KO.12Y&^",JD'^) C$?C,2P
M[Y[A<WJ#XUF8QKTH1W%'\_]L<RG_=S6$#*?"U7V9E:<=DMYK5)3K7<=:AF^V
M0!2'9+9LD14U518*5G5@W(#&10 Y5]G&U:_"<\@ <?I^I$F$=Z/<W?&\TJ==
M@>E]; IHL%P22+Z#9^GL5IPBVVA&"!H,^GT;JTE/6]]^<IWER*9S/ST";RX6
M-W0XKH!P.EX'97IV8OII+$(+W_=M4[4%@9YC*^V1QH"(*82\0#A9Y@2XIA(,
MJ3-'VHKW.4?#"57B<5($(7.NO_):V+MDX%QNBF/]VYEZH7$/"LM/$,"F\\%,
MRED6THT[+BJ%M"VTJ[<UTTT_/Z%=+RQZD%YMYD-!FG!"=2)C#$%X1=,[1AZA
MBV7XL(4Z-2KER.JYX7X?XODD&$X85C<1^/Q+>0C\\T1H1K#/C3*>M=IV(IH\
M_]-Q_]V^@"BN38*IW0GVM,DOG@/<UGY [&C_\)C@HS;K]Y_H%ZZZ)3,PCN6&
M)^[4DK.BG9:1LT12S.AE2A<8)#*!-\-A0BF4S<^+QEMB!F Z:N%<;=XX?C(*
MBI.MT^-/H72N  CKG3#)XKUO?/\(<M=6*!Z@D,#<GJ+;?;^/.N?883*MJ_<X
MAT6A/5$MV3+'&1L/OH4E%&$Q;#FM_2HXF/*VFS;%O( 3F$>[X5!PDEZ.%@=\
MET?@%/4BS_UHY ?35+3/51,ROUU5*' ';^^OUXV1N>8QAE4R2+6D$@-E!452
M47%&C03)E)K+VW):Q+-[G&KOQ)>2UKDW]LK*VQ5PHS'RE(@*E'>X>H[47'Y[
M(5(A<"$MG-78T@I>.%5+.%N@A4H^B/N=AJP&I<":G(T==QMQ;XB_A*(4X _B
M&%1<8 8+ X=",2/C B,6QDY%B5W-"&TWF+T>>>;/NAXGLA[/2<CT(\*PIC_T
MUE0!KK"HP;6A<9+ QAC@@,IF9,)IZ.Q53;[%;)30C0E"92(QU7OS%:=LTU-9
M@F1XKHCA'9L/H!W5<Z[QC>\+A)Q)W4W*&&^,>"(MS)"8C<**&&[1D0:UWQ]5
M]%C!\,TG$T7O;RFHPA!LK 864D[%.#3)>;8LYO 'UPB,](%ZJE*!2D1IKOK7
M&Q;88<A%;%M!1CS+X=>$\!8/T[F]R9HJG^GX<55R2P9]=0&"9IECZ001T8$1
MA)^FSMTU_M0J? W)S4 V=3/NZ^T%CFUON;,[+4_.37>@DEJ[,3(CX*.+QX.>
M#+P;M-EPP9'%EJNKV9:J0!&<EL$"MUYTF!GQ]@P6OQ#*1)83OX)=U\R+F6Z4
MH;R5%\^<%M$T@)>;4]_/2MI#7)0@_<Z*-7D8\">Q\F477,,8W8- " G\Z8*$
M IEL0GK74&L+'L^E-)%CDJMP:DSHP45$9(Y0<[@1T7R?$M@M)?#X$Z4$'M^G
M!#[7E,#RFMKK!,2G6&<8#2(A1M1Z8J9<*A*@3V9S/:=Y,D:H[MXW8.;=5:=N
MJ4(#::ZI]-*J"K3!#:UVVM.O".4M8#>S^L^L:H>J\5H:\"^A^Q"3=_NZ+XGY
MFLAGN22"]EUW):58LU9L>A(42^44F-YJSOLKTKL2AG0&'Z070DM4$?38(3R>
M' !&2U)FX?";)QEU8J$4@IP W)D^W" U#6][?6UC7A6!)R@CB#2H.GRI%+WD
M#$_>M&FRJNKVE(A/UU0!"Y>E0'A27LY D5)'4Z%(I5 4G*KV$JN'?>NO@/_*
ML1A=M7P7'$BBI2^P\56U#&+7:S0TUUKVKY=<V)M[TT$&V-Q/DDAJW9ON8,!F
M=4M>$JYS[^!&;H!V-,@&"/XA]P+<^QI.%E$1]ZD6_L,%$PU#0[* 2PS'1+[(
MQ;),UC!\PC\V/>$2SCE!LGQ*+NU1U#0!$8O"@?<D+Y4Z08L,\:XLUS)=;)DJ
M[W]MA-LK8)ESGP,5-:B>:(RLPRF93>J1\"B%V;4\PC/L-I(QP%1'P3-TBMT.
M$=LXE3=1CI-()D[* YKQA*!68--KUY)KXFEOBW&+:00/<O.VRAE#MM5,>F9>
MB9LI(HX&?J VVLF5FH774 6DBU2S;*6?G696.3VP_,(*?KN"?6-MHV92C3-4
M3EXK#1@78BDWW"IIPYR:SLS+"J^F(2@@ZT]?>HLZBN2&AG916UU+1]DEWJ2@
MJ";7*RC62JG13MSS"*1-U]@M[JDQ(I.?\NUAALW:-X<>I9*D2U,SI04FDOW^
MXA/,1.4*ITZ*I-<:M!^L&QM5T)F!I]XVX(3RM U9*9 _LV7D.$:;#(LFV3WT
M,\E!)1L5RH?PI@P8-<=BNFQV#GD3-WP%2Y8D=561L2PA9E=?N5)NC"GZV2RY
MC SJ[Y)3B;(LF <I:>%1:J9ZYJP@)3G!YX3).NFWQ!Y1XU(QWF$@;OO.1JDP
M@;AJV)M5RR4G8I:7K*M"+Y#>C1PYPU95CB%(I]P[(Z0]-/TC*<Z!S;"#4D*\
MF_00P#;O 0AH@ 'J%_V<@1B--V\P4[S&E.Z@05G>P* <IK<]!TI/_RRDZ)D$
MMDN3;V;;T\(QKZY\XXY> D5;.ZRS2U_9*Q4\HT0V6L?8]]@V:41+3G!%,>,N
MQHH_^2Q=ADNU8T8_Z%09H*\^OOJ*(E^2?WW4O22_4090-Z.KU6<]]?WB:$^S
M&<D1BE>D&&9\G[=NU^F8) 1I<.)D2 4>L6S@P6R\-&R]4&2S9^E@,Q)X GV&
MC!@21\;*N:V#X=DNJ)*-_,'0A[:*-[VA+H\8O'W+9*.U,?BZ;P\XSK>ML#D"
MJ7G8#V^M7 #Q!;U!.&YEX?;4A:2ZR7'#SYY72I#6[U8U KT;T'QC$;&<17P%
M;9)I>T&F2C\@&OW2])(#JT)VX$2H6U@FX>;+%+.-0@/(1]D$$T=@J?S#63$M
M7'H]KLGO$U6[):J^_D2)JJ_O$U6?:Z*JNKZ]Y^!_*'>ZEGO.27(I%5YTHL(9
M2B#'I]"SU+<,( WH<\KQ<L349QYVEE\J0\=()0BO)G4[;N2$0I07Z?1861LN
M >\*;5,=$0:GFFJ1U5*I?LDUZ74K.:L&[!$LQVFZU4H<8-9"F!=T/\B&-7;'
M&K]EC=FS9KAIUO$D9XP++LW;U5L;&T;K8Y-16_G6EFL8P&O4Q7U3-.^3'S-J
M&>#JJ^5O6M9"ROGXR<MBA@4O4J_T%'GUIZJ$G<UYU4->@)@F;QL#VJ\EL7;%
M=WYR;89-WK;_G9?4A.ZUISSUU>+E?)MXI?N\.5K<V=!L &_D[]KS#K8,]BPX
M**DY(,21Z3E8,63=-8U%@Q)(2H^)NO3A>:$Q7.-U(?^3&C5*_A2+^)!YV,B%
M#^H8$"S<E9I-Y;:D08V"T/C2L21B*A0&!' N04K3X[C_-".JR%:7<(@A['(W
MCR2.OWLV24'1M/& CTQOM$*=AC+ZM#006X%\W-37)]TH(1T?KT,FN"5#U"I8
M7;A(V=)'E:,<NU>'^%R&IF]4.S;?U'@*@DHW]#ZZ_,'JI\XRQC'13FV>@2MI
M!S$V*]@NC\7=[F#4:'TC*T(<J^ 2^,OM ;[.6!AEE]S)BACBQB.F@MR#Y@I#
M@0<I/4R4V:"**<K ++A[)^&W:Y^$'GMR/'&5"K'/%4&C.[BP]>U47C+,1A%!
MN(8NA+%3+$DRYD%(20/HDG:W&(XR;WW'.X[@8>7/S0!5+G8US<V<2/ER :?H
M,L>Z=)XW+3ULYO4$&CY>GKSPG]%%.V' T]$W#P\95" QE[U!O@0_@A__#,AT
MFNN7^4DU&[>%0(4KEUO\1C@\=76.H49T*$@/+\G^IL(;,IQL/6C: [R173-#
M(TB[*W@C&O3T<ZQ!BS;_Q;OA&+"JVBL;!9I8"ZYOG"P&2'F3]KJ"!"$U )%Z
MRW)! \@CD]E>M1TJV!QXCVD,;<(F6X+5,X>I324SP161DOB\6A/+ 'VEO/$T
M@U)-FR#TWY"Y2"WM3\MJ"IOW,P7@%530AQ($;Y3O_^@JN%Z4\P[.C..*K>"?
M)PX=NA?<XQ]?O'IS\BDO\5V(97[SB6*9W]S',C_76&9[7:6T8[@ 1.C>R60
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MTFHF&ET?=D8F"DSJ'D/.$8AR:DF-/5[;34K-LC70JOD>G4J7A-\QC8-T>+2
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MPA,-7@,W&/U,BH<&VHU5O-2XN/LY O$?E+]0&06M=>7W7O/"-LQ(0-@G1.>
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M!>Z@T%I<&3%@'4%/CTL]LG8H%4D>E2VC.7+GMO' Y35<I&8R^<'AN$^ [9@
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M4'?U7)_7U-Y"TQ?V'"X.9@_54S8I9'Z+UR&.\56D9JMQ^9UP)TYQT]-'GQC
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M*2DR@ (5*JG+$;M&3D$O-O?KH7>F6  <,U, ")&?"E;G3UHNG5&G5EJ4FZX
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MXB%2J&!':+4E:#E.L.Z\NFV9UN_OZ\WN:SHVR> 0<6Q9B]E-R4K<LZ=S5WR
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MDA^"/I:;[MT-?R4,KR67W&.S%F)-EX5K!5?IC3/!&C;)@\-C>N8WAU\YW-=
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M@R\B%2DO1$$+13:4D1)GVN/>JMS7,[4$&Y1?=%E<+ .C(=:?E&#U#8+H?.-
M HGH&C>;VZWS#JK\S5>]- +]WZL#?-UI#&4EGX(+3IT-3D\/'^WE^Z]>[@<=
MM1QF)@+8F:CV*-$<!J]_+F>F"3<0W%,Z/9OO53Y]FZH#X04[//8/7OY?];SJ
M^N=OU4V_!,=IGA>/U@T=&@IMD&C_Y<O]GQZM 9T*@<[R[$UP 64@P8>]X!C2
M>A[I_=T72ORF;]165R_?&Q?S?Z:TK/:47/BJMXMZ P%M$;[K#F44VV,4TB^K
MI(+* Y*)NUL)L9407[2$.,52HR- ::O@ 'QT*8$-()5BD^0$JQ&L0=BRB4W6
M(4BUO)C_K32J\PRB"E>JRR?9<*'^_%E?_NI@/W@?%44".4$D*1[MW>_RLH)<
MHP^=X.7!_OZ/C_9BL9W_E:A_CHHH^!B-KJ/LX3KO,RKTEO[KEE[^SRDLA9Q7
MPB/OZHV(2!X\543R8!N1? X12=9GE38+.67/2Y\EF769C-)X'G1FP"JNE-F+
MIY#:G1)<';W9(,D>[?5:6$<%O/:?)8[#EZ!Y??%+" 8O,F6?S9)G\")SOB,5
MU(]&!3B@QB;NCEP+)1?>ZZ)9C8;>+*%VF1@0=2-339?/I3I4*M[>"[J&RD3?
MX_7,-= *R!D'J?/(I"KJ:S#)6F?=8J8XHO!\]^;5R^!B[\.>,&4.$3-##3!"
MMD3!.^VL/XHP.34TU8JC:*[3AAN7D6,_4Q(1KM68 ^Y%F-VN1K(+N81%KKH5
MG-E</Q-K3<2S#+R9SGJ6+Y)/UQD,JA_IW"9.@V_29.BF\Q=%/,RO,H3B1X9;
MS/P>YK,BB;F6YL:\PWW\$$)HZ=Q"#ZA1&<5J_I+*$D3]MG>Y%\ ^#78XH9V\
MJ 66<^/4P*^0Q%_-BLP$0 S<9!BH)U9 1*54"(#:V&VI\Q<>4/"+'[Q\^_/@
MEY]GO\A&(^KEMX-?\(+]M[Q\H*R? @01K@X+F,79V50[-E&&.B;S0B:V02$_
MY-0.FT\-Z?_3&*&(39SG*_>_*UF?4<(K+5)W$^XXX]U8R[5!;T*,U,3#>!&*
MP_Y!W;<MFH7K3 L5ZR,?: @H#;UO:NM%!JUG#];;:18ZQVRHBL?4=&MQV'R0
M!4X?4MAYJ"%\=&A;+WM3\F Q*N@SCPT4B!.65&5 [&Z2"--$U%:>IG.)5&![
MW&P3R'@-?>E@H$EX VZX; & ?P$=%,&PHXILGXW%-NYR.',N\*^(,)!Z&U3]
MB_GE1DH@> 3DX*RP6M04[M#K27</%I2O&5_YIO0%Q5ZM'Q2[G"&6E&91[)0
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MD@"LK(H9(9/]'0]G5=Q NG7T_55S(LEXO.3)#PZTR>A)F:LU5[W=T>?(I-:
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M/B#T[V26,G[+)GO/?UK?4+TP]OPQ9#=]Y C,!8-P*^6B%![$&JJ^FTAJ.%F
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MI,2[LJ:>T%D?C&::_$0F[;L@*]Y$ZCMTRB))Q\Y;;#5$ \9W\_;ZNGYJ.0]
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M#GF#5Y\U**5C,NH?@WPT5T?'=35)?_G_4$L#!!0    ( #!'>ELGE:6F1Q4
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M",E]H\'N V#;=4C5_ENK$C;GR>:C3:8C9($U/5\[DNI!X,43Y&I1R^^5OJY
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M,]@S&-ZAT'26^RNYLUPIEH8:#"#"CW\!4$L#!!0    ( #!'>EL4/6AM6@0
M $D5   1    <'EX<RTR,#(U,3(S,2YX<V355UUOVS84?1^P_\#IG9;DH 5L
MQ"FR9BT,I!V0.$#?"EJB;6(4J9%48__[75*B+,FRK=A T;U1O.?P?O+J\O;#
M-N/H!U6:23$+XE$4("H2F3*QG@4OS_C^^>-\'B!MB$@)EX+. B&##W>__W;[
M!\:?J:"*&)JBY0XM-H5(J7J0&47?_GQZ1!C%\32.[[^@E\5'-([&[W <X_%[
MC.]NMSJ=ZF1#,X+  J&GL#$+-L;DTS!\?7T=O=Z,I%J'XRB*PV]?'I\=-JC
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MY_UJ('^:?^7U*Z<-^/P/4$L#!!0    ( #!'>ELQ 5O]_P0  )$O   5
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MN(2^/5JHHR,TIIN'2#P:Z2B&M00SE=-XQ*[6EYC1KLH,3.0T*_5F@+<;LS9
M&X[V'KTOG@RN)_'[YF#9\O9)3+9F'91)^5<4U7B<:),TU?(,&==\!FF?X9SG
M7)]D9]G*94PM&A7\1R6B/&>\NGG"^JOZ=2.1 [& 4X(=8#"K(5R*#.%&.;,0
MGS$]D(UTP4L9M$YG+J?UB"HHT.3NKHF/YMP7K!3-'98+?80TSYJ/ 7T2L^-B
MJE(7*D[H"$6O(0E!>!T7@!CQ5BRE45Q?!80!FD<!"Q.Q3&PCT%PG))10HB)7
MX-CJ;_N>>4N==Z/S;MR9=\.')+\=*KSI%BZL*FK!5K]5E@WNQK\.ID-JWL4L
M\[?!@)B)E84XM7V%6%#'1>,,0Z%,X1A=LJHIAQ2G:D:;P6^:OB+AK=FY7>AF
M;G(8:JS[E:H6TB&JZ>RE2WW7UT="C_VJV."L?8+^P%HGP<9F[!]3<1B7MJZT
MF#LE5'=2"1#@4M30XB88")!CA-YO3S%^S1B/Z!).'#A6<"M7S]^VS*VXB$ 1
MQJ#J_PD[A:M[P$1(L8AW[:8!>R37<Z'Z>Y].CD\_'1Z<??;QUKV>,NT-!+Y;
MDX47\RV7*P'9^LKQW;N6%\YU9X&5=J6YM@#K+HV5+1S1CS<9T)TAQI E=HHV
MRYW@<7RR[L:[&\-OXBZ]DY>_0_>J.T/O9 PGUBG\R3B%?<+H!8U=ZMV'E<)S
M^C-ZGN]D,'?TY@X^YKOX\$2?9GV07#^HD,[Z3;,J]QRT]4"*^WY92,4/V-P\
M/N/%9HI@@N-6!7\C3AYV"GD (C5EV1H3-&6\"-[?K_NH9K1KQ&2#]XZR7'L^
M'\D;6^CN9M>XKW<L]-[<28#H#ES(=0M),NFPU/%<JE3A4YC'XYKCT&W)Q*/?
MS>!0@6U#]#J1+9A7DMJP/7MX _GY9 1SO<82J2?_YXSSFM"5%$:]JD0Y-QV\
M\)QK.L66K+U[,_@]JX")LBJ)P!)5T8QAC'R)CU:V'=R\P0$C#BI,$>OK 9+H
M%)[,H#+6-/3H'VWR]@>II,AH8544]8!T3=J;6+R^(2\+8GRO]:G=%5W=+553
MHF%]"XW3HJ\Q*Y5\N@V96W-,)+HH*#,/LV!C;9WQRRA@,[B18G]_5[WMA0W#
MXKC*Z_$6V %$I##84#KXJ(I(_17\G&1]$"RGE"T<_*KR+[H699F.^EEB2HO!
M>#K=-(7$QWZCN^<F0H@W)8H G#!&8=#6K.3/F@.;P#GU]^>;N\\>*'_XYVY#
MGD=Q#IL" BPC]QA!?8#V=C[D#9K 9>C_P@Q<#8N<BZ^,Y!5>3U+6*!1\H7F
M0JA4D7J8/FW#C<TG\X6L0R"0F!]<XLAQ,YR6H:"5D< #/2X-K6^0!QT7E#^.
M!XZ)59;D7B+Q;%E^.C<JM!D<I19]@6G/'W\/,^,I<9Z.Q0N=;U"B-Z%'Y.V'
M*"E".%$8P-4*ZCF&M:Q2WUS-K#70$9WGWKHE:B+QL(+<DKU@J"ZTS>*'9>74
M?#XV01.L0@H"(WRA>8GWVAP;,N>T2H6@Q+2?HY$T/J.8J?1Q8!EK6]=2:CCM
M"?N@65;<:$3PM$%55K#. ^FE3E *LHJGU6B$Z>.4[;#S.C@:$0U9>(6WA'<'
M.V1K@;B^)9 "%QJIJ<H[L2.07XT$>YCR!K%R20G"%4$EOLKK:OU%EL#/00'W
M49(]!E_CX@MS1E'F67J>X+XRO&;$H@%U*U+7G-9%L02\$=5)5ES[NBW40?Y]
M5LB6LWS-OC&O" 8J++.\+J;FT'*<SFJ\;./A2@@UPD)&^CK!#B9?U#>$A%VD
M\>3H]%]_O-\_.#L^.;51-2P]V8#]R6'@K_3E,.['UBL#\WG/\V']1>T9@NWO
MX>D]!ID<[# 598,6-7.)TO,@C"G"'HXM=LP5PE4I0;V8>)''$N[8HKHJA5"S
M%PR<"4>8^]AB),,E8P0$BA@6BK36".2@"J<2G*MR^GMV&X-]EIXY/!*,"CJM
M)(L"K8P<Y2/!X !?83))0CIT6BPO_5C--'C45 RR;TNPM"4B=6<>NBX[I,L.
M6=?:E[MJ1J6H@I/V1?;H$1V-9_MO/QQB ]:#XX]GAQ_/EG;$OB=U(M<\!WV*
MGIMC/LN&^7G_\<[6,Y"(NS_"_SQ__F0VZ7QNB?OSW=LNY7<,M__V^//9,NV(
M+@K.?CDZ#?R(O/HZU)=GM]M?CL3XS'1%< $=BS2OS7]ONVTV'M[$DIU^_IPV
M^5[O]'748;PVD&O78Y]KL]_;N=EVKP)COS\^^6W_Y-VRG9;+-CX<'__KZ.//
MKLWXFNR[68:;;ODJ<#BEV"S;\/8\G'78:I[^WN[Z\_;GT\,_CM__ 6?QP>'A
MNZ5;#I>CHF8NO^9N4\6<T8-HPVLJ/._1PHUI#G?O&0]A'7GP8/_3T=G^AS].
MP43ZU[*->7=X>G!R].GLZ/@C:=)\;T#WK@=/UI=C[_GZ\R:<-B?[<'Q><^_-
M;>NQ[781]K 5^KJ?N^\.WY[]<7IX\/GDZ.SH\+H[CW<'[N[U((#FDNQM/P"5
M^^3HYU^NS?A\TWKLNBS 'C8;7'>F__SQZ-I[3?>LQU;S]/=V;BC>5X&MWQV=
MGIT<O?V,N[C4NOJPST+=NV<]-KRV"GL[#\!A]N'P9]!<?]T_.SM<[C&CBP.Y
M>#UVO#[_O9T'8%@?_OO3X<G9Z?:RW9;KUF.?[:3W=IZM/U?_]LOAR>$?OQ]_
M_N-@_^,?[X\^+G61TAT!W $&^L< [PA^/89OCCZ^/SX!]E@;$=^R-'L[#\!D
M/SE\#Q/_>'"XC!*\'4>_Z?')I^.3_;/#=\';WP/[D/6@!;<F>SLO%I! &\[0
M]P8:6+^<&Q=XE_AL+?0^)QQ[U_7#MP#FT()=@)4ME#,]#R^!4A$G^OJX";W@
M,5YH4F$/#R3[[TDOP(X&YUZR\5 G Y-87!L&C!4AF#>#SY+)#R.FJULOZ]4J
MAQ95OK47AM5RUB71LZT"9G[-&*9_CB077)5<+< +)&A)A5U/"W$<*.ZOR25Y
M@P9&VU=6H<W 5-@B+,QPY8=^3376:LN&5J986%]V]1HRVE=#-9S26RLARW6B
M+QA1SW0WO?U2K> MEXR-U!?)-/>ZD4<ZC)E1IXU:-:_D+)NM;;,E$?,@V.IU
M<5=+S6]-9U8^'_9UDDV\DIXAC!0G)4+DR%N3H\9K3LQK%M+OO13ILV#W2VO0
M@"(*+#Q M)VVRA:I1&,HFD8]VASJO@T8]KOG_&:)YD)B7Y[2WT+Y7D?5.D[2
M'#:H58_\1M ^.,@#8-SW,0SD5V1FC]);VF9>C0_,C;]I+L\A"*.J'&8YK"A-
M& ^X,K-BSQX;44S8@MB\U+VI5NY*SRJ !+7I9K 4)<JDK#> '&>T%4XT+^G,
MQ!M8+DIVO.+$=/K.=!BQ98($@<HE!S;!W<DEZ3XM[8Y->C:]0:Z9OV<]U$54
M'A%3P5U4JBYG>:23&-X[M=58N#9.&,\@1K7 /K6@/5D-81'8TYKQJE]>V"CU
MF5]2V#,%A:X"L.>J$3V4@D9185,WK($-C(#'LXA;(\/#>W)*P<BYG5]3V>2]
M1Q6PLF6(6 R17_!.%EFB.>V#0"$9YXSZU!!N58R[CI? 5W'*^KH<ON.L8/Q4
M1EJ0JE2_!G _75I=W!.,\*:>HV?5HCJ!2K5CH:E[NPB\N368+5MA:K1J )^S
MLW EF 8[<Z!AU;UJ%J\&,R HBG.NSJM)TT\),5SP#LV&N%^1V+I"!=U*<@MI
M"854'PZ!MA(&YBA,&:8OCYEB6XZ]*-,&O8]TS "[OH@ZZS_ 5LZEVFD@,>II
M<(](NREN:HOR63LYG-XID E AFD)_%I#=;@2:L(,S>1 "DB+]>.[)X7 !AR;
M"_U0BB^H+41BJ[@::IXVZE>_F;.VH:E_RTDPCCV.I8B!IE1NQE.8=_$AZ4Z\
MKZPPK&T762DM>W8E5:?U\?YV<!FCZ=%E'1(R6VX!1I[$PM23S6OS-! 1UZ90
MD$#]UL?EM3H,?3^98"Q2(Q$1NB\X3M&_?.Y:L'M.FX-&=W;Y&G:F^555M*BB
M$^WZNA=LGLSJ?CTF"8+OJ@\(U==-;&O_#LA_@K1J2(F[21&<)O)+'X1-#(OA
M;)N)E. SV4_B0AL53QJQ606Q<)>L!?#R^[/VNK36TKKEE6E2D18LK]ESR^&7
MO,ZK#*(2D=:JKW6L[S.K*'5^]L%=2=]7MLF86SB-RW77,89Z95 MU% O!%I#
ME\J;^&JH#*AGS5']K/)8^KTD6#%SFA=90TM4B^4:5J_ALY'6BJ(M+7"SZH;W
MXKJ.S2N"?[6H6_[JT*+TX- +=8ZCL^$8<K^,&6>D35L-%7O[WSR-+=!#W(!L
MB"U<0[Q7@\O!/=U/TPJT,L8D01_+>U@I8,Z-?PE(BPZF&M10;M'Z3H=<U+Z[
M347MSPQ6!C[J_U:@@>D\F<K3"O]Q_]<^CGN[%O+$7Q48O?2X_ZY2'>QNL3YP
M"K:SO&F+R^?-FU!+T']5@@".FK$Q?+]&"3XC3T -LD- S:G')W;><)O(U J?
MP?K549N+ %_)))?+$DC S8NW'1X8RA/ &7CF?(<MFPP,4R=*;A._KL5=X*95
MB$E1(RSQ7Q&#I*CPS[D0!Z_0F;GOW)_SKB6W%6-#P!._I-DDY2Z_/=;8.%@&
M0\SYBHL8Q)6BCBVP62";$D9%(N:(05V-<YI67[JF;P9'OO_&&'AY8QBU<!_>
MC^MM0%3$.]F^T/*C6CY5()2*6KUFZ,7LU8;9\TR=$!N($'OB,V!MJJ0DFS0#
M"A+PH) D0A^=8KP*"8,%J0@[O6$;&T60]0BO?R06>J@*S=8SV$A1+8+8$-/\
M=##1$XI/PG/1NA^1CRK)@$3($9#;X''#N-]$X;%F)M7B(]]6A]9.^T7%H'?;
MU?;.$@[X&#%825;H%G6A*T<2B'XP^Z*-),N^2'-N\0$8LQ+%HTC%D5:IB#7\
M^'GS=#/XE,<7: 5ZR0H?X)]S/M)/,#8Z<LV/7SX7ADLT<$IA>B<)2B,*!/RY
M_96FA?'.#_OM_97-^227;1^:RVSF!+4-WT]\5X<?VO"_'02PKG#J8-X3'4 D
MFZ^\:GBDCJL<W<=%*V3/9[:B?7M94,\\<]GM5]$6T@$A?E,_@^<_L&Z&7HN?
M :2/RQY9X$MH=1F0?"RPD37*QX*#X2%&RK$;(E!T,']!B3;(I4(-.)1UK0"+
MQ&$\ANN:,^CK)-87,U_#"V>^RK E?35[*0KGYI>H<8]:7J<O<3N:W\9HK\T\
M(XF_P,'1_!8.UYFO\""8<0I1FXUX=FI9>IYA*DOC:^P<-_-=AG8DGNG-'W*-
M(;#9K[,_6Z;'^G+S6^HZ-T-B<3+SLDGM;E$_4TR^H2;GP#M)E:O$180F61ZQ
MOF*\K[#LP"L6(9*D)AW</>RD,:0H$X5),3MI/GD9O[OW&J.D+;A+A&P/E(O2
M*FT)C(SQ%WO^M:J?5:7I1WR/6XGNOJ@=8@^U5_"U!T<QQS[HL27%.R,0/4DV
M-JHB-?\D)%O6KU%^1U6(JB*HH!0&QROAV_-<C<3Q3@WU,-V.S75V)<F5MLT3
M:HYT.I6HG!8SJ[,@W?5F5$A$> VM9H8ZV_=N*?W-34->2I'?PK.\E );AG>;
MR>#DVQ"R,V#)=8I@:AR!2"PIH8/COP-=PED]1KV)[1DZ$4+[D';Z%(#@K(A)
M0HO%U-'<PZ,YO-PHUB/& ,_&Z%'!#A*DR;6343/N:-0IF[V95N15PG88<)#3
MT3D9HB2DQ B)H*,*B18_>4#PX"UA?!J],!TM/BQ:1!J"^RJTS2I.Y":8X1P=
M//'_*NO=82(E?&TU9HEI?+@L&,^G'>T\+-J16@ 217E 1ED\S#("YLWU>95P
MOVWCG"15CK![\52=*^$Z*GI85.11BBC]%K">W&,I68.G)1UR3HG":@$87BWK
MM-.D'ACMD 9$CB.)-I FGJB4<VW[Y),85-SFW$@<%YSPE2D+2*\O8PX*6ZT>
M_3PFEA5F2:+ZDMI#ER1QJ%,N$S,]VSLZ?(!TZ#DO<AUJM._@V:"?2P%>GDU5
M K^/U90%' >Y+;G!)4)C'1T]9#JJR3,NV##&GD=B(MM8,X_9^8K.\@33IC'A
M ;/N8? 4#"XEF-/I7!V=63HS41N*(\;L8*7@6!YQ%@87K#CC4,]Q;"%569]9
M4<)Q:DHA.,&>+V\XU9APK_)H"E@UO;1X?T>S#XYFG;?+"4:4ERG%0^7XS,&*
MP&@D.BKB$M-<_#Y82'A8_<$6J)<,(VDMZ?GF-0AKG<K+:YW=O,A;(V(\T8&$
MAOT MXDG>O?E>D!MRRA[".\8B/TV!EZF>&-:KS<O*HK,FL"A'_R#;>TKV]7'
M3W=4%PI>C.Q-R5@X4/&$SNM= V/P@IMN.CS16KU1AA%S!)Q0!= (R1!5Q(63
M2WZQQ\SMDFAG IJ2?,EQIYXMM/-7VI6E]K54J62V ,#FF%$=K A6+($-L!J6
M)A.G2.E3R@7L<6D>I:%E@QY%<*TY@VE7=N'L!M3J9-]7.1K:B!M!;?VHRF5^
M+)=Z,@44NH;GF/+7GI39V+Y+LB8F&8QR&JCDR^(Y>%W0ZEEI-KP\?Q0U@ !<
M1A83IDV41U"\K;5>3[!<TA]ZBND2KMA7HC8Z+TP)F2E!5.&0*(?,2I-6X%NA
MINTM)P=C5!N3* >Y&FG:'T61]4W,K<%B2E488<4U[B[I-E$30GB(,DY$Q!I!
M*@O%WG^PFPYY ;>\8."0Y0%[> ^W&L0<4TXOEJ7!R)0ICTR!A#S:L)(6!2W7
M)%^M-&7U\N?GU2?5J4F2Q24IE/,I^>^Y><_BQ/*[Z"%KA*HJF)PX!].$"'M(
M?K0!I*?EAO*D1"YK)%BZTG=R:Q MF,/Q"L^3I!"16=@*TF67S:<IXF40)$G%
M^;PD#Z_(JR9[7M7RZG%?,FP6V+Y,]26B."W-VU\)FK])&O!-JSGUE%69$%?<
MI%ZR'9;A2J61(B^:-9"UK&_I#<KI/O@G=ZZ;N])M@Y*SN:CE5-!1(:U%Z4)<
MTCJKTQ@+<U)+.6/A![>OE.GOYWPW77*M:<2X6Q'P8L[!=AD4MX?=#'X&J6L.
MA]J+9\X#D)LAM:RM=,/L67RPS)/01BP+BD2*AGEBTC91(6F*Y64O8JV4R 5U
MCAXM/!Z_#1D,# ^J!"ZM/<9K2??KB'_4S-&]1D-=+_7>I*I96Z(72':>]2"W
M%M4 6:7&$6.(L9X:;P?$L5+>2Z'&(,JK\YK0 <)0GAE#9<(RI,A+#\ D=GD>
M*5-Q;H8+ETE_Y-S&1EC;"C$CE//ES>M'F);HI^R3N&Y4QL/RLI:=U98'0RVA
M*LK&2GE9A(PT@0FLI*CA1@RUU$%XLJ)%*+ (=XI$&.>PF< /E*V+FS9'IGL"
MJ7Z/B#9/&-?46LD8=LG!<M@ETH<T(GYF]YHVFJ/;;U<&(5D;CEYH0VEL4AM#
MLDQ3_4]1Y1=ZBGH.^T=J-A/="(,8J]R<LYX3IN>]W>PBWFTPT5@%-&+R'-%C
M4@8NP,?6;#,@UK EC]BIE6XM;'HR W_0C3PY4Z%.N#3TBAPQXG*0P8O17%:E
M,/D:/3^O7TR\L];EPUU[T._>'O2N"HFDYUBMC*B]Q=@*%@\WYVRZW!^#<$4M
M>24G=07@*A3ERG?F$PJ9E*8$ BL'IX0.*XY9@KGB9VW85##!F6*0'15%>*K
M\0]Z@CW#V E+0%$F3Q%-CR)+8KBK&J'!9S!%XQ'>Q1&!L"+/(9IEXLP-OP3%
M7Q7"F1;DR,<2[3!.85V"Q[]\/#TX>"+/6T>E^+@]2W04AQ=9J?I8]S@&0R?*
M8,."Q[\>'?S/\1-2Z494R4SG?"[[5 3 P1L[6]L]0IPQ&)QBS^">@7:!VD<9
MHR-\ W5:U"C_K CO]?'^.UQJU"2K-/ZKPN).3BPMP'S"4LX,8Y4;;X/W<3^'
M(RVD,1V^>_O_OO_X!/%3X)RC@Z-B5W)>87"(M-;1&*X' O.*VFA/ P;K-O>
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M\9V5ZHOF\LE2\(2-/Y!D+#P.,7>2K* 4'.NY]OV4/5P<E'92X,^ -(R]RB8
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MITHM4:6>=:I4ITJM@RIUL/_IZ&S_PQ^GL.?_:BA2[PY/#TZ./E%;:%"HY-*
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M)FN<]@8* )_,99,+$.;@A>1TQ_JL$-8M(N^*JQNEUS!,P(W=4#7-_2I+962
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MM"F-8\]JNB;TLJQKBWG;]<DB<UG:CY_QX#)?CL\N&^D[<2'5N@U<FQ0U[L%
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M\NP>\]QR'6;GV,V:H\S8DSLKYIX(_F@MC="8.F]D=RH\G%-A@3>R>0Z0Q!D
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M$MH%(>,<*S)C$$#P$YT?(#7RN/C"UC:BW^ '@U_(!EI6%'$_3J1'NG_G(*F
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M5G<)4P1*#R[[C>8C_P[/.H%GO07#U'N/"SHK%[3,*++UAPI=0%J!5 %:U.6
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MNQ@N(CN#/DT5W5R T]DP]CT5\JC!UNX("G4T-&OPW(Y:.!)' =8AZ.8T$-B
MUU9)E'N)70S>9-'+T 0XCIGY+"O'T8V:*F9Q-$1E\3RLI+)V9\/T?NDV*B<4
ME<VD+:4V%-%^^::<'MMRNJ^H\H-Y-4DT^K#2Q%/)#]+,1=TMIM,EE0&O.-6
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MXF",(WUU%G,*K *?DOP5-P.^O0Q'$>C=8WQ:[+U[]]&G%?^>I)_+?W4"=J&
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MD\Y5R5,?Z&M"D[)C3!IF3W'X$3XHHS7P.-WG#G0]YN"L\^I.DQ^?4<8GID#
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M"[HM"<61B,N!RN\P!U%[5;Q-P4/J4W$$O"!-T:]A%XBP@N.1GB0@HS%'VM/
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M]KUF'%>%<>W3;X?H74,Y@L"[J<T40*4I3?@$SKZ#8T'B )8V^A&S)/K:#)Z
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M7(/G_N;L\NKB[)=//*1\7<Z>=@ /_QO=OQ5D^7<@W1?J [K(>W]\=76Z3G8
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M/;[*6;D*N\>I$6S-QE5;IK-F)=6EB&1C\HND]07-0'VNP0#Y;?V>Q)QP5K;
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M6@&>-;3.+ZW93E+U;HV*TG17V0YQWA&9EW0NA^PY!H!G$ 5WI<&0\T!@'3'
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M),Z2B(I/1[;%X,QG:1X_,IU*"2$06=,5)IEV',<8X.2Y;=Z&F0&W:4*<\X;
M^5*)J12X&N#?2"+T-(W!KV>B_1UTW363++I7F.E$DXB-6N(\;OFRYY%BY,RG
M2!?7?F#Z.I9V00DG40Z!PKH453-I-MUX7.\PMALH,2F/[=Q->QJD F"A7ZCQ
M*@T&(4]WQM-%A-0*GY:MG")6_,:54=A%NG=-EE'>$TZX<3<QI)1+X)U'%;2\
MSH:X_$!ON.]#C*#S*2%Y<9,N+=8(1\L7Q6TP3NB)<;0W,>L+1RY+#0H$Z1
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M()A.$S4&L4 X7=IIYN8<\P*QM+P0L<24"M(HY-8P([7(FVP(%^&@XS %K[?
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M,S0U,RYH=&U02P$"% ,4    "  P1WI;^WCJN6D+  !+-   #0
M    @ $Y$@  97A?.#DS-#4T+FAT;5!+ 0(4 Q0    ( #!'>EL#!4["]A8
M ,F@   -              "  <T=  !E>%\X.3,T-34N:'1M4$L! A0#%
M  @ ,$=Z6SDA'5X'J@  C# &  T              ( ![C0  &5X7S@Y,S0X
M,BYH=&U02P$"% ,4    "  P1WI;H72D[W:R  !=%00 #0
M@ $@WP  97A?.#DS-#@S+FAT;5!+ 0(4 Q0    ( #!'>ELGE:6F1Q4  /\5
M   -              "  <&1 0!P>7AI<VQO9V\N:G!G4$L! A0#%     @
M,$=Z6Q0]:&U:!   214  !$              ( !,Z<! '!Y>',M,C R-3$R
M,S$N>'-D4$L! A0#%     @ ,$=Z6S$!6_W_!   D2\  !4
M ( !O*L! '!Y>',M,C R-3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( #!'>EMR
MK?)9RP@  #IF   5              "  >ZP 0!P>7AS+3(P,C4Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    "  P1WI;LXDN)+4$  "A,   %0
M@ 'LN0$ <'EX<RTR,#(U,3(S,5]P<F4N>&UL4$L! A0#%     @ ,$=Z6R((
M[.]:Z0  T?4' !,              ( !U+X! '!Y>',R,#(U,3$R-5]S,RYH
8=&U02P4&      P # #F @  7Z@"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>pyxs20251125_s3_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pyxs-20251231.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-4334">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-4335">2025</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-12-31" id="ixv-4336">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2025-01-01_2025-12-31" id="ixv-4337">0001782223</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d_2025-01-01_2025-12-31" id="c3">S-3</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="d_2025-01-01_2025-12-31" id="c4">PYXIS ONCOLOGY, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-12-31" id="c5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2025-01-01_2025-12-31" id="c6">83-1160910</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-12-31" id="c7">321 Harrison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-12-31" id="c8">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-12-31" id="c9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-12-31" id="c10">02118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-12-31" id="c11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-12-31" id="c12">453-3596</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-12-31" id="c13">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-12-31" id="c14">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-12-31" id="c15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="d_2025-01-01_2025-12-31" id="c16">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>ex_893452_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <context id="offrl_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001782223</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-25</startDate>
            <endDate>2025-11-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-426">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-427">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-428">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-429">0001782223</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-430">Pyxis Oncology, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-434"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-435"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_3"
      decimals="INF"
      id="ixv-436"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_4"
      decimals="INF"
      id="ixv-437"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_5"
      decimals="INF"
      id="ixv-438"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_6"
      decimals="INF"
      id="ixv-439"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FormTp contextRef="rc" id="ixv-518">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-519">Pyxis Oncology, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-520">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-521">Common Stock, par value $0.001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-522">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-523">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-524">Preferred Stock, par value $0.001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_2" id="ixv-525">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_3" id="ixv-526">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_3" id="ixv-527">Debt Securities</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_3" id="ixv-528">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_4" id="ixv-529">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_4" id="ixv-530">Rights to purchase common stock, preferred stock, debt securities or units</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_4" id="ixv-531">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_5" id="ixv-532">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_5" id="ixv-533">Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_5" id="ixv-534">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_6" id="ixv-535">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_6" id="ixv-536">Units</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_6" id="ixv-537">true</ffd:Rule457oFlg>
    <ffd:PrevslyPdFlg contextRef="offrl_7" id="ixv-538">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ffd:OfferingSctyTp>
    <ffd:Rule457oFlg contextRef="offrl_7" id="ixv-540">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-541"
      unitRef="USD">350000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-542"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_7"
      decimals="INF"
      id="ixv-543"
      unitRef="USD">48335.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-544" unitRef="USD">350000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-545" unitRef="USD">48335.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-546" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-547" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-548" unitRef="USD">48335.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_7" id="ixv-549">(1)	An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.
(2)	Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.
(3)	Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $350,000,000.
(4)	The registration fee has been calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
